0001493152-21-015795.txt : 20210701 0001493152-21-015795.hdr.sgml : 20210701 20210701061548 ACCESSION NUMBER: 0001493152-21-015795 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 50 CONFORMED PERIOD OF REPORT: 20210331 FILED AS OF DATE: 20210701 DATE AS OF CHANGE: 20210701 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Wellness Center USA, Inc. CENTRAL INDEX KEY: 0001516887 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 272980395 STATE OF INCORPORATION: NV FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 333-173216 FILM NUMBER: 211063947 BUSINESS ADDRESS: STREET 1: 2500 WEST HIGGINS ROAD, STE. 780 CITY: HOFFMAN ESTATES STATE: IL ZIP: 60169 BUSINESS PHONE: (847) 925-1885 MAIL ADDRESS: STREET 1: 2500 WEST HIGGINS ROAD, STE. 780 CITY: HOFFMAN ESTATES STATE: IL ZIP: 60169 10-Q 1 form10-q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2021

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________ to ___________

WELLNESS CENTER USA, INC.

(Name of small business issuer in its charter)

NEVADA

333-173216

27-2980395

(State or other jurisdiction of incorporation or organization)

Commission

File Number

(IRS Employee

Identification No.)

145 E. University Boulevard, Tucson, AZ 85705

(Address of Principal Executive Offices)

(847) 925-1885

(Issuer Telephone number)

(Former name or former address, if changed since last report)

2500 West Higgins Road, Ste. 780, Hoffman Estates, IL, 60169

Securities registered under Section 12(b) of the Exchange Act:

Title of each class registered:	Name of each exchange on which registered:
None	None

Securities registered under Section 12(g) of the Exchange Act:
Common Stock, par value $0.001 (Title of class)

Indicate by check mark whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or smaller reporting company filer. See definition of “accelerated filer” and “large accelerated filer” in Rule 12b-2 of the Exchange Act (Check one):

Large Accelerated Filer [ ]	Non-Accelerated Filer [ ]
Accelerated Filer [ ]	Smaller Reporting Company [X]
	Emerging growth Company [ ]

Indicate by check mark whether the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.

Yes [ ] No [X]

The number of shares issued and outstanding of each of the issuer’s classes of common equity as of March 31, 2021 was 121,027,077.

FORM 10-Q

WELLNESS CENTER USA, INC.

MARCH 31, 2021

TABLE OF CONTENTS

PART I— FINANCIAL INFORMATION

Item 1.	Condensed Consolidated Financial Statements	3
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	18
Item 3	Quantitative and Qualitative Disclosures About Market Risk	26
Item 4.	Control and Procedures	26

PART II— OTHER INFORMATION

Item 1	Legal Proceedings	28
Item 1A	Risk Factors	28
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	28
Item 3.	Defaults Upon Senior Securities	28
Item 4.	Mine Safety Disclosures.	28
Item 5.	Other Information	28
Item 6.	Exhibits	29

SIGNATURE		30

Wellness Center USA, Inc.

Condensed Consolidated Balance Sheets

	March 31,			September 30,
	2021			2020
		(Unaudited)
ASSETS
Current Assets
Cash	$	146,139		$	51,320
Accounts receivable		9,018			-
Inventories, net		132,493			94,560
Prepaid expenses and other current assets		-			500
Total Current Assets		287,650			146,380

Right of use asset		-			6,961
Total Other Assets		-			6,961

TOTAL ASSETS	$	287,650		$	153,341

LIABILITIES AND SHAREHOLDERS’ DEFICIT
Current Liabilities
Accounts payable and accrued expenses	$	517,864		$	408,297
Payroll taxes payable, past due		84,834			92,334
Lease liability		-			6,961
Lease abandonment liability		672,878			672,878
Loans payable from officers and shareholders, including $830,250
past due at March 31, 2021		1,825,250			1,165,250
Total Current Liabilities		3,100,826			2,345,720

Long-term Liabilities
U.S. Small Business Administration PPP loan payable		37,166			37,166
Total Liabilities		3,137,992			2,382,886

Shareholders’ Deficit
Common stock, par value $0.001, 200,000,000 shares authorized;
121,027,077 and 118,252,077 shares issued and outstanding, respectively		121,027			118,252
Additional paid-in capital		25,155,855			25,053,616
Accumulated deficit		(27,977,238	)		(27,583,363	)
Total Wellness Center USA shareholders’ deficit		(2,700,356	)		(2,411,495	)

Non-controlling interest		(149,986	)		181,950
Total Shareholder’s deficit		(2,850,342	)		(2,229,545	)

TOTAL LIABILITIES AND SHAREHOLDERS’ DEFICIT	$	287,650		$	153,341

The accompanying notes are an integral part of these condensed consolidated financial statements.

Wellness Center USA, Inc.

Condensed Consolidated Statements of Operations

	Three Months Ended						Six Months Ended
	March 31,						March 31,
	2021			2020			2021			2020
	(Unaudited)						(Unaudited)

Trade sales	$	51,650		$	5,000		$	142,149		$	5,000

Cost of goods sold		58,950			-			139,050			-

Gross profit (loss)		(7,300	)		5,000			3,099			5,000

Operating expenses		362,218			423,130			670,759			760,403

Loss from operations		(369,518	)		(418,130	)		(667,660	)		(755,403	)

Other expenses
Cost of warrant modification		-			(507,265	)		-			(507,265	)
Interest expense		(31,993	)		(16,211	)		(58,151	)		(25,534	)
Total other expenses		(31,993	)		(523,476	)		(58,151	)		(532,799	)

NET LOSS		(401,511	)		(941,606	)		(725,811	)		(1,288,202	)

Net loss attributable to non-controlling interest		188,334			22,050			331,936			44,179

NET LOSS ATTRIBUTABLE TO WELLNESS CENTER USA, INC.		(213,177	)		(919,556	)		(393,875	)		(1,244,023	)

BASIC AND DILUTED LOSS PER SHARE	$	(0.00	)	$	(0.01	)	$	(0.01	)	$	(0.01	)

WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING
BASIC AND DILUTED		120,333,327			107,497,077			119,639,577			107,497,077

The accompanying notes are an integral part of these condensed consolidated financial statements.

Wellness Center USA, Inc.

Condensed Consolidated Statements of Shareholders’ Deficit (Unaudited)

	Common Stock				Additional Paid-in		Accumulated			Total WCUI			Non-controlling
	Shares		Amount		Capital		Deficit			Deficit			Interest			Total

Balance, December 31, 2020 (unaudited)		119,639,577	$	119,639	$	25,104,736	$	(27,764,061	)	$	(2,539,686	)	$	38,348		$	(2,501,338	)

Fair value of vested stock options		-		-		10,882		-			10,882			-			10,882

Fair value of common stock issued for services		1,387,500		1,388		40,237		-			41,625			-			41,625

Net loss for the three months ended March 31, 2021		-		-		-		(213,177	)		(213,177	)		(188,334	)		(401,511	)

Balance, March 31, 2021 (unaudited)		121,027,077	$	121,027	$	25,155,855	$	(27,977,238	)	$	(2,700,356	)	$	(149,986	)	$	(2,850,342	)


Balance, September 30, 2020		118,252,077	$	118,252	$	25,053,616	$	(27,583,363	)	$	(2,411,495	)	$	181,950		$	(2,229,545	)

Fair value of vested stock options		-		-		21,764		-			21,764			-			21,764

Fair value of common stock issued for services		2,775,000		2,775		80,475		-			83,250			-			83,250

Net loss for the six months ended March 31, 2021		-		-		-		(393,875	)		(393,875	)		(331,936	)		(725,811	)

Balance, March 31, 2021 (unaudited)		121,027,077	$	121,027	$	25,155,855	$	(27,977,238	)	$	(2,700,356	)	$	(149,986	)	$	(2,850,342	)


Balance, December 31, 2019 (unaudited)		107,497,077	$	107,497	$	23,868,885	$	(25,686,754	)	$	(1,710,372	)	$	395,520		$	(1,314,852	)

Fair value of vested stock options		-		-		65,800		-			65,800			-			65,800

Fair value of common stock issued for services		-		-		507,265		-			507,265			-			507,265

Net loss for the three months ended March 31, 2020		-		-		-		(919,556	)		(919,556	)		(22,050	)		(941,606	)

Balance, March 31, 2020 (unaudited)		107,497,077	$	107,497	$	24,441,950	$	(26,606,310	)	$	(2,056,863	)	$	373,470		$	(1,683,393	)


Balance, September 30, 2019		107,497,077	$	107,497	$	23,777,647	$	(25,362,287	)	$	(1,477,143	)	$	393,149		$	(1,083,994	)

Fair value of vested stock options		-		-		131,538		-			131,538			-			131,538

Cost of warrant modification		-		-		507,265		-			507,265			-			507,265

Contribution of capital by joint venture partner		-		-		25,500		-			25,500			24,500			50,000

Net loss for the six months ended March 31, 2020		-		-		-		(1,244,023	)		(1,244,023	)		(44,179	)		(1,288,202	)

Balance, March 31, 2020 (unaudited)		107,497,077	$	107,497	$	24,441,950	$	(26,606,310	)	$	(2,056,863	)	$	373,470		$	(1,683,393	)

The accompanying notes are an integral part of these condensed consolidated financial statements.

Wellness Center USA, Inc.

Condensed Consolidated Statements of Cash Flows

	Six Months Ended March 31,
	2021			2020
	(Unaudited)
Cash Flows from Operating Activities
Net loss	$	(725,811	)	$	(1,288,202	)

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense		-			1,562
Amortization of right-of-use asset		6,961			10,483
Provision for excess and slow moving inventories		100,000			-
Fair value of common shares issued for services		83,250			-
Fair value of stock options issued for services		21,764			131,538
Cost of warrant modification		-			507,265
Changes in Assets and Liabilities
(Increase) Decrease in:
Accounts receivable		(9,018	)		(5,000	)
Inventories		(137,933	)		(10,660	)
Prepaid expenses and other assets		500			(500	)
(Decrease) Increase in:
Accounts payable and accrued expenses		109,567			132,496
Payroll taxes payable		(7,500	)		(1,500	)
Lease liability		(6,961	)		(10,483	)
Net cash used in operating activities		(565,181	)		(533,001	)

Cash Flows from Financing Activities
Proceeds from loans payable from officers and shareholders		660,000			470,000
Contribution of capital by joint venture partner		-			50,000
Net cash provided by financing activities		660,000			520,000

Net increase (decrease) in cash		94,819			(13,001	)

Cash beginning of period		51,320			53,147
Cash end of period	$	146,139		$	40,146

Supplemental cash flows disclosures:
Interest paid	$	-		$	-
Taxes paid	$	-		$	-

Supplemental non-cash disclosures:
Initial recognition of right-of-use assets and operating lease
liabilities upon adoption of ASC Topic 842	$	-		$	27,841
Reclassification of prepaid expenses to inventories	$	-		$	55,000

The accompanying notes are an integral part of these condensed consolidated financial statements.

WELLNESS CENTER USA, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

FOR THE SIX MONTHS ENDED MARCH 31, 2021 and 2020

NOTE 1 – BASIS OF PRESENTATION

Organization and Operations

Wellness Center USA, Inc. (“WCUI” or the “Company”) was incorporated in June 2010 under the laws of the State of Nevada. The Company initially engaged in online sports and nutrition supplements marketing and distribution. The Company subsequently expanded into additional businesses within the healthcare and medical sectors through acquisitions, including Psoria-Shield Inc. (“PSI”) and StealthCo Inc. (“SCI”), d/b/a Stealth Mark, Inc.

The Company currently operates in the following business segments: (i) distribution of targeted Ultra Violet (“UV”) phototherapy devices for dermatology and sanitation purposes; and (ii) authentication and encryption products and services. The segments are operated, respectively, through PSI and SCI.

Basis of Presentation of Unaudited Financial Information

The accompanying unaudited condensed consolidated financial statements of Wellness Center USA, Inc. and Subsidiaries (the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all normal recurring adjustments considered necessary for a fair presentation have been included. Operating results for the six months ended March 31, 2021 are not necessarily indicative of the results that may be expected for the year ending September 30, 2021.

COVID-19 Considerations

During the period ended March 31, 2021, the COVID-19 pandemic did not have a material net impact on our operating results. In the future, the pandemic may cause reduced demand for our products if, for example, the pandemic results in a recessionary economic environment which negatively effects the consumers who purchase our products.

Our ability to operate without significant negative operational impact from the COVID-19 pandemic will in part depend on our ability to protect our employees and our supply chain. The Company has endeavored to follow the recommended actions of government and health authorities to protect our employees. Since the onset of the COVID-19 pandemic, we maintained the consistency of our operations. However, the uncertainty resulting from the pandemic could result in an unforeseen disruption to our workforce and supply chain (for example an inability of a key supplier or transportation supplier to source and transport materials) that could negatively impact our operations.

Through March 31, 2021, the COVID-19 pandemic has not negatively impacted the Company’s liquidity position as of such date. Through March 31, 2021, the Company continues to generate cash flows through financing activities to meet its short-term liquidity needs, and it expects to maintain access to those shareholder loans. The Company has not observed any material impairments of its assets or a significant change in the fair value of its assets due to the COVID-19 pandemic.

Going Concern

The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying condensed consolidated financial statements, the Company has not yet generated significant revenues and has incurred recurring net losses. During the six months ended March 31, 2021, the Company incurred a net loss of $725,811 and used cash in operations of $565,181, and had a shareholders’ deficit of $2,850,342 as of March 31, 2021. In addition, loans payable of $830,250 and payroll taxes of $84,834 are past due. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to raise additional funds and implement its strategies. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

In addition, the Company’s independent registered public accounting firm, in its report on the Company’s September 30, 2020 financial statements, has raised substantial doubt about the Company’s ability to continue as a going concern.

At March 31, 2021, the Company had cash on hand in the amount of $146,139. The ability to continue as a going concern is dependent on the Company attaining and maintaining profitable operations in the future and raising additional capital soon to meet its obligations and repay its liabilities arising from normal business operations when they come due. Since inception, we have funded our operations primarily through equity and debt financings and we expect to continue to rely on these sources of capital in the future. During the six months ended March 31, 2021, the Company received $660,000 through short-term loans from officers and shareholders.

No assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to the Company. Even if the Company is able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing or cause substantial dilution for our stockholders, in case of equity financing.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Consolidation

The consolidated financial statements include the Company’s subsidiaries and the accounts of its subsidiaries for which it was determined that Company has operational and management control. The Company’s consolidated subsidiaries and/or controlled entities are as follows:

Name of consolidated subsidiary or entity	State or other jurisdiction of incorporation or organization	Date of incorporation or formation (date of acquisition/disposition, if applicable)	Attributable interest at September 30, 2020			Attributable interest at March 31, 2021
Psoria-Shield Inc. (“PSI”)	The State of Florida	June 2009 (August 2012)		51%	(1)		51%	(1)
StealthCo, Inc. (“StealthCo”)	The State of Illinois	March 2014		100	%		100	%
Psoria Development Company LLC. (“PDC”)	The State of Illinois	January 2015/November 2018		0	%		0	%
NEO Phototherapy LLC (“NEO”)	The State of Illinois	December 2018		0	%		0	%
Protec Scientific, Inc (“Protec”)	The State of New York	April 2020		32	%		32	%

(1) - Effective April 30, 2020, the Company’s 51% interest in NEO was converted into a 51% interest in PSI.

Use of Estimates

The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date, and reported amounts of revenue and expenses during the reporting period. Significant estimates are used in the valuation of accounts receivable and allowance for uncollectible amounts, inventory and obsolescence reserves, accruals for potential liabilities, valuations of stock-based compensation, and realization of deferred tax assets, among others. Actual results could differ from these estimates.

Income (Loss) Per Share

Basic loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of outstanding common shares during the period. Diluted loss per share is computed by dividing the net loss applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued. For the six months ended March 31, 2021 and 2020, the basic and diluted shares outstanding were the same, as potentially dilutive shares were considered anti-dilutive. At March 31, 2021 and 2020, the dilutive impact of outstanding stock options of 12,602,738 and 14,837,738 shares, respectively, and outstanding warrants for 54,379,758 and 66,484,049 shares, respectively, have been excluded because their impact on the loss per share is anti-dilutive.

Revenue Recognition

The company records revenue under the guidance of Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers (Topic 606) which requires a company to recognize revenue to depict the transfer of goods or services to a customer at an amount that reflects the consideration it expects to receive in exchange for those goods or services.

For trade sales, the Company generates its revenue from sales contracts with customers with revenues being generated upon the shipment of merchandise, or for consulting services, revenue is recognized in the period services are rendered and earned under service arrangements with clients.

We sell our products through two main sales channels: 1) directly to customers who use our products (the “Direct Channel”) and 2) to distribution partners who resell our products (the “Indirect Channel”).

Under the Direct Channel, we sell our products to and we receive payment directly from customers who purchase our products. Under our Indirect Channel, we have entered into distribution agreements that allow the distributors to sell our products and fulfill performance obligations under the agreements.

We determine revenue recognition through the following steps:

●

Identification of the contract, or contracts, with a customer

●

Identification of the performance obligations in the contract

●

Determination of the transaction price

●

Allocation of the transaction price to the performance obligations in the contract

●

Recognition of revenue when, or as, we satisfy a performance obligation.

Revenue is generally recognized upon shipment or when a service has been completed, unless we have significant performance obligations for services still to be completed. We recognize revenue when a material reversal is no longer probable. Payments received before the relevant criteria for revenue recognition are satisfied are recorded as deferred revenue. There was no deferred revenue at March 31, 2021 and September 30, 2020.

Non-controlling Interests

PSI

In December 2018, PSI entered into a Joint Venture Agreement with GEN2 for further development, marketing, licensing and/or sale of PSI technology and products to be conducted through NEO Phototherapy, Inc. (“NEO”). PSI and GEN2 were the members of NEO, owning 50.5% and 36.0%, respectively, of NEO. As of April 30, 2020, the Company controlled 51% of the joint venture, GEN2 controlled 39% and another individual controlled the remaining 10%.

Effective April 30, 2020, the GEN2 shareholders exchanged their common shares in GEN2, and the individual exchanged his membership interests in NEO, for common shares representing 49% ownership in PSI. The Company retained its common shares in PSI, which provides the Company a 51% economic interest in the PSI technology and products developed by the joint venture. During three and six months ended March 31, 2021, PSI recorded a loss of $187,077 and $338,510, respectively, relating to its operations, of which $91,668 and $165,870, respectively, was allocated to the non-controlling interest.

As of September 30, 2019, GEN2 had received $975,000 of investments to contribute to NEO. Repayment of the $975,000 investment will begin through and upon the date which PSI has realized and retained cumulative net income/distributable cash in the amount of $300,000. As of March 31, 2021, PSI had not recorded any cumulative net income/distributable cash. The minority interest of PSI ownership consists of accredited investors, and investment participation of $750,000 from several WCUI officers and directors, including Calvin R. O’Harrow and Roy M. Harsch.

Protec

In May 2020, the Company’s subsidiary, PSI, agreed to become a majority shareholder in Protec Scientific, Inc. (“Protec”), a company formed in April 2020. As of September 30, 2020, PSI had contributed $191,000 to Protec with the Company’s share being approximately 32%, based on its PSI ownership. The remaining share is attributed to PSI’s minority shareholders. During the year ended September 30, 2020, Protec received an additional $120,000 from non-affiliated investors. The additional investments gave the non-controlling interests a 68% ownership interest in Protec. During the three and six months ended March 31, 2021, Protec recorded a loss of $141,365 and $242,857, respectively, of which $96,665 and $166,065 was allocated to the non-controlling interests.

Inventories

Inventories are stated at the lower of cost or net realizable value. Cost is computed on a first-in, first-out basis. At March 31, 2021, primarily all of the inventories consisted of raw materials or work-in-progress. The Company provides inventory reserves based on excess and obsolete inventories determined primarily by future demand forecasts. The write down amount, if any, is measured as the difference between the cost of the inventory and net realizable value based upon assumptions about future demand and charged to the provision for inventory, which is a component of cost of sales. At the point of the loss recognition, a new, lower cost basis for that inventory is established, and subsequent changes in facts and circumstances do not result in the restoration or increase in that newly established cost basis. At March 31, 2021, the Company recorded a reserve of $100,000 for excess and slow moving inventories. At September 30, 2020, no reserve was recorded for excess, slow moving or obsolete inventory.

Stock-Based Compensation

The Company periodically issues stock-based compensation to officers, directors, and consultants for services rendered, and as part of financing transactions. Such issuances vest and expire according to terms established at the issuance date. Stock-based payments to officers, directors, employees, and for acquiring goods and services from non-employees, which include grants of employee stock options, are recognized in the financial statements based on their fair values in accordance with Topic 718. Stock option grants, which are generally time vested, will be measured at the grant date fair value and charged to operations on a straight-line basis over the vesting period.

The fair value of the Company’s common stock option and warrant grants are estimated using a Black-Scholes Merton option pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the common stock options, estimated forfeitures and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes option pricing model, and based on actual experience. The assumptions used in the Black-Scholes Merton option pricing model could materially affect compensation expense recorded in future periods.

Recently Issued Accounting Pronouncements

In June 2016, the FASB issued ASU No. 2016-13, Credit Losses - Measurement of Credit Losses on Financial Instruments (“ASC 326”). The standard significantly changes how entities will measure credit losses for most financial assets, including accounts and notes receivables. The standard will replace today’s “incurred loss” approach with an “expected loss” model, under which companies will recognize allowances based on expected rather than incurred losses. Entities will apply the standard’s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The standard is effective for interim and annual reporting periods beginning after December 15, 2019. The adoption of ASU 2016-13 is not expected to have a material impact on the Company’s financial position, results of operations, and cash flows.

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

NOTE 3 – LOANS PAYABLE FROM OFFICERS AND SHAREHOLDERS

As of September 30, 2020, loans payable from officers and shareholders of $1,165,250 were outstanding. During the six months ended March 31, 2021, the Company borrowed $660,000 from its officers and shareholders. All of the loans are unsecured, have an interest rate of eight percent and are due one year from the date of issuance. As of March 31, 2021, loans payable to officers and shareholders of $1,825,250 were outstanding and $830,250 was past due.

NOTE 4 – LEASE LIABILITIES

Operating Lease

In February 2019, the Company’s PSI subsidiary entered into a 24-month non-cancellable lease for its office facilities that will require monthly payments of $1,850 through January 2021. The Company adopted ASU 2016-02, Leases, effective October 1, 2019, which requires a lessee to record a right-of-use asset and a corresponding lease liability at the inception of the lease initially measured at the present value of the lease payments. The Company classified the lease as an operating lease and determined that the value of the lease asset and liability at the inception of the lease was $27,841, using a discount rate of 4.00%. As of September 30, 2020, the value of the lease asset and liability was $6,961, respectively. During the three and six months ended March 31, 2021, the Company made payments of $1,613 and $6,961, respectively, towards the lease liability. As of March 31, 2021, the lease liability was fully paid off.

ASU 2016-02 requires recognition in the statement of operations of a single lease cost, calculated so that the cost of the lease is allocated over the lease term, generally on a straight-line basis. Rent expense for the three and six months ended March 31, 2021 was $1,794 and $7,142, respectively. During the three and six months ended March 31, 2021, the Company reflected amortization of right of use asset of $1,613 and $6,961, respectively, related to this lease, resulting in no net asset balance as of March 31, 2021.

Other Leases

The Company leased its corporate office facility in Hoffman Estates, Illinois pursuant to a non-cancellable lease initiated in July 2016 and expiring February 28, 2024. The lease terms require a monthly payment of approximately $11,000. The Company vacated the facility in April 2019, in favor of its present facilities in Tucson AZ, which are provided by a shareholder on a rent-free basis. The Company is in negotiations with the owners regarding the settlement of its lease obligations and expects that the property will be subleased or a settlement with the landlord will be reached at an amount significantly less than the remaining payment obligations. At the date of vacation, the Company had a remaining lease obligation of $631,587.

On or about June 29, 2020, we received notice that Hanover Hoffman Estates, LLC (“HHE”), filed case number 2020L006092 in the Circuit Court of Cook County alleging our failure to pay Base Rent and abandonment of certain office space in Hoffman Estates, Illinois subject to a Commercial Lease dated May 26, 2016. HHE seeks at least $672,878 in base rent and other amounts under the lease, as well as treble damages from our ex-CEO and two past Directors who were serving on our Board as of the date of the lease. We are currently evaluating the allegations, defenses and alternate actions, and continuing settlement negotiations. As of March 31, 2021, the Company has recorded the full amount of the judgement due.

NOTE 5 – SHAREHOLDERS’ EQUITY

Restricted Stock Grants

In April 2020, the Company’s Board of Directors approved the issuance of a combined total of 20,170,000 restricted shares of the Company’s common stock to its Officers and Directors. A total of 7,120,000 shares vested in April 2020, while 1,800,000 will vest monthly from April 2020 through March 2021, and 11,250,000 will vest monthly from April 2020 through March 2023. Of the 13,050,000 shares that vest over time, a total of 1,387,500 and 2,775,000 shares vested during the three and six months ended March 31, 2021, respectively.

The following table summarizes restricted common stock activity:

	Number of Restricted Shares			Fair Value			Weighted Average Grant Date Fair Value

Non-vested, September 30, 2020		10,275,000		$	308,250		$	0.03
Granted		-			-			-
Vested		(2,775,000	)		(83,250	)		0.03
Forfeited		-			-			-
Non-vested, March 31, 2021		7,500,000		$	225,00		$	0.03

During the three and six months ended March 31, 2021, the Company recorded $41,625 and $83,250, respectively, of stock compensation for the value of restricted common stock vesting during the period, and as of March 31, 2021, unvested compensation of $225,000 remained that will be amortized over the remaining vesting period.

Stock Options

On December 22, 2010, effective retroactively as of June 30, 2010, the Company’s Board of Directors approved the adoption of the “2010 Non-Qualified Stock Option Plan” (“2010 Option Plan”) by unanimous consent. The 2010 Option Plan was initiated to encourage and enable officers, directors, consultants, advisors and key employees of the Company to acquire and retain a proprietary interest in the Company by ownership of its common stock. A total of 7,500,000 of the authorized shares of the Company’s common stock may be subject to, or issued pursuant to, the terms of the plan. Effective January 1, 2018, the Board of Directors approved to increase the number of authorized shares of the Company’s common stock that may be subject to, or issued pursuant to, the terms of the plan from 7,500,000 to 30,000,000.

The Company’s policy is to recognize compensation cost for awards with only service conditions and a graded vesting schedule on a straight-line basis over the requisite service period for the entire award. Additionally, the Company’s policy is to issue new shares of common stock to satisfy stock option exercises. The Company applied fair value accounting for all share based payments awards. The fair value of each option granted is estimated on the date of grant using the Black-Scholes option-pricing model.

The table below summarizes the Company’s stock option activities for the six months ended March 31, 2021:

	Number of Option Shares			Exercise Price Range Per Share		Weighted Average Exercise Price

Balance, September 30, 2020		14,127,738		$	0.03 - 2.00	$	0.29
Granted		-			-		-
Cancelled		-			-		-
Exercised		-			-		-
Expired		(1,525,000	)		0.14 - 2.00		1.36
Balance, March 31, 2021		12,602,738		$	0.03 - 0.40	$	0.10
Vested and exercisable, March 31, 2021		10,102,738		$	0.03 - 0.40	$	0.11

Unvested, March 31, 2021		2,500,000		$	0.04	$	0.04

The following table summarizes information concerning outstanding and exercisable options as of March 31, 2021:

		Options Outstanding						Options Exercisable
Range of Exercise Prices		Number Outstanding		Average Remaining Contractual Life (in years)		Weighted Average Exercise Price		Number Exercisable		Average Remaining Contractual Life (in years)		Weighted Average Exercise Price

$	0.03 - 0.39		12,540,238		5.09	$	0.09		10,040,238		4.12	$	0.11
	0.40		62,500		1.00		0.40		62,500		1.00		0.40
$	0.03 - 0.40		12,602,738		5.07	$	0.10		10,102,738		4.10	$	0.11

During the three and six months ended March 31, 2021, the Company recorded $10,882 and $21,764, respectively, of stock compensation for the value of options vesting during the period, and as of March 31, 2021, unvested compensation of $75,000 remained that will be amortized over the remaining vesting period.

The total aggregate intrinsic value for option shares outstanding at March 31, 2021 was $625. As of March 31, 2021, there were 17,397,262 shares of stock options remaining available for issuance under the 2010 Plan.

Stock Warrants

The table below summarizes the Company’s warrants activities for the six months ended March 31, 2021:

	Number of Warrant Shares			Exercise Price Range Per Share		Weighted Average Exercise Price

Balance, September 30, 2020		67,634,049			$ 0.07 - 0.40	$	0.16
Granted		-			-		-
Cancelled		-			-		-
Exercised		-			-		-
Expired		(13,254,291	)		0.15		0.15
Balance, March 31, 2021		54,379,758		$	0.07 - 0.40	$	0.17
Vested and exercisable, March 31, 2021		54,379,758		$	0.07 - 0.40	$	0.17

The following table summarizes information concerning outstanding and exercisable warrants as of March 31, 2021:

		Warrants Outstanding						Warrants Exercisable
Range of Exercise Prices		Number Outstanding		Average Remaining Contractual Life (in years)		Weighted Average Exercise Price		Number Exercisable		Average Remaining Contractual Life (in years)		Weighted Average Exercise Price

$	0.12 – 0.20		47,175,093		1.97	$	0.15		47,175,093		1.97	$	0.15
	0.21 – 0.40		7,204,665		0.40		0.26		7,204,665		0.40		0.26

$	0.12 – 0.67		54,379,758		1.76	$	0.17		54,379,758		1.76	$	0.17

There was no aggregate intrinsic value for warrant shares outstanding at March 31, 2021.

NOTE 6 – SEGMENT REPORTING

Reportable segments are components of an enterprise about which separate financial information is available and that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company’s reportable segments are based on products and services, geography, legal structure, management structure, or any other manner in which management disaggregates a company.

The Company operates in the following business segments:

(i) Medical Devices: which stems from PSI, its subsidiary acquired on August 24, 2012, a developer, manufacturer, marketer and distributer of targeted Ultra Violet (“UV”) phototherapy devices for the treatment of skin diseases.

(ii) Authentication and Encryption Products and Services: which stems from StealthCo, its wholly-owned subsidiary formed on March 18, 2014, which has engaged in the business of selling, licensing or otherwise providing certain authentication and encryption products and services since acquisition of certain assets from SMI on April 4, 2014.

The detailed segment information of the Company is as follows:

Assets By Segment

	March 31, 2021
	Corporate		Medical Devices		Authentication and Encryption		Total
ASSETS
Current Assets
Cash	$	523	$	141,994	$	3,622	$	146,139
Accounts receivable		-		9,018		-		9,018
Inventories		-		132,493		-		132,493
Prepaid expenses and other current assets		-		-		-		-
Total current assets		523		283,505		3,622		287,650

TOTAL ASSETS	$	523	$	283,505	$	3,622	$	287,650

Operations by Segment for the Three Months Ended March 31, 2021 and 2020

	For the Three Months Ended
	March 31, 2021
	Corporate			Medical Devices			Authentication and Encryption			Total

Trade Sales	$	-		$	51,650		$	-		$	51,650

Cost of goods sold		-			58,950			-			58,950

Gross profit		-			(7,300	)		-			(7,300	)

Operating expenses		46,661			308,543			7,014			362,218

Loss from operations	$	(46,661	)	$	(315,843	)	$	(7,014	)	$	(369,518	)

	For the Three Months Ended
	March 31, 2020
							Stealthco
	WCUI			PSI			Authentication and
	Corporate			Medical Devices			Encryption			Total

Trade Sales	$	-		$	-		$	5,000		$	5,000

Cost of goods sold		-			-			-			-

Gross profit		-			-			5,000			5,000

Operating expenses		142,500			206,824			73,806			423,130

Loss from operations	$	(142,500	)	$	(206,824	)	$	(68,806	)	$	(418,130	)

Operations by Segment for the Six Months Ended March 31, 2021 and 2020

	For the Six Months Ended
	March 31, 2021
	Corporate			Medical Devices			Authentication and Encryption			Total

Trade Sales	$	-		$	142,149		$	-		$	142,149

Cost of goods sold		-			139,050			-			139,050

Gross profit		-			3,099			-			3,099

Operating expenses		95,770			565,014			9,975			670,759

Loss from operations	$	(95,770	)	$	(561,915	)	$	(9,975	)	$	(667,660	)

	For the Six Months Ended
	March 31, 2020
							Stealthco
	WCUI			PSI			Authentication
	Corporate			Medical Devices			and Encryption			Total

Trade Sales	$	-		$	-		$	5,000		$	5,000

Cost of goods sold		-			-			-			-

Gross profit		-			-			5,000			5,000

Operating expenses		240,962			382,110			137,331			760,403

Loss from operations	$	(240,962	)	$	(382,110	)	$	(132,331	)	$	(755,403	)

NOTE 7 – LEGAL MATTERS

The Company is periodically engaged in legal proceedings arising from and relating to its business operations. Except as otherwise described herein and in Note 4, we currently are not involved in any other litigation that we believe could have a material adverse effect on our financial condition or results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our Company or any of our subsidiaries, threatened against or affecting our Company, our common stock, any of our subsidiaries or of our Company’s or our subsidiaries’ officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect on our financial condition or results of operations.

We continue efforts to preserve revenue and reduce operating expenses through actions including, but not limited to, facilities consolidation and staff reductions, which we hope to implement through negotiated transactions with lessors, employees and other third parties. Such actions may result in disputes with and claims by such parties which, if not resolved through negotiations, may impact negatively the Company’s ability to continue as a going concern. To date, the Company has negotiated settlement of all ex-employee wage and benefits claims except for two. The first regards unpaid wages claimed due together with interest at the rate of 4% per annum on such amount as the Company originally agreed upon in settlement negotiations. The ex-employee claims additional amounts due for certain statutory damages under the Illinois Wage Payment and Collection which currently could exceed $21,600.00 and would increase at the rate of 2% of the wages due per month plus attorneys’ fees if the employee elects to file suit for a violation of the Act and is successful in obtaining a judgment on his claim.

The second claim was filed with the Illinois Department of Labor asserting a violation of the Illinois Wage Payment and Collection Act by the Company’s former CEO. That claim alleges unpaid wages in the amount of $158,714.60 and unpaid vacation pay in the amount of $20,833.33 for a total amount of $179,547.90, as well as certain statutory damages including, but not limited to, 2% of the wages due per month plus attorneys’ fees if the ex-CEO elects to file suit for a violation of the Act and is successful in obtaining a judgment on his claim. The Company has filed its response to such claim with the Department denying the substantive allegations therein and asserting certain factual and legal defenses, including breach of fiduciary duty, as a bar to all claimed compensation. The claim remains pending, but as the date hereof, no suit has been filed against the Company asserting a violation of the Act based on said claim.

NOTE 8 – SUBSEQUENT EVENTS

Subsequent to March 31, 2021, the Company borrowed $66,000 from its officers and shareholders. All of the loans are unsecured, have an interest rate of eight percent and are due one year from the date of issuance.

On April 1, 2021, the Company’s Board of Directors approved the issuance of a combined total of 3,750,000 restricted shares of the Company’s common stock to certain of its Officers and Directors for future services to be performed. The shares vest monthly from April 2023 through March 2024. The fair value of the shares on the date of grant was $187,500.

The Board also approved the issuance of a combined total of 10,085,714 restricted shares of the Company’s common stock to certain of its Officers and Directors in connection with their officer and shareholder loans. A total of 7,060,000 of the shares vested upon grant and 3,025,714 shares vest in April 2025. The fair value of the shares on the date of grant was $504,286.

On April 1, 2021, the Company’s Board of Directors approved the grant of stock options to its Chief Executive Officer (CEO) to purchase 1,300,000 shares of the Company’s common stock with an exercise price of $0.05 per share. The options expire ten years from the date of grant. The option grants are for future services to be performed by the CEO. The shares vest monthly from April 2023 through March 2024. The fair value of the shares on the date of grant was approximately $65,000.

The Board also approved the grant of stock options to its CEO to purchase 13,449,429 shares of the Company’s common stock with an exercise price of $0.05 per share. The options expire ten years from the date of grant. The option grants are in connection with his officer and shareholder loans. A total of 9,052,500 of the shares vested upon grant and 4,396,929 shares vest in April 2025. The fair value of the shares on the date of grant was approximately $670,000. In connection with the option grants, the CEO agreed to cancel 5,277,778 of his warrant shares that were scheduled to expire from September 2021 through December 2021.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward Looking Statements

Except for historical information, the following discussion contains forward-looking statements based upon current expectations that involve certain risks and uncertainties. Such forward-looking statements include statements regarding, among other things, (a) our projected sales and profitability, (b) our growth strategies, (c) anticipated trends in our industry, (d) our future financing plans, (e) our anticipated needs for working capital, (f) our lack of operational experience and (g) the benefits related to ownership of our common stock. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “will,” “should,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. This information may involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from the future results, performance, or achievements expressed or implied by any forward-looking statements. These statements may be found under “Description of Business,” and “Analysis of Financial Condition and Results of Operations”, as well as in this Report generally. Actual events or results may differ materially from those discussed in forward-looking statements as a result of various factors, including, without limitation, the risks outlined under “Risk Factors” in our Annual Report on Form 10-K and in other Reports we have filed with the Securities and Exchange Commission, as well as matters described in this Report generally. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements contained in this Report will in fact occur as projected.

The following discussion and analysis provides information which management believes is relevant to an assessment and understanding of our results of operations and financial condition. The discussion should be read along with our financial statements and notes thereto. This section includes a number of forward-looking statements that reflect our current views with respect to future events and financial performance. You should not place undue certainty on these forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from our predictions.

Description of Business

Background.

Wellness Center USA, Inc. (“WCUI” or the “Company”) was incorporated in June 2010 under the laws of the State of Nevada. We initially engaged in online sports and nutrition supplements marketing and distribution. We subsequently expanded into additional businesses within the healthcare and medical sectors through acquisitions, including Psoria-Shield Inc. (“PSI”) and StealthCo Inc. (“SCI”), d/b/a Stealth Mark, Inc.

The Company currently operates in two business segments: (i) distribution of targeted Ultra Violet (“UV”) phototherapy devices for dermatology and sanitation purposes; and (ii) authentication and encryption products and services. The segments are conducted through our subsidiaries, PSI and SCI.

COVID-19 Uncertainties

In March 2020, the World Health Organization declared the outbreak of COVID-19 a global pandemic. The responses by federal, state and local governments to restrict public gatherings and travel rapidly grew to include stay-at-home orders, school closures and mandatory restrictions on non-essential businesses and services that has adversely affected workforces, economies, and financial markets resulting in a significant economic downturn. The Company’s corporate office is located in Tucson, Arizona and its manufacturing facility is in Utica, New York. Since March 2020, we have been following the recommendations of local health authorities to minimize exposure risk for our employees, including temporary closures of our offices and having employees work remotely to the extent possible. The order, which has subsequently been modified to provide for a gradual re-opening of businesses and travel, is to remain in place until further notice.

While this disruption is currently expected to be temporary, there is considerable uncertainty around the duration. We are actively monitoring the COVID-19 situation and its impact in the markets we serve. We are taking all precautionary measures as directed by health authorities and local and national governments. Due to continuing uncertainties regarding the ultimate scope and trajectory of COVID-19’s spread and evolution, it is impossible to predict the total impact that the pandemic will have on our business. If public and private entities continue to implement restrictive measures, the material adverse effect on our business, results of operations, financial condition and cash flows could persist.

PSI

PSI was incorporated under the laws of the state of Florida on June 17, 2009. We acquired all of the issued and outstanding shares of stock in PSI on August 24, 2012.

Joint Ventures

In December 2018, PSI entered into a Joint Venture Agreement with GEN2 for further development, marketing, licensing and/or sale of PSI technology and products. Pursuant to the Joint Venture Agreement, the venture will be conducted through NEO Phototherapy, Inc. (“NEO”). PSI and GEN2 will be the members of NEO, owning 50.5% and 36.0%, respectively, of the Units issued in connection with the organization of NEO. An additional 13.5% of such Units will be reserved for issuance as incentives for key employees and consultants. As of September 30, 2020, GEN2 had received $975,000 of investments to contribute to NEO. As of April 30, 2020, the Company controlled 51% of the joint venture, GEN2 controlled 39% and another individual controlled the remaining 10%.

Effective April 30, 2020, the joint venture with GEN2 was reorganized. GEN2 shareholders exchanged their common shares in GEN2, and the individual exchanged his membership interests in NEO, for common shares representing 49% ownership in PSI. The Company retained its common shares in PSI, which provides the Company a 51% economic interest in the PSI technology and products developed by the joint venture. During three and six months ended March 31, 2021, PSI recorded a loss of $187,077 and $338,510, respectively, relating to its operations, of which $91,668 and $165,870, respectively, was allocated to the non-controlling interest.

Repayment of the $975,000 investment will begin through and upon the date which PSI has realized and retained cumulative net income/distributable cash in the amount of $300,000. The minority interest of PSI ownership consists of accredited investors, and investment participation of $750,000 from several WCUI officers and directors, including Calvin R. O’Harrow and Roy M. Harsch.

In May 2020, the Company’s subsidiary, PSI, agreed to become a majority shareholder in Protec Scientific, Inc. (“Protec”), a company formed in April 2020 by John Yorke for the purpose of designing, developing and marketing products that use spectral photonic emissions across a variety of applications. As of September 30, 2020, PSI had advanced $191,000 to Protec in furtherance of its agreement to acquire approximately 62% of Protec, with the Company’s share being approximately 32%, based on its PSI ownership. The remaining 30% share is to be attributed to PSI’s minority shareholders, based on their PSI ownership. During the year ended September 30, 2020, Protec received an additional $120,000 from non-affiliated investors, of which $74,400 was recorded to additional paid-in capital and $45,600 to the non-controlling interests. The additional investments gave the non-controlling interests a 38% ownership interest in Protec. During the three and six months ended March 31, 2021, Protec recorded a loss of $141,365 and $242,857, respectively, of which $96,665 and $166,065 was allocated to the non-controlling interests.

Psoria-Light

PSI designs, develops and markets a targeted ultraviolet (“UV”) phototherapy device called the Psoria-Light. The Psoria-Light is designated for use in targeted PUVA photochemistry and UVB phototherapy and is designed to treat certain skin conditions including psoriasis, vitiligo, atopic dermatitis (eczema), seborrheic dermatitis, and leukoderma.

Psoriasis, eczema, and vitiligo, are common skin conditions that can be challenging to treat, and often cause the client significant psychosocial stress. Clients may undergo a variety of treatments to address these skin conditions, including routine consumption of systemic and biologic drug therapies which are highly toxic, reduce systemic immune system function, and come with a host of chemotherapy-like side effects. Ultraviolet (UV) phototherapy is a clinically validated alternate treatment modality for these disorders.

Traditionally, “non-targeted” UV phototherapy was administered by lamps that emitted either UVA or UVB light to both diseased and healthy skin. While sunblocks or other UV barriers may be used to protect healthy skin, the UV administered in this manner must be low dosage to avoid excessive exposure of healthy tissue. Today, “targeted” UV phototherapy devices administer much higher dosages of light only to affected tissue, resulting in “clearance” in the case of psoriasis and eczema, and “repigmentation” in the case of vitiligo, at much faster rates than non-targeted (low dosage) UV treatments.

Targeted UV treatments are typically administered to smaller total body surface areas, and are therefore used to treat the most intense parts of a client’s disease. Non-targeted UV treatment is typically used as a follow-up and for maintenance, capable of treating large surfaces of the body. Excimer laser devices (UVB at 308nm) are expensive and consume dangerous chemicals (Xenon and Chlorine). Mercury lamp devices (UVB and/or UVA) require expensive lamp replacements regularly and require special disposal (due to mercury content). Additionally, mercury lamp devices typically deliver wavelengths of light below 300nm. While within the UVB spectrum, it has been shown that wavelengths below 300nm produce significantly more “sunburn” type side effects than do wavelengths between 300 and 320nm without improvement in therapeutic benefit.

The Psoria-Light is a targeted UV phototherapy device that produces UVB light between 300 and 320 nm as well as UVA light between 350 and 395nm. It does not require consumption of dangerous chemicals or require special environmental disposal, and is cost effective for clinicians, which should result in increased patient access to this type of treatment. It has several unique and advanced features that we believe will distinguish it from the non-targeted and targeted UV phototherapy devices that are currently being used by dermatologists and other healthcare providers. These features include the following: the utilization of deep narrow-band UVB (“NB-UVB”) LEDs as light sources; the ability to produce both UVA or NB-UVB therapeutic wavelengths; an integrated high resolution digital camera and client record integration capabilities; the ability to export to an external USB memory device a PDF file of treatment information including a patent pending graph that includes digital images plotted against user tracked metrics which can be submitted to improve medical reimbursements; an accessory port and ability to update software; ease of placement and portability; advanced treatment site detection safety sensor; international language support; a warranty which includes the UV lamp(s); and a non-changeable treatment log (that does not include HIPPA information).

The Psoria-Light consists of three components: a base console, a color display with touchscreen control, and a hand-held delivery device with a conduit (or tether) between the handheld device and the base console. PSI requires clearance by the United States Food and Drug Administration (“FDA”) to market and sell the device in the United States as well as permission from TUV SUD America Inc., PSI’s Notified Body, to affix the CE mark to the Psoria-Light in order to market and sell the device in countries of the European Union.

To obtain FDA clearance and permission to affix the CE mark, PSI was required to conduct EMC and electrical safety testing, which it completed in the second quarter of 2011. PSI received FDA clearance on February 11, 2011 (no. K103540) and was granted permission to affix the CE mark on November 10, 2011. In its 510(k) application with the FDA (application number K103540), PSI asserted that the Psoria-Light was “substantially equivalent” in intended use and technology to two predicate devices, the X -Trac Excimer Laser, which has wide acceptance in the medical billing literature and has a large installed base in the U.S., and the Dualight, another competing targeted UV phototherapy device.

PSI has established an ISO 13485 compliant quality system for the Psoria-Light, which was first audited in the third quarter of 2011. This system is intended to ensure PSI devices will be manufactured in a controlled and reliable environment and that its resources follow similar practices and is required for sales in countries requiring a CE mark. PSI has also received Certified Space Technology designation from the Space Foundation, based on PSI’s incorporation of established NASA-funded LED technology.

PSI began Psoria-Light Beta deployment in January 2012. It is currently operating at a loss, and there is no assurance that its business development plans and strategies will ever be successful. PSI’s success depends upon the acceptance by healthcare providers and clients of Psoria-Light treatment as a preferred method of treatment for psoriasis and other UV-treatable skin conditions. Psoria-Light treatment appears to have been beneficial to clients, without demonstrable harmful side effects or safety issues, as evidenced by more than 10,000 treatments completed on more than 1,000 clients, domestically and Mexico, since 2012. In order for the Company to continue PSI operations, it will need additional capital and it will have to successfully coordinate integration of PSI operations without materially and adversely affecting continuation and development of other Company operations.

SCI

SCI was incorporated under the laws of the state of Illinois on March 18, 2014. SCI acquired certain Stealth Mark assets on April 4, 2014 and operates as a wholly-owned subsidiary of the Company. It is a provider of: a) Stealth Mark encryption and authentication solutions offering advanced technologies within the security and supply chain management vertical sectors (Intelligent Microparticles), and b) advanced data intelligence services offering proprietary, unprecedented, and actionable technology for industries, companies, and agencies on a global scale (ActiveDuty™).

Intelligent Microparticles

SCI provides clients premiere authentication technology for the protection of a variety of products and brands from illicit counterfeiting and diversion activities. Its technology is applicable to a wide range of industries affected by counterfeiting, diversion and theft including, but not limited to, pharmaceuticals, defense/aerospace, automotive, electronics, technology, consumer and personal care goods, designer products, beverage/spirits, and many others.

SCI delivers the client a complete, simple to use, easy to implement, and cost effective turnkey system that is extremely difficult to compromise. SCI’s technology includes a combination of proprietary software and intelligent microparticle marks that are unduplicatable and undetectable to the human eye. These taggants are created with proprietary materials that create unique numerical codes that are assigned meaning by the client and are machine readable without the use of rare earth or chemical tracers. They have been used in covert and overt operations with easy to implement technology and do-it-yourself in-the-field forensic caliber verification.

In April 2018, the Company’s subsidiary, SCI, concluded licensing of a patent for technology that is the next generation of Stealth Mark. Working with researchers at the Oak Ridge National Labs, the patent signifies development of a new technology that will generate an invisible marking system with attributes currently unavailable in the anti-counterfeit marketplace today. The formula and techniques have been shown through extensive testing to be resilient to manufacturing processes and can be used on a wide range of materials from woven and non-woven fabrics, cardboard, metal, concrete, plastics, leather, wood, and paper. In addition, the complexity of the information that can be encoded with the system makes counterfeiting difficult.

ActiveDuty™

SCI’s ActiveDuty™ data intelligence services offer unique, unprecedented, actionable technology for industries, companies, and agencies on a global scale. Comprised of a suite of powerful analytical tools, including artificial intelligence and social-psychology, the service provides timely and actionable intelligence to clients. ActiveDuty™ is adaptable to a broad spectrum of illicit activities within both private and public sectors such as, but not limited to, counterfeiting, sex and human trafficking, money laundering, and a variety of other markets.

The proprietary algorithmic architecture of ActiveDuty™ creates the first systemic reporting mechanism to deliver strategic and tactical results supported by an intense worldwide analysis of patterns of human behavior. The ActiveDuty™ global framework is heuristic in nature, capable of comprehending big data across the digital spectrum and speaks all the major languages. Up until now, there has not existed a unified system that could actively measure this lifecycle that is a collection of discreet and seemingly random behaviors of criminals anywhere within the digital domain. Criminals change their identities but not their basic behaviors.

Analysis of Financial Condition and Results of Operations

Results of Operations for the three months ended March 31, 2021 compared to the three months ended March 31, 2020.

Revenue and Cost of Goods Sold

Revenue for the three months ended March 31, 2021 and 2020 was $51,650 and $5,000, respectively. The increase in revenue in 2021 related to the increase in revenues at PSI due to the roll-out of their new Aurora medical device. Cost of sales for the three months ended March 31, 2021 was $58,950. There was no cost of sales for the three months ended March 31, 2020. Gross profit (deficit) for the three months ended March 31, 2021 and 2020 was ($7,300) and $5,000, respectively. The reason for the gross deficit in 2021 was due to inventory write downs of $50,000.

Operating Expenses

Operating expenses for the three months ended March 31, 2021 and 2020 were $362,218 and $423,130, respectively. The decrease in operating expenses in 2021 was due primarily to the decrease in consulting fees, employee-related costs and stock compensation.

Other Expenses

Other expenses during the three months ended March 31, 2021 consisted of $ $31,993 of interest expense. Other expenses during the three months ended March 31, 2020 consisted of $507,265 relating to the cost of the modification of terms of stock warrants and $16,211 of interest expense, totaling to $523,476.

Net Loss

Our net loss for the three months ended March 31, 2021 was $401,511, compared to a net loss of $941,606 for the three months ended March 31, 2020. The decrease in the net loss in 2021 was primarily due to the decrease in operating and other expenses.

Results of Operations for the six months ended March 31, 2021 compared to the six months ended March 31, 2020.

Revenue and Cost of Goods Sold

Revenue for the six months ended March 31, 2021 and 2020 was $142,149 and $5,000, respectively. The increase in revenue in 2021 related to the increase in revenues at PSI due to the roll-out of their new Aurora medical device. Cost of sales for the six months ended March 31, 2021 was $139,050. There was no cost of sales for the six months ended March 31, 2020. Gross profit for the six months ended March 31, 2021 and 2020 was $3,099 and $5,000, respectively. The reason for the low margin in 2021 was due to inventory write downs of $100,000.

Operating Expenses

Operating expenses for the six months ended March 31, 2021 and 2020 were $670,759 and $760,403, respectively. The decrease in operating expenses in 2021 was due primarily to the decrease in consulting fees, employee-related costs and stock compensation.

Other Expenses

Other expenses during the six months ended March 31, 2021 consisted of $58,151 of interest expense. Other expenses during the six months ended March 31, 2020 consisted of $507,265 relating to the cost of the modification of terms of stock warrants and $25,534 of interest expense, totaling to $532,799.

Net Loss

Our net loss for the six months ended March 31, 2021 was $725,811, compared to a net loss of $1,288,202 for the six months ended March 31, 2020. The decrease in the net loss in 2021 was primarily due to the decrease in operating and other expenses.

Results of Operations by Segment

The Company currently maintains two business segments:

(i)

Medical Devices: which it provided through PSI, its subsidiary acquired on August 24, 2012, a developer, manufacturer, marketer and distributer of targeted Ultra Violet (“UV”) phototherapy devices for the treatment of skin diseases; and

(ii)

Authentication and Encryption Products and Services: which it provided through SCI, its wholly-owned subsidiary that on April 4, 2014 acquired certain assets of SMI Holdings, Inc. d/b/a Stealth Mark, Inc., including Stealth Mark tradenames and marks, and related encryption and authentication solutions offering advanced product security technologies within the security and supply chain management vertical sectors.

The detailed segment information of the Company is as follows:

Operations by Segment for the Three Months Ended March 31, 2021 and 2020

	For the Three Months Ended
	March 31, 2021
	Corporate			Medical Devices			Authentication and Encryption			Total

Trade Sales	$	-		$	51,650		$	-		$	51,650

Cost of goods sold		-			58,950			-			58,950

Gross profit		-			(7,300	)		-			(7,300	)

Operating expenses		46,661			308,543			7,014			362,218

Loss from operations	$	(46,661	)	$	(315,843	)	$	(7,014	)	$	(369,518	)

	For the Three Months Ended
	March 31, 2020
	WCUI			PSI			Stealthco
	Corporate			Medical Devices			Authentication and Encryption			Total

Trade Sales	$	-		$	-		$	5,000		$	5,000

Cost of goods sold		-			-			-			-

Gross profit		-			-			5,000			5,000

Operating expenses		142,500			206,824			73,806			423,130

Loss from operations	$	(142,500	)	$	(206,824	)	$	(68,806	)	$	(418,130	)

Revenue for the Medical Devices segment for the three months ended March 31, 2021 was $51,650. There was no revenue or cost of goods sold for the Medical Devices segment for the three months ended March 31, 2020. The increase in 2021 was due to the increase in trade sales. Cost of goods sold for the three months ended March 31, 2021 was $58,950 and the gross deficit was $7,300. The negative gross profit was primarily due to the write down of inventories of $50,000 during the quarter. Operating expenses for the three months ended March 31, 2021 and 2020 was $308,543 and $206,824, respectively. The increase in operating expenses in 2021 was primarily due to the increase in employee-related costs and contract labor. The loss from operations for the three months ended March 31, 2021 and 2020 was $315,843 and $206,824, respectively.

Revenue for the Authentication and Encryption segment for the three months ended March 31, 2020 was $5,000. There was no revenue or cost of goods sold for the Authentication and Encryption segment for the three months ended March 31, 2021. The decrease in revenues in 2021 was due to the decrease in trade sales and consulting services. There was no cost of goods sold for the three months ended March 31, 2020 and the gross profit was $5,000. The gross profit decrease in 2021 was due to the decrease in sales. Operating expenses for the three months ended March 31, 2021 and 2020 was $7,014 and $73,806, respectively. The decrease in operating expenses in 2021 was primarily due to the decrease in stock compensation costs and employee-related costs. The loss from operations for the three months ended March 31, 2021 and 2020 was $7,014 and $68,806, respectively.

The Corporate segment primarily provides executive management services for the Company. Operating expenses for the three months ended March 31, 2021 and 2020 was $46,661 and $142,500, respectively. The decrease in operating expenses in 2021 was primarily due to the decrease in professional fees and stock compensation. The loss from operations for the three months ended March 31, 2021 and 2020 was $46,661 and $142,500, respectively.

Operations by Segment for the Six Months Ended March 31, 2021 and 2020

	For the Six Months Ended
	March 31, 2021
	Corporate			Medical Devices			Authentication and Encryption			Total

Trade Sales	$	-		$	142,149		$	-		$	142,149

Cost of goods sold		-			139,050			-			139,050

Gross profit		-			3,099			-			3,099

Operating expenses		95,770			565,014			9,975			670,759

Loss from operations	$	(95,770	)	$	(561,915	)	$	(9,975	)	$	(667,660	)

	For the Six Months Ended
	March 31, 2020
	WCUI			PSI			Stealthco
	Corporate			Medical Devices			Authentication and Encryption			Total

Trade Sales	$	-		$	-		$	5,000		$	5,000

Cost of goods sold		-			-			-			-

Gross profit		-			-			5,000			5,000

Operating expenses		240,962			382,110			137,331			760,403

Loss from operations	$	(240,962	)	$	(382,110	)	$	(132,331	)	$	(755,403	)

Revenue for the Medical Devices segment for the six months ended March 31, 2021 was $142,149. There was no revenue or cost of goods sold for the Medical Devices segment for the six months ended March 31, 2020. The increase in 2021 was due to the increase in trade sales. Cost of goods sold for the six months ended March 31, 2021 was $139,050 and the gross profit was $3,099. The low profit margin in 2021 was primarily due to the write down of inventories of $100,000 in 2021. Operating expenses for the six months ended March 31, 2021 and 2020 was $565,014 and $382,110, respectively. The increase in operating expenses in 2021 was primarily due to the increase in employee-related costs and contract labor. The loss from operations for the six months ended March 31, 2021 and 2020 was $561,915 and $382,110, respectively.

Revenue for the Authentication and Encryption segment for the six months ended March 31, 2020 was $5,000. There was no revenue or cost of goods sold for the Authentication and Encryption segment for the six months ended March 31, 2021. The decrease in revenues in 2021 was due to the decrease in trade sales and consulting services. There was no cost of goods sold for the six months ended March 31, 2020 and the gross profit was $5,000. The gross profit decrease in 2021 was due to the decrease in sales. Operating expenses for the six months ended March 31, 2021 and 2020 was $9,975 and $137,331, respectively. The decrease in operating expenses in 2021 was primarily due to the decrease in stock compensation costs and employee-related costs. The loss from operations for the six months ended March 31, 2021 and 2020 was $9,975 and $132,331, respectively.

The Corporate segment primarily provides executive management services for the Company. Operating expenses for the six months ended March 31, 2021 and 2020 was $95,770 and $240,962, respectively. The decrease in operating expenses in 2021 was primarily due to the decrease in professional fees and stock compensation. The loss from operations for the six months ended March 31, 2021 and 2020 was $95,770 and $240,962, respectively.

Liquidity and Capital Resources

Comparison of six months ended March 31, 2021 and 2020

As of March 31, 2021, we had $146,139 in cash, negative working capital of $2,813,176 and an accumulated deficit of $27,977,238.

As of March 31, 2020, we had $40,146 in cash, negative working capital of $1,700,895 and an accumulated deficit of $26,606,310.

Cash flows used in operating activities

During the six months ended March 31, 2020, the Company used cash flows in operating activities of $533,001, compared to $565,181 used in the six months ended March 31, 2021. During the six months ended March 31, 2020, the Company incurred a net loss of $1,288,202 and $650,848 of non-cash expenses, compared to a net loss of $725,811 and $211,975 of non-cash expenses during the six months ended March 31, 2021.

Cash flows used in investing activities

During the six months ended March 31, 2021 and 2020, the Company had no cash flows from investing activities.

Cash flows provided by financing activities

During the six months ended March 31, 2021, the Company had proceeds from loans payable from officers and shareholders of $660,000. During the six months ended March 31, 2020, the Company had proceeds from loans payable from officers and shareholders of $470,000 and proceeds of $50,000 from contributions of capital by its joint venture partner.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

Summary of Critical Accounting Policies.

The Company has identified critical accounting policies that, as a result of the judgments, uncertainties, uniqueness and complexities of the underlying accounting standards and operations involved could result in material changes to its financial condition or results of operations under different conditions or using different assumptions. The Company’s most critical accounting policies include, but are not limited to, those related to fair value of financial instruments, revenue recognition, stock based compensation for obtaining employee services, and equity instruments issued to parties other than employees for acquiring goods or services. Details regarding the Company’s use of these policies and the related estimates are described in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2020, filed with the Securities and Exchange Commission on February 8, 2021. There have been no material changes to the Company’s critical accounting policies that impact the Company’s financial condition, results of operations or cash flows for the six months ended March 31, 2021.

Recently Issued Accounting Pronouncements

See Management’s discussion of recent accounting policies included in footnote 2 to the condensed consolidated financial statements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Not required for smaller reporting Companies.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Regulations under the Securities Exchange Act of 1934 (the “Exchange Act”) require public companies to maintain “disclosure controls and procedures,” which are defined as controls and other procedures that are designed to ensure that information required to be disclosed by the issuer in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. A material weakness is a control deficiency (within the meaning of the Public Company Accounting Oversight Board (PCAOB) Auditing Standard 2201) or combination of control deficiencies that result in more than a remote likelihood that a material misstatement of the annual or interim financial statements will not be prevented or detected.

The Company carried out an evaluation, with the participation of the Company’s management, including the Company’s Chief Executive Officer (“CEO”), of the effectiveness of the Company’s disclosure controls and procedures (as defined under Rule 13a-15(e) under the Exchange Act) as of March 31, 2021, the end of the period covered by this report. Based upon that evaluation, the Company’s CEO concluded that the Company’s disclosure controls and procedures are not effective at the reasonable assurance level due to the material weaknesses described below:

1. The lack of an independent audit committee and the lack of internal personnel necessary to provide accurate and timely regulatory filings.

2. The Company does not have written documentation of its internal control policies and procedures. Written documentation of key internal controls over financial reporting is a requirement of Section 404 of the Sarbanes-Oxley Act which is applicable to the Company. Management evaluated the impact of its failure to have written documentation of its internal controls and procedures on its assessment of its disclosure controls and procedures and has concluded that the control deficiency that resulted represented a material weakness.

3. The Company does not have sufficient segregation of duties within its accounting functions, which is a basic internal control. Due to its size and nature, segregation of all conflicting duties may not always be possible and may not be economically feasible. However, to the extent possible, the initiation of transactions, the custody of assets and the recording of transactions should be performed by separate individuals. Management evaluated the impact of its failure to have segregation of duties on its assessment of its disclosure controls and procedures and has concluded that the control deficiency that resulted represented a material weakness.

4. The Company does not have sufficient segregation of duties so that one person can initiate, authorize and execute transactions.

5. The Company has insufficient full time personnel with an appropriate level of technical accounting knowledge to SEC reporting requirements to timely meet the filing requirements

In light of the material weaknesses, the management of the Company performed additional analysis and other post-closing procedures to ensure our consolidated financial statements were prepared in accordance with the accounting principles generally accepted in the United States of America. Accordingly, we believe that our consolidated financial statements included herein fairly present, in all material respects, our consolidated financial condition, consolidated results of operations and cash flows as of and for the reporting periods then ended.

Changes in internal control over financial reporting.

There have been no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15 (f) under the Exchange Act) during the six months ended March 31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

The Company is periodically engaged in legal proceedings arising from and relating to its business operations. Except as otherwise described herein, we currently are not involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our Company or any of our subsidiaries, threatened against or affecting our Company, our common stock, any of our subsidiaries or of our Company’s or our subsidiaries’ officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect on our financial condition or results of operations.

On or about June 29, 2020, the Company received notice that Hanover Hoffman Estates, LLC (“HHE”), filed case number 2020L006092 in the Circuit Court of Cook County alleging failure to pay Base Rent and abandonment of certain office space in Hoffman Estates, Illinois subject to a Commercial Lease dated May 26, 2016. HHE seeks at least $672,888 in base rent and other amounts under the lease, as well as treble damages from our ex-CEO and two past Directors who were serving on our Board as of the date of the lease. The Company has continued evaluation of the allegations, defenses and alternate actions, and it is engaged settlement negotiations which are on-going.

Item 1A. Risk Factors

Not required for smaller reporting companies.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None

Item 6. Exhibits

Exhibit No.		Description
31.1		Certification of Principal Executive Officer Pursuant to Rule 13a-14*
31.2		Certification of Principal Financial Officer Pursuant to Rule 13a-14*
32.1		CEO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act*
32.2		CFO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act*
101.INS		XBRL Instance Document**
101.SCH		XBRL Taxonomy Extension Schema**
101.CAL		XBRL Taxonomy Extension Calculation Linkbase**
101.DEF		XBRL Taxonomy Extension Definition Linkbase**
101.LAB		XBRL Taxonomy Extension Label Linkbase**
101.PRE		XBRL Taxonomy Extension Presentation Linkbase**

* Filed herewith.

**Pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933 or Section 18 of the Securities Exchange Act of 1934 and otherwise are not subject to liability.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, there unto duly authorized.

	WELLNESS CENTER USA, INC.

Date: July 1, 2021	By:	/s/ Paul D. Jones
		Paul D. Jones President
		(Duly Authorized Principal Executive Officer)

	WELLNESS CENTER USA, INC.

Date: July 1, 2021	By:	/s/ Douglas W. Samuelson
		Douglas W. Samuelson Chief Financial Officer and Principal Accounting Officer
		(Duly Authorized Principal Accounting Officer)

POWER OF ATTORNEY

Each person whose signature appears below hereby constitutes and appoints severally Paul D. Jones, his true and lawful attorney-in-fact and agent, with full power of substitution and re-substitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, and hereby grants to such attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

SIGNATURE	TITLE	DATE

/s/ Calvin O’Harrow	Chief Executive Officer, Director	July 1, 2021
Calvin O’Harrow

/s/ Douglas W. Samuelson	Chief Financial Officer and Principal Accounting Officer	July 1, 2021
Douglas W. Samuelson

/s/ Paul D. Jones	Director, President	July 1, 2021
Paul D. Jones

/s/ Thomas E. Scott

Director, Secretary

July 1, 2021

Thomas E. Scott

/s/ William E. Kingsford	Director	July 1, 2021
William E. Kingsford

/s/ Roy M. Harsch	Director, Chairman	July 1, 2021
Roy M. Harsch

EX-31.1 2 ex31-1.htm

Exhibit 31.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Calvin O’Harrow, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Wellness Center USA, Inc. for the quarterly period ended March 31, 2021;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) designed such disclosure controls and procedures, or caused such internal control over financial reporting to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, if any, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period cover by this report based on such evaluation; and

d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting;

Date: July 1, 2021

	/s/ Calvin O’Harrow
Name:	Calvin O’Harrow
Title:	Chief Executive Officer and Director

EX-31.2 3 ex31-2.htm

Exhibit 31.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Douglas W. Samuelson, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Wellness Center USA, Inc. for the quarterly period ended March 31, 2021;

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting;

Date: July 1, 2021

	/s/ Douglas W. Samuelson
Name:	Douglas W. Samuelson
Title:	Chief Accounting Officer and Chief Financial Officer

EX-32.1 4 ex32-1.htm

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2021 of Wellness Center USA, Inc., a Nevada corporation (the “Company”), as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Calvin O’Harrow, Chief Executive Officer and Director of the Company, certify, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of Section 13(a) or15(d) of the Securities and Exchange Act of 1934, as amended; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

Date: July 1, 2021

	/s/ Calvin O’Harrow
Name:	Calvin O’Harrow
Title:	Chief Executive Officer and Director

EX-32.2 5 ex32-2.htm

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2021 of Wellness Center USA, Inc., a Nevada corporation (the “Company”), as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Douglas W. Samuelson, Chief Accounting Officer and Chief Financial Officer of the Company certify, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of Section 13(a) or15(d) of the Securities and Exchange Act of 1934, as amended; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

Date: July 1, 2021

	/s/ Douglas W. Samuelson
Name:	Douglas W. Samuelson
Title:	Chief Accounting Officer and Chief Financial Officer

EX-101.INS 6 wcui-20210331.xml XBRL INSTANCE FILE 0001516887 2021-01-01 2021-03-31 0001516887 WCUI:TwoThousandTenNonQualifiedStockOptionPlanMember 2018-01-02 0001516887 us-gaap:CommonStockMember 2019-09-30 0001516887 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001516887 us-gaap:RetainedEarningsMember 2019-09-30 0001516887 WCUI:TotalWCUIDeficitMember 2019-09-30 0001516887 us-gaap:NoncontrollingInterestMember 2019-09-30 0001516887 us-gaap:CorporateMember 2019-10-01 2020-03-31 0001516887 WCUI:MedicalDevicesMember 2019-10-01 2020-03-31 0001516887 WCUI:AuthenticationandEncryptionMember 2019-10-01 2020-03-31 0001516887 WCUI:GEN2Member 2019-09-30 0001516887 2019-09-30 0001516887 2019-02-28 0001516887 2019-02-01 2019-02-28 0001516887 us-gaap:CommonStockMember 2020-03-31 0001516887 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001516887 us-gaap:RetainedEarningsMember 2020-03-31 0001516887 WCUI:TotalWCUIDeficitMember 2020-03-31 0001516887 us-gaap:NoncontrollingInterestMember 2020-03-31 0001516887 2020-03-31 0001516887 us-gaap:IndividualMember 2020-04-30 0001516887 WCUI:BoardOfDirectorsMember 2020-04-01 2020-04-30 0001516887 WCUI:VestMonthlyAprilTwoThousandTwentyThroughMarchTwoThousandAndTwentyOneMember 2020-04-01 2020-04-30 0001516887 WCUI:VestMonthlyAprilTwoThousandTwentyThroughMarchTwoThousandAndTwentyThreeMember 2020-04-01 2020-04-30 0001516887 WCUI:VestOverTimeMember 2020-04-01 2020-04-30 0001516887 WCUI:ProtecScientificIncMember 2020-05-01 2020-05-30 0001516887 WCUI:HanoverHoffmanEstatesLLCMember 2020-06-28 2020-06-29 0001516887 2020-09-30 0001516887 us-gaap:CommonStockMember 2020-09-30 0001516887 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001516887 us-gaap:RetainedEarningsMember 2020-09-30 0001516887 WCUI:TotalWCUIDeficitMember 2020-09-30 0001516887 us-gaap:NoncontrollingInterestMember 2020-09-30 0001516887 us-gaap:CorporateMember 2021-03-31 0001516887 WCUI:MedicalDevicesMember 2021-03-31 0001516887 WCUI:AuthenticationandEncryptionMember 2021-03-31 0001516887 us-gaap:CorporateMember 2020-10-01 2021-03-31 0001516887 WCUI:MedicalDevicesMember 2020-10-01 2021-03-31 0001516887 WCUI:AuthenticationandEncryptionMember 2020-10-01 2021-03-31 0001516887 WCUI:TwoThousandTenNonQualifiedStockOptionPlanMember 2017-12-29 0001516887 srt:MinimumMember 2020-10-01 2021-03-31 0001516887 srt:MaximumMember 2020-10-01 2021-03-31 0001516887 srt:MinimumMember 2020-09-30 0001516887 srt:MaximumMember 2020-09-30 0001516887 WCUI:ExercisePriceRangeOneMember 2020-10-01 2021-03-31 0001516887 WCUI:ExercisePriceRangeTwoMember 2020-10-01 2021-03-31 0001516887 WCUI:ExercisePriceRangeTwoMember 2020-12-31 0001516887 us-gaap:WarrantMember 2020-09-30 0001516887 us-gaap:WarrantMember srt:MinimumMember 2020-10-01 2021-03-31 0001516887 us-gaap:WarrantMember srt:MinimumMember 2020-09-30 0001516887 us-gaap:WarrantMember srt:MaximumMember 2020-10-01 2021-03-31 0001516887 us-gaap:WarrantMember srt:MaximumMember 2020-09-30 0001516887 WCUI:StockOptionsMember 2020-10-01 2021-03-31 0001516887 WCUI:StockOptionsMember 2019-10-01 2020-03-31 0001516887 WCUI:WarrantsMember 2020-10-01 2021-03-31 0001516887 WCUI:WarrantsMember 2019-10-01 2020-03-31 0001516887 WCUI:PsoriaShieldIncMember 2021-03-31 0001516887 WCUI:ProtecScientificIncMember 2020-10-01 2021-03-31 0001516887 WCUI:PsoriaShieldIncMember 2020-10-01 2021-03-31 0001516887 WCUI:StealthCoIncMember 2020-10-01 2021-03-31 0001516887 WCUI:StealthCoIncMember 2021-03-31 0001516887 WCUI:StealthCoIncMember 2020-09-30 0001516887 WCUI:PsoriaDevelopmentCompanyLLCMember 2020-10-01 2021-03-31 0001516887 WCUI:PsoriaDevelopmentCompanyLLCMember 2021-03-31 0001516887 WCUI:PsoriaDevelopmentCompanyLLCMember 2020-09-30 0001516887 WCUI:NeoPhototherapyLLCMember 2020-10-01 2021-03-31 0001516887 WCUI:NeoPhototherapyLLCMember 2021-03-31 0001516887 WCUI:NeoPhototherapyLLCMember 2020-09-30 0001516887 WCUI:ProtecScientificIncMember 2020-09-30 0001516887 WCUI:AprilTwentyTwoThousandTwentyMember 2020-10-01 2021-03-31 0001516887 2020-12-31 0001516887 us-gaap:CommonStockMember 2020-12-31 0001516887 us-gaap:CommonStockMember 2019-12-31 0001516887 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001516887 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001516887 us-gaap:RetainedEarningsMember 2020-12-31 0001516887 us-gaap:RetainedEarningsMember 2019-12-31 0001516887 WCUI:TotalWCUIDeficitMember 2020-12-31 0001516887 WCUI:TotalWCUIDeficitMember 2019-12-31 0001516887 us-gaap:NoncontrollingInterestMember 2020-12-31 0001516887 us-gaap:NoncontrollingInterestMember 2019-12-31 0001516887 2019-12-31 0001516887 WCUI:PsoriaShieldIncMember 2020-09-30 0001516887 us-gaap:RestrictedStockMember 2020-10-01 2021-03-31 0001516887 us-gaap:RestrictedStockMember 2021-03-31 0001516887 us-gaap:StockOptionMember 2020-10-01 2021-03-31 0001516887 us-gaap:StockOptionMember 2021-03-31 0001516887 us-gaap:StockOptionMember WCUI:TwoThousandTenPlanMember 2021-03-31 0001516887 us-gaap:WarrantMember 2021-03-31 0001516887 us-gaap:WarrantMember 2020-10-01 2021-03-31 0001516887 us-gaap:WarrantMember WCUI:ExercisePriceRangeOneMember 2020-10-01 2021-03-31 0001516887 us-gaap:WarrantMember WCUI:ExercisePriceRangeOneMember 2021-03-31 0001516887 us-gaap:WarrantMember WCUI:ExercisePriceRangeTwoMember 2020-10-01 2021-03-31 0001516887 us-gaap:WarrantMember WCUI:ExercisePriceRangeTwoMember 2021-03-31 0001516887 us-gaap:SubsequentEventMember WCUI:BoardOfDirectorsMember WCUI:AprilTwoThousandTwentyThreeThroughMarchTwoThousandTwentyFourMember 2021-03-29 2021-04-01 0001516887 us-gaap:SubsequentEventMember WCUI:OfficersandDirectorsMember WCUI:AprilTwoThousandTwentyFiveMember 2021-03-29 2021-04-01 0001516887 us-gaap:SubsequentEventMember WCUI:OfficersandDirectorsMember 2021-03-29 2021-04-01 0001516887 us-gaap:SubsequentEventMember WCUI:CEOMember WCUI:AprilTwoThousandTwentyThreeThroughMarchTwoThousandTwentyFourMember 2021-03-29 2021-04-01 0001516887 us-gaap:SubsequentEventMember WCUI:CEOMember WCUI:AprilTwoThousandTwentyThreeThroughMarchTwoThousandTwentyFourMember 2021-04-01 0001516887 us-gaap:SubsequentEventMember WCUI:CEOMember 2021-03-29 2021-04-01 0001516887 us-gaap:SubsequentEventMember WCUI:CEOMember 2021-04-01 0001516887 us-gaap:SubsequentEventMember WCUI:CEOMember WCUI:AprilTwoThousandTwentyFiveMember 2021-03-29 2021-04-01 0001516887 us-gaap:SubsequentEventMember WCUI:CEOMember WCUI:SeptemberTwoThousandTwentyOneThroughDecemberTwoThousandTwentyOneMember 2021-03-29 2021-04-01 0001516887 2021-03-31 0001516887 2020-01-01 2020-03-31 0001516887 2020-10-01 2021-03-31 0001516887 2019-10-01 2020-03-31 0001516887 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001516887 us-gaap:CommonStockMember 2021-03-31 0001516887 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001516887 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001516887 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001516887 us-gaap:RetainedEarningsMember 2021-03-31 0001516887 WCUI:TotalWCUIDeficitMember 2021-01-01 2021-03-31 0001516887 WCUI:TotalWCUIDeficitMember 2021-03-31 0001516887 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-03-31 0001516887 us-gaap:NoncontrollingInterestMember 2021-03-31 0001516887 us-gaap:CommonStockMember 2020-10-01 2021-03-31 0001516887 us-gaap:AdditionalPaidInCapitalMember 2020-10-01 2021-03-31 0001516887 us-gaap:RetainedEarningsMember 2020-10-01 2021-03-31 0001516887 WCUI:TotalWCUIDeficitMember 2020-10-01 2021-03-31 0001516887 us-gaap:NoncontrollingInterestMember 2020-10-01 2021-03-31 0001516887 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001516887 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001516887 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001516887 WCUI:TotalWCUIDeficitMember 2020-01-01 2020-03-31 0001516887 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-03-31 0001516887 us-gaap:CommonStockMember 2019-10-01 2020-03-31 0001516887 us-gaap:AdditionalPaidInCapitalMember 2019-10-01 2020-03-31 0001516887 us-gaap:RetainedEarningsMember 2019-10-01 2020-03-31 0001516887 WCUI:TotalWCUIDeficitMember 2019-10-01 2020-03-31 0001516887 us-gaap:NoncontrollingInterestMember 2019-10-01 2020-03-31 0001516887 WCUI:ProtecScientificIncMember 2020-10-01 2021-03-31 0001516887 WCUI:AprilTwentyTwoThousandTwentyMember 2021-03-31 0001516887 us-gaap:RestrictedStockMember 2021-01-01 2021-03-31 0001516887 us-gaap:StockOptionMember 2021-01-01 2021-03-31 0001516887 WCUI:AprilTwentyTwoThousandTwentyMember 2021-01-01 2021-03-31 0001516887 WCUI:ProtecScientificIncMember 2021-01-01 2021-03-31 0001516887 WCUI:ProtecScientificIncMember 2020-09-30 0001516887 srt:MinimumMember 2021-03-31 0001516887 srt:MaximumMember 2021-03-31 0001516887 WCUI:ExercisePriceRangeOneMember 2021-03-31 0001516887 us-gaap:WarrantMember srt:MinimumMember 2021-03-31 0001516887 us-gaap:WarrantMember srt:MaximumMember 2021-03-31 0001516887 WCUI:ProtecScientificIncMember 2021-03-31 0001516887 us-gaap:CorporateMember 2021-01-01 2021-03-31 0001516887 WCUI:MedicalDevicesMember 2021-01-01 2021-03-31 0001516887 WCUI:AuthenticationandEncryptionMember 2021-01-01 2021-03-31 0001516887 us-gaap:CorporateMember 2020-01-01 2020-03-31 0001516887 WCUI:MedicalDevicesMember 2020-01-01 2020-03-31 0001516887 WCUI:AuthenticationandEncryptionMember 2020-01-01 2020-03-31 0001516887 WCUI:PsoriaShieldIncMember 2018-12-31 0001516887 WCUI:GenTwoFundingIncMember 2018-12-31 0001516887 WCUI:AprilTwentyTwoThousandTwentyMember WCUI:NeoPhototherapyLLCMember 2021-03-31 0001516887 WCUI:AprilTwentyTwoThousandTwentyMember WCUI:PsoriaShieldIncMember 2020-09-30 0001516887 WCUI:AprilTwentyTwoThousandTwentyMember WCUI:PsoriaShieldIncMember 2021-03-31 0001516887 WCUI:AprilTwentyTwoThousandTwentyMember WCUI:NeoPhototherapyLLCMember 2020-09-30 0001516887 WCUI:ExEmployeeMember 2020-10-01 2021-03-31 0001516887 WCUI:FormerCEOMember 2020-10-01 2021-03-31 0001516887 us-gaap:SubsequentEventMember WCUI:OfficersandShareholdersMember 2021-06-30 0001516887 us-gaap:CorporateJointVentureMember 2020-04-30 0001516887 WCUI:GEN2Member 2019-04-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

51320

523

141994

3622

146139

181950

-149986

0.001

30000000

200000000

7500000

200000000

118252077

121027077

118252077

121027077

-7300

5000

3099

5000

3099

5000

-7300

5000

362218

240962

382110

137331

95770

565014

9975

423130

670759

760403

46661

308543

7014

142500

206824

73806

-369518

-240962

-382110

-132331

-95770

-561915

-9975

242857

338510

-418130

-667660

-755403

187077

141365

-46661

-315843

-7014

-142500

-206824

-68806

-31993

-523476

-58151

-532799

-188334

165870

-22050

-331936

-44179

91668

-213177

-919556

-393875

-1244023

-0.00

-0.01

1562

83250

-500

500

-565181

-533001

660000

520000

660000

470000

25053616

25155855

120000

58950

139050

58950

146380

523

283505

3622

287650

6961

153341

523

283505

3622

287650

121027077 21764 131538

51650

5000

142149

5000

142149

5000

51650

5000

500

94819

-13001

53147

40146

51320

146139

109567

132496

120333327

107497077

119639577

107497077

6961

27841

6961

94560

132493

-7500

-1500

137933

10660

107497

23777647

-25362287

-1477143

393149

-1083994

107497

24441950

-26606310

-2056863

373470

-1683393

-2229545

118252

25053616

-27583363

-2411495

181950

-2501338

119639

107497

25104736

23868885

-27764061

-25686754

-2539686

-1710372

38348

395520

-1314852

-2850342

121027

25155855

-27977238

-2700356

-149986

107497077

118252077

119639577

107497077

121027077

10882

65800

21764

131538

10882

21764

65800

131538

41625

507265

83250

1388

40237

41625

2775

80475

83250

507265

1387500

2775000

-401511

-941606

-725811

-1288202

-213177

-188334

-393875

-331936

-919556

-22050

-1244023

-44179

50000

25500

24500

1794

672878

7142

0.04

21600

179548

0.02 0.02

7120000

1800000

11250000

13050000

2775000

21764

3025714

7060000

9052500

4396929

1387500

10882

1300000

13449429

P4Y1M13D

P1Y

P4Y1M6D

83250

41625

225000

75000

14127738

62500

17397262

12602738

12540238

5277778

0.29

0.40

0.10

0.09

0.03

0.39

0.40

P5Y1M2D

P1Y

P5Y26D

62500

10102738

10040238

0.40

0.11

67634049

54379758

47175093

7204665

-13254291

54379758 47175093 7204665 0.16 0.07 0.40 0.17 0.07 0.40 0.15 0.07 0.40 0.17 The State of Florida The State of Illinois The State of Illinois The State of Illinois The State of New York

12602738

14837738

54379758

66484049

100000

0.10

0.505

0.360

0.51

0.39

GEN2 shareholders exchanged their common shares in GEN2, and the individual exchanged his membership interests in NEO, for common shares representing 49% ownership in PSI. The Company retained its common shares in PSI, which provides the Company a 51% economic interest in the PSI technology and products developed by the joint venture. During three and six months ended March 31, 2021, PSI recorded a loss of $187,077 and $338,510, respectively, relating to its operations, of which $91,668 and $165,870, respectively, was allocated to the non-controlling interest.

975000

750000

Psoria-Shield Inc. ("PSI") StealthCo, Inc. ("StealthCo") Psoria Development Company LLC. ("PDC") NEO Phototherapy LLC ("NEO") Protec Scientific, Inc ("Protec") 2009-06 2014-03 2015-01 2018-12 2020-04 2012-08 2018-11

0.51

1.00

0.00

0.32

0.51

0.32

0.51

66000

P24M

1613

1850

6961

0.0400

2021-01-31

1613

6961

10483

20170000

3750000

10085714

158715 20833

9018

31993

16211

58151

25534

9018

5000

0.03

2.00

0.05

0.03

0.40

0.14 2.00 0.03 0.40 P1Y9M3D P1Y11M19D P0Y4M24D P1Y9M3D P1Y11M19D P0Y4M24D .17 0.15 0.26 0.17 0.15 0.26 0.67 0.20 0.40 0.12 0.12 0.21

187500

504286

65000

670000

408297

517864

92334

84834

672878 672878

1165250

1825250

2345720

3100826

37166

2382886

3137992

118252

121027

-27583363

-27977238

-2411495

-2700356

153341

287650

-507265 -507265 55000 Wellness Center USA, Inc. 0001516887 10-Q 2021-03-31 false --09-30 Yes Yes Non-accelerated Filer true false false Q2 2021

660000

300000

11000

625

166065 96665

10275000

7500000

2775000

308250

22500

83250

0.03

1525000

1.36

10102738

2500000

0.04

0.11

0.04

830250

NOTE 1 – BASIS OF PRESENTATION   Organization and Operations   Wellness Center USA, Inc. (“WCUI” or the “Company”) was incorporated in June 2010 under the laws of the State of Nevada. The Company initially engaged in online sports and nutrition supplements marketing and distribution. The Company subsequently expanded into additional businesses within the healthcare and medical sectors through acquisitions, including Psoria-Shield Inc. (“PSI”) and StealthCo Inc. (“SCI”), d/b/a Stealth Mark, Inc.   The Company currently operates in the following business segments: (i) distribution of targeted Ultra Violet (“UV”) phototherapy devices for dermatology and sanitation purposes; and (ii) authentication and encryption products and services. The segments are operated, respectively, through PSI and SCI.   Basis of Presentation of Unaudited Financial Information   The accompanying unaudited condensed consolidated financial statements of Wellness Center USA, Inc. and Subsidiaries (the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all normal recurring adjustments considered necessary for a fair presentation have been included. Operating results for the six months ended March 31, 2021 are not necessarily indicative of the results that may be expected for the year ending September 30, 2021.   COVID-19 Considerations   During the period ended March 31, 2021, the COVID-19 pandemic did not have a material net impact on our operating results. In the future, the pandemic may cause reduced demand for our products if, for example, the pandemic results in a recessionary economic environment which negatively effects the consumers who purchase our products.   Our ability to operate without significant negative operational impact from the COVID-19 pandemic will in part depend on our ability to protect our employees and our supply chain. The Company has endeavored to follow the recommended actions of government and health authorities to protect our employees. Since the onset of the COVID-19 pandemic, we maintained the consistency of our operations. However, the uncertainty resulting from the pandemic could result in an unforeseen disruption to our workforce and supply chain (for example an inability of a key supplier or transportation supplier to source and transport materials) that could negatively impact our operations.   Through March 31, 2021, the COVID-19 pandemic has not negatively impacted the Company’s liquidity position as of such date. Through March 31, 2021, the Company continues to generate cash flows through financing activities to meet its short-term liquidity needs, and it expects to maintain access to those shareholder loans. The Company has not observed any material impairments of its assets or a significant change in the fair value of its assets due to the COVID-19 pandemic.   Going Concern   The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying condensed consolidated financial statements, the Company has not yet generated significant revenues and has incurred recurring net losses. During the six months ended March 31, 2021, the Company incurred a net loss of $725,811 and used cash in operations of $565,181, and had a shareholders’ deficit of $2,850,342 as of March 31, 2021. In addition, loans payable of $830,250 and payroll taxes of $84,834 are past due. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to raise additional funds and implement its strategies. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.   In addition, the Company’s independent registered public accounting firm, in its report on the Company’s September 30, 2020 financial statements, has raised substantial doubt about the Company’s ability to continue as a going concern.   At March 31, 2021, the Company had cash on hand in the amount of $146,139. The ability to continue as a going concern is dependent on the Company attaining and maintaining profitable operations in the future and raising additional capital soon to meet its obligations and repay its liabilities arising from normal business operations when they come due. Since inception, we have funded our operations primarily through equity and debt financings and we expect to continue to rely on these sources of capital in the future. During the six months ended March 31, 2021, the Company received $660,000 through short-term loans from officers and shareholders.   No assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to the Company. Even if the Company is able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing or cause substantial dilution for our stockholders, in case of equity financing.

NOTE 3 – LOANS PAYABLE FROM OFFICERS AND SHAREHOLDERS   As of September 30, 2020, loans payable from officers and shareholders of $1,165,250 were outstanding. During the six months ended March 31, 2021, the Company borrowed $660,000 from its officers and shareholders. All of the loans are unsecured, have an interest rate of eight percent and are due one year from the date of issuance. As of March 31, 2021, loans payable to officers and shareholders of $1,825,250 were outstanding and $830,250 was past due.

NOTE 4 – LEASE LIABILITIES   Operating Lease   In February 2019, the Company’s PSI subsidiary entered into a 24-month non-cancellable lease for its office facilities that will require monthly payments of $1,850 through January 2021. The Company adopted ASU 2016-02, Leases, effective October 1, 2019, which requires a lessee to record a right-of-use asset and a corresponding lease liability at the inception of the lease initially measured at the present value of the lease payments. The Company classified the lease as an operating lease and determined that the value of the lease asset and liability at the inception of the lease was $27,841, using a discount rate of 4.00%. As of September 30, 2020, the value of the lease asset and liability was $6,961, respectively. During the three and six months ended March 31, 2021, the Company made payments of $1,613 and $6,961, respectively, towards the lease liability. As of March 31, 2021, the lease liability was fully paid off.   ASU 2016-02 requires recognition in the statement of operations of a single lease cost, calculated so that the cost of the lease is allocated over the lease term, generally on a straight-line basis. Rent expense for the three and six months ended March 31, 2021 was $1,794 and $7,142, respectively. During the three and six months ended March 31, 2021, the Company reflected amortization of right of use asset of $1,613 and $6,961, respectively, related to this lease, resulting in no net asset balance as of March 31, 2021.   Other Leases   The Company leased its corporate office facility in Hoffman Estates, Illinois pursuant to a non-cancellable lease initiated in July 2016 and expiring February 28, 2024. The lease terms require a monthly payment of approximately $11,000. The Company vacated the facility in April 2019, in favor of its present facilities in Tucson AZ, which are provided by a shareholder on a rent-free basis. The Company is in negotiations with the owners regarding the settlement of its lease obligations and expects that the property will be subleased or a settlement with the landlord will be reached at an amount significantly less than the remaining payment obligations. At the date of vacation, the Company had a remaining lease obligation of $631,587.   On or about June 29, 2020, we received notice that Hanover Hoffman Estates, LLC (“HHE”), filed case number 2020L006092 in the Circuit Court of Cook County alleging our failure to pay Base Rent and abandonment of certain office space in Hoffman Estates, Illinois subject to a Commercial Lease dated May 26, 2016. HHE seeks at least $672,878 in base rent and other amounts under the lease, as well as treble damages from our ex-CEO and two past Directors who were serving on our Board as of the date of the lease. We are currently evaluating the allegations, defenses and alternate actions, and continuing settlement negotiations. As of March 31, 2021, the Company has recorded the full amount of the judgement due.

Use of Estimates   The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date, and reported amounts of revenue and expenses during the reporting period. Significant estimates are used in the valuation of accounts receivable and allowance for uncollectible amounts, inventory and obsolescence reserves, accruals for potential liabilities, valuations of stock-based compensation, and realization of deferred tax assets, among others. Actual results could differ from these estimates.

Income (Loss) Per Share   Basic loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of outstanding common shares during the period. Diluted loss per share is computed by dividing the net loss applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued. For the six months ended March 31, 2021 and 2020, the basic and diluted shares outstanding were the same, as potentially dilutive shares were considered anti-dilutive. At March 31, 2021 and 2020, the dilutive impact of outstanding stock options of 12,602,738 and 14,837,738 shares, respectively, and outstanding warrants for 54,379,758 and 66,484,049 shares, respectively, have been excluded because their impact on the loss per share is anti-dilutive.

Inventories   Inventories are stated at the lower of cost or net realizable value. Cost is computed on a first-in, first-out basis. At March 31, 2021, primarily all of the inventories consisted of raw materials or work-in-progress. The Company provides inventory reserves based on excess and obsolete inventories determined primarily by future demand forecasts. The write down amount, if any, is measured as the difference between the cost of the inventory and net realizable value based upon assumptions about future demand and charged to the provision for inventory, which is a component of cost of sales. At the point of the loss recognition, a new, lower cost basis for that inventory is established, and subsequent changes in facts and circumstances do not result in the restoration or increase in that newly established cost basis. At March 31, 2021, the Company recorded a reserve of $100,000 for excess and slow moving inventories. At September 30, 2020, no reserve was recorded for excess, slow moving or obsolete inventory.

Stock-Based Compensation   The Company periodically issues stock-based compensation to officers, directors, and consultants for services rendered, and as part of financing transactions. Such issuances vest and expire according to terms established at the issuance date. Stock-based payments to officers, directors, employees, and for acquiring goods and services from non-employees, which include grants of employee stock options, are recognized in the financial statements based on their fair values in accordance with Topic 718. Stock option grants, which are generally time vested, will be measured at the grant date fair value and charged to operations on a straight-line basis over the vesting period.   The fair value of the Company’s common stock option and warrant grants are estimated using a Black-Scholes Merton option pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the common stock options, estimated forfeitures and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes option pricing model, and based on actual experience. The assumptions used in the Black-Scholes Merton option pricing model could materially affect compensation expense recorded in future periods.

Recently Issued Accounting Pronouncements   In June 2016, the FASB issued ASU No. 2016-13, Credit Losses - Measurement of Credit Losses on Financial Instruments (“ASC 326”). The standard significantly changes how entities will measure credit losses for most financial assets, including accounts and notes receivables. The standard will replace today’s “incurred loss” approach with an “expected loss” model, under which companies will recognize allowances based on expected rather than incurred losses. Entities will apply the standard’s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The standard is effective for interim and annual reporting periods beginning after December 15, 2019. The adoption of ASU 2016-13 is not expected to have a material impact on the Company’s financial position, results of operations, and cash flows.   Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

The following table summarizes information concerning outstanding and exercisable options as of March 31, 2021:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="2" style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center">Options Outstanding</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center">Options Exercisable</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Range of Exercise Prices</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Number Outstanding</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Average Remaining Contractual Life (in years)</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Number Exercisable</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Average Remaining Contractual Life (in years)</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 1%">$</td> <td style="width: 17%; text-align: right">0.03 - 0.39</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">12,540,238</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">5.09</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">0.09</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">10,040,238</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">4.12</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">0.11</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.40</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">62,500</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1.00</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.40</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">62,500</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1.00</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.40</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.03 - 0.40</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">12,602,738</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">5.07</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.10</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">10,102,738</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">4.10</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.11</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

The following table summarizes information concerning outstanding and exercisable warrants as of March 31, 2021:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center">Warrants Outstanding</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center">Warrants Exercisable</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1.5pt solid">Range of Exercise Prices</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Number Outstanding</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Average Remaining Contractual Life (in years)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Number Exercisable</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Average Remaining Contractual Life (in years)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 1%">$</td> <td style="width: 17%; text-align: right">0.12 – 0.20</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">47,175,093</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">1.97</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">0.15</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">47,175,093</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">1.97</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">0.15</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.21 – 0.40</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">7,204,665</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.40</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.26</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">7,204,665</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.40</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.26</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.12 – 0.67</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">54,379,758</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">1.76</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.17</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">54,379,758</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">1.76</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.17</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

NOTE 8 – SUBSEQUENT EVENTS   Subsequent to March 31, 2021, the Company borrowed $66,000 from its officers and shareholders. All of the loans are unsecured, have an interest rate of eight percent and are due one year from the date of issuance.   On April 1, 2021, the Company’s Board of Directors approved the issuance of a combined total of 3,750,000 restricted shares of the Company’s common stock to certain of its Officers and Directors for future services to be performed. The shares vest monthly from April 2023 through March 2024. The fair value of the shares on the date of grant was $187,500.   The Board also approved the issuance of a combined total of 10,085,714 restricted shares of the Company’s common stock to certain of its Officers and Directors in connection with their officer and shareholder loans. A total of 7,060,000 of the shares vested upon grant and 3,025,714 shares vest in April 2025. The fair value of the shares on the date of grant was $504,286.   On April 1, 2021, the Company’s Board of Directors approved the grant of stock options to its Chief Executive Officer (CEO) to purchase 1,300,000 shares of the Company’s common stock with an exercise price of $0.05 per share. The options expire ten years from the date of grant. The option grants are for future services to be performed by the CEO. The shares vest monthly from April 2023 through March 2024. The fair value of the shares on the date of grant was approximately $65,000.   The Board also approved the grant of stock options to its CEO to purchase 13,449,429 shares of the Company’s common stock with an exercise price of $0.05 per share. The options expire ten years from the date of grant. The option grants are in connection with his officer and shareholder loans. A total of 9,052,500 of the shares vested upon grant and 4,396,929 shares vest in April 2025. The fair value of the shares on the date of grant was approximately $670,000. In connection with the option grants, the CEO agreed to cancel 5,277,778 of his warrant shares that were scheduled to expire from September 2021 through December 2021.

830250

507265

-6961

-10483

100000

50000

975000

631587

In May 2020, the Company's subsidiary, PSI, agreed to become a majority shareholder in Protec Scientific, Inc. ("Protec"), a company formed in April 2020. As of September 30, 2020, PSI had contributed $191,000 to Protec with the Company's share being approximately 32%, based on its PSI ownership. The remaining share is attributed to PSI's minority shareholders. During the year ended September 30, 2020, Protec received an additional $120,000 from non-affiliated investors. The additional investments gave the non-controlling interests a 68% ownership interest in Protec. During the three and six months ended March 31, 2021, Protec recorded a loss of $141,365 and $242,857, respectively, of which $96,665 and $166,065 was allocated to the non-controlling interests.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES   Basis of Consolidation   The consolidated financial statements include the Company’s subsidiaries and the accounts of its subsidiaries for which it was determined that Company has operational and management control. The Company’s consolidated subsidiaries and/or controlled entities are as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center">Name of consolidated subsidiary or entity</td> <td> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">State or other jurisdiction of incorporation or organization</td> <td> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">Date of incorporation or formation (date of acquisition/disposition, if applicable)</td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Attributable interest at September 30, 2020</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Attributable interest at March 31, 2021</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Psoria-Shield Inc. (“PSI”)</td> <td> </td> <td style="text-align: center">The State of Florida</td> <td> </td> <td style="text-align: center">June 2009 (August 2012)</td> <td> </td> <td> </td> <td style="text-align: right">51%</td> <td>(1)</td> <td> </td> <td> </td> <td style="text-align: right">51%</td> <td>(1)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 43%">StealthCo, Inc. (“StealthCo”)</td> <td style="width: 1%"> </td> <td style="width: 12%; text-align: center">The State of Illinois</td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: center">March 2014</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 12%; text-align: right">100</td> <td style="width: 1%">%</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 12%; text-align: right">100</td> <td style="width: 1%">%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Psoria Development Company LLC. (“PDC”)</td> <td> </td> <td style="text-align: center">The State of Illinois</td> <td> </td> <td style="text-align: center">January 2015/November 2018</td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>NEO Phototherapy LLC (“NEO”)</td> <td> </td> <td style="text-align: center">The State of Illinois</td> <td> </td> <td style="text-align: center">December 2018</td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Protec Scientific, Inc (“Protec”)</td> <td> </td> <td style="text-align: center">The State of New York</td> <td> </td> <td style="text-align: center">April 2020</td> <td> </td> <td> </td> <td style="text-align: right">32</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">32</td> <td>%</td></tr> </table>   (1) - Effective April 30, 2020, the Company’s 51% interest in NEO was converted into a 51% interest in PSI.   Use of Estimates   The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date, and reported amounts of revenue and expenses during the reporting period. Significant estimates are used in the valuation of accounts receivable and allowance for uncollectible amounts, inventory and obsolescence reserves, accruals for potential liabilities, valuations of stock-based compensation, and realization of deferred tax assets, among others. Actual results could differ from these estimates.   Income (Loss) Per Share   Basic loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of outstanding common shares during the period. Diluted loss per share is computed by dividing the net loss applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued. For the six months ended March 31, 2021 and 2020, the basic and diluted shares outstanding were the same, as potentially dilutive shares were considered anti-dilutive. At March 31, 2021 and 2020, the dilutive impact of outstanding stock options of 12,602,738 and 14,837,738 shares, respectively, and outstanding warrants for 54,379,758 and 66,484,049 shares, respectively, have been excluded because their impact on the loss per share is anti-dilutive.   Revenue Recognition   The company records revenue under the guidance of Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers (Topic 606) which requires a company to recognize revenue to depict the transfer of goods or services to a customer at an amount that reflects the consideration it expects to receive in exchange for those goods or services.   For trade sales, the Company generates its revenue from sales contracts with customers with revenues being generated upon the shipment of merchandise, or for consulting services, revenue is recognized in the period services are rendered and earned under service arrangements with clients.   We sell our products through two main sales channels: 1) directly to customers who use our products (the “Direct Channel”) and 2) to distribution partners who resell our products (the “Indirect Channel”).   Under the Direct Channel, we sell our products to and we receive payment directly from customers who purchase our products. Under our Indirect Channel, we have entered into distribution agreements that allow the distributors to sell our products and fulfill performance obligations under the agreements.   We determine revenue recognition through the following steps:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px; text-align: justify"> </td> <td style="width: 48px; text-align: justify">●</td> <td style="text-align: justify">Identification of the contract, or contracts, with a customer</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px; text-align: justify"> </td> <td style="width: 48px; text-align: justify">●</td> <td style="text-align: justify">Identification of the performance obligations in the contract</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px; text-align: justify"> </td> <td style="width: 48px; text-align: justify">●</td> <td style="text-align: justify">Determination of the transaction price</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px; text-align: justify"> </td> <td style="width: 48px; text-align: justify">●</td> <td style="text-align: justify">Allocation of the transaction price to the performance obligations in the contract</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px; text-align: justify"> </td> <td style="width: 48px; text-align: justify">●</td> <td style="text-align: justify">Recognition of revenue when, or as, we satisfy a performance obligation.</td></tr> </table>   Revenue is generally recognized upon shipment or when a service has been completed, unless we have significant performance obligations for services still to be completed. We recognize revenue when a material reversal is no longer probable. Payments received before the relevant criteria for revenue recognition are satisfied are recorded as deferred revenue. There was no deferred revenue at March 31, 2021 and September 30, 2020.   Non-controlling Interests   PSI   In December 2018, PSI entered into a Joint Venture Agreement with GEN2 for further development, marketing, licensing and/or sale of PSI technology and products to be conducted through NEO Phototherapy, Inc. (“NEO”). PSI and GEN2 were the members of NEO, owning 50.5% and 36.0%, respectively, of NEO. As of April 30, 2020, the Company controlled 51% of the joint venture, GEN2 controlled 39% and another individual controlled the remaining 10%.   Effective April 30, 2020, the GEN2 shareholders exchanged their common shares in GEN2, and the individual exchanged his membership interests in NEO, for common shares representing 49% ownership in PSI. The Company retained its common shares in PSI, which provides the Company a 51% economic interest in the PSI technology and products developed by the joint venture. During three and six months ended March 31, 2021, PSI recorded a loss of $187,077 and $338,510, respectively, relating to its operations, of which $91,668 and $165,870, respectively, was allocated to the non-controlling interest.   As of September 30, 2019, GEN2 had received $975,000 of investments to contribute to NEO. Repayment of the $975,000 investment will begin through and upon the date which PSI has realized and retained cumulative net income/distributable cash in the amount of $300,000. As of March 31, 2021, PSI had not recorded any cumulative net income/distributable cash. The minority interest of PSI ownership consists of accredited investors, and investment participation of $750,000 from several WCUI officers and directors, including Calvin R. O’Harrow and Roy M. Harsch.   Protec   In May 2020, the Company’s subsidiary, PSI, agreed to become a majority shareholder in Protec Scientific, Inc. (“Protec”), a company formed in April 2020. As of September 30, 2020, PSI had contributed $191,000 to Protec with the Company’s share being approximately 32%, based on its PSI ownership. The remaining share is attributed to PSI’s minority shareholders. During the year ended September 30, 2020, Protec received an additional $120,000 from non-affiliated investors. The additional investments gave the non-controlling interests a 68% ownership interest in Protec. During the three and six months ended March 31, 2021, Protec recorded a loss of $141,365 and $242,857, respectively, of which $96,665 and $166,065 was allocated to the non-controlling interests.   Inventories   Inventories are stated at the lower of cost or net realizable value. Cost is computed on a first-in, first-out basis. At March 31, 2021, primarily all of the inventories consisted of raw materials or work-in-progress. The Company provides inventory reserves based on excess and obsolete inventories determined primarily by future demand forecasts. The write down amount, if any, is measured as the difference between the cost of the inventory and net realizable value based upon assumptions about future demand and charged to the provision for inventory, which is a component of cost of sales. At the point of the loss recognition, a new, lower cost basis for that inventory is established, and subsequent changes in facts and circumstances do not result in the restoration or increase in that newly established cost basis. At March 31, 2021, the Company recorded a reserve of $100,000 for excess and slow moving inventories. At September 30, 2020, no reserve was recorded for excess, slow moving or obsolete inventory.   Stock-Based Compensation   The Company periodically issues stock-based compensation to officers, directors, and consultants for services rendered, and as part of financing transactions. Such issuances vest and expire according to terms established at the issuance date. Stock-based payments to officers, directors, employees, and for acquiring goods and services from non-employees, which include grants of employee stock options, are recognized in the financial statements based on their fair values in accordance with Topic 718. Stock option grants, which are generally time vested, will be measured at the grant date fair value and charged to operations on a straight-line basis over the vesting period.   The fair value of the Company’s common stock option and warrant grants are estimated using a Black-Scholes Merton option pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the common stock options, estimated forfeitures and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes option pricing model, and based on actual experience. The assumptions used in the Black-Scholes Merton option pricing model could materially affect compensation expense recorded in future periods.   Recently Issued Accounting Pronouncements   In June 2016, the FASB issued ASU No. 2016-13, Credit Losses - Measurement of Credit Losses on Financial Instruments (“ASC 326”). The standard significantly changes how entities will measure credit losses for most financial assets, including accounts and notes receivables. The standard will replace today’s “incurred loss” approach with an “expected loss” model, under which companies will recognize allowances based on expected rather than incurred losses. Entities will apply the standard’s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The standard is effective for interim and annual reporting periods beginning after December 15, 2019. The adoption of ASU 2016-13 is not expected to have a material impact on the Company’s financial position, results of operations, and cash flows.   Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

NOTE 5 – SHAREHOLDERS’ EQUITY   Restricted Stock Grants   In April 2020, the Company’s Board of Directors approved the issuance of a combined total of 20,170,000 restricted shares of the Company’s common stock to its Officers and Directors. A total of 7,120,000 shares vested in April 2020, while 1,800,000 will vest monthly from April 2020 through March 2021, and 11,250,000 will vest monthly from April 2020 through March 2023. Of the 13,050,000 shares that vest over time, a total of 1,387,500 and 2,775,000 shares vested during the three and six months ended March 31, 2021, respectively.   The following table summarizes restricted common stock activity:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Number of Restricted Shares</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Fair Value</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Weighted Average Grant Date Fair Value</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 49%">Non-vested, September 30, 2020</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right">10,275,000</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">308,250</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">0.03</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Granted</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Vested</td> <td> </td> <td> </td> <td style="text-align: right">(2,775,000</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">(83,250</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">0.03</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Forfeited</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Non-vested, March 31, 2021</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">7,500,000</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">225,00</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.03</td> <td> </td></tr> </table>   During the three and six months ended March 31, 2021, the Company recorded $41,625 and $83,250, respectively, of stock compensation for the value of restricted common stock vesting during the period, and as of March 31, 2021, unvested compensation of $225,000 remained that will be amortized over the remaining vesting period.   Stock Options   On December 22, 2010, effective retroactively as of June 30, 2010, the Company’s Board of Directors approved the adoption of the “2010 Non-Qualified Stock Option Plan” (“2010 Option Plan”) by unanimous consent. The 2010 Option Plan was initiated to encourage and enable officers, directors, consultants, advisors and key employees of the Company to acquire and retain a proprietary interest in the Company by ownership of its common stock. A total of 7,500,000 of the authorized shares of the Company’s common stock may be subject to, or issued pursuant to, the terms of the plan. Effective January 1, 2018, the Board of Directors approved to increase the number of authorized shares of the Company’s common stock that may be subject to, or issued pursuant to, the terms of the plan from 7,500,000 to 30,000,000.   The Company’s policy is to recognize compensation cost for awards with only service conditions and a graded vesting schedule on a straight-line basis over the requisite service period for the entire award. Additionally, the Company’s policy is to issue new shares of common stock to satisfy stock option exercises. The Company applied fair value accounting for all share based payments awards. The fair value of each option granted is estimated on the date of grant using the Black-Scholes option-pricing model.   The table below summarizes the Company’s stock option activities for the six months ended March 31, 2021:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Number of Option Shares</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Exercise Price Range Per Share</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 46%">Balance, September 30, 2020</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right">14,127,738</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">0.03 - 2.00</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">0.29</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Granted</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Cancelled</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Exercised</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Expired</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(1,525,000</td> <td>)</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.14 - 2.00</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1.36</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Balance, March 31, 2021</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double; text-align: right">12,602,738</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.03 - 0.40</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.10</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Vested and exercisable, March 31, 2021</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double; text-align: right">10,102,738</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.03 - 0.40</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.11</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Unvested, March 31, 2021</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double; text-align: right">2,500,000</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.04</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.04</td> <td> </td></tr> </table>   The following table summarizes information concerning outstanding and exercisable options as of March 31, 2021:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center">Options Outstanding</td> <td> </td> <td> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center">Options Exercisable</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Range of Exercise Prices</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Number Outstanding</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Average Remaining Contractual Life (in years)</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Number Exercisable</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Average Remaining Contractual Life (in years)</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 1%">$</td> <td style="width: 17%; text-align: right">0.03 - 0.39</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">12,540,238</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">5.09</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">0.09</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">10,040,238</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">4.12</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">0.11</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.40</td> <td> </td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">62,500</td> <td> </td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1.00</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.40</td> <td> </td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">62,500</td> <td> </td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1.00</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.40</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.03 - 0.40</td> <td> </td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double; text-align: right">12,602,738</td> <td> </td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double; text-align: right">5.07</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.10</td> <td> </td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double; text-align: right">10,102,738</td> <td> </td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double; text-align: right">4.10</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.11</td> <td> </td></tr> </table>   During the three and six months ended March 31, 2021, the Company recorded $10,882 and $21,764, respectively, of stock compensation for the value of options vesting during the period, and as of March 31, 2021, unvested compensation of $75,000 remained that will be amortized over the remaining vesting period.   The total aggregate intrinsic value for option shares outstanding at March 31, 2021 was $625. As of March 31, 2021, there were 17,397,262 shares of stock options remaining available for issuance under the 2010 Plan.   Stock Warrants   The table below summarizes the Company’s warrants activities for the six months ended March 31, 2021:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Number of Warrant Shares</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Exercise Price Range Per Share</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 46%">Balance, September 30, 2020</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right">67,634,049</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right">$ 0.07 - 0.40</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">0.16</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Granted</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Cancelled</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Exercised</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Expired</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(13,254,291</td> <td>)</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.15</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.15</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Balance, March 31, 2021</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">54,379,758</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.07 - 0.40</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.17</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Vested and exercisable, March 31, 2021</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">54,379,758</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.07 - 0.40</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.17</td> <td> </td></tr> </table>   The following table summarizes information concerning outstanding and exercisable warrants as of March 31, 2021:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center">Warrants Outstanding</td> <td> </td> <td> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center">Warrants Exercisable</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1.5pt solid">Range of Exercise Prices</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Number Outstanding</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Average Remaining Contractual Life (in years)</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Number Exercisable</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Average Remaining Contractual Life (in years)</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 1%">$</td> <td style="width: 17%; text-align: right">0.12 – 0.20</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">47,175,093</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">1.97</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">0.15</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">47,175,093</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">1.97</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">0.15</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.21 – 0.40</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">7,204,665</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.40</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.26</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">7,204,665</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.40</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.26</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.12 – 0.67</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">54,379,758</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">1.76</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.17</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">54,379,758</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">1.76</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.17</td> <td> </td></tr> </table>   There was no aggregate intrinsic value for warrant shares outstanding at March 31, 2021.

NOTE 6 – SEGMENT REPORTING   Reportable segments are components of an enterprise about which separate financial information is available and that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company’s reportable segments are based on products and services, geography, legal structure, management structure, or any other manner in which management disaggregates a company.   The Company operates in the following business segments:   (i) Medical Devices: which stems from PSI, its subsidiary acquired on August 24, 2012, a developer, manufacturer, marketer and distributer of targeted Ultra Violet (“UV”) phototherapy devices for the treatment of skin diseases.   (ii) Authentication and Encryption Products and Services: which stems from StealthCo, its wholly-owned subsidiary formed on March 18, 2014, which has engaged in the business of selling, licensing or otherwise providing certain authentication and encryption products and services since acquisition of certain assets from SMI on April 4, 2014.   The detailed segment information of the Company is as follows:   Assets By Segment   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center">March 31, 2021</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Corporate</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Medical Devices</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Authentication and Encryption</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>ASSETS</td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Current Assets</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 42%">Cash</td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">523</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">141,994</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">3,622</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">146,139</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Accounts receivable</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">9,018</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">9,018</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Inventories</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">132,493</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">132,493</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Prepaid expenses and other current assets</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Total current assets</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">523</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">283,505</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">3,622</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">287,650</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>TOTAL ASSETS</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">523</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">283,505</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">3,622</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">287,650</td> <td> </td></tr> </table>   Operations by Segment for the Three Months Ended March 31, 2021 and 2020   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="14" style="text-align: center">For the Three Months Ended</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center">March 31, 2021</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Corporate</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Medical Devices</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Authentication and Encryption</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 42%">Trade Sales</td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">51,650</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">51,650</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Cost of goods sold</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">58,950</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">58,950</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Gross profit</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(7,300</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(7,300</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Operating expenses</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">46,661</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">308,543</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">7,014</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">362,218</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Loss from operations</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(46,661</td> <td>)</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(315,843</td> <td>)</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(7,014</td> <td>)</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(369,518</td> <td>)</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="14" style="text-align: center">For the Three Months Ended</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center">March 31, 2020</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Stealthco</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center">WCUI</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center">PSI</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Authentication and</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Corporate</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Medical Devices</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Encryption</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 42%">Trade Sales</td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">5,000</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">5,000</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Cost of goods sold</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Gross profit</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">5,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">5,000</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Operating expenses</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">142,500</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">206,824</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">73,806</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">423,130</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Loss from operations</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(142,500</td> <td>)</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(206,824</td> <td>)</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(68,806</td> <td>)</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(418,130</td> <td>)</td></tr> </table>   Operations by Segment for the Six Months Ended March 31, 2021 and 2020   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="14" style="text-align: center">For the Six Months Ended</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center">March 31, 2021</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Corporate</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Medical Devices</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Authentication and Encryption</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 42%">Trade Sales</td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">142,149</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">142,149</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Cost of goods sold</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">139,050</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">139,050</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Gross profit</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3,099</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3,099</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Operating expenses</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">95,770</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">565,014</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">9,975</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">670,759</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Loss from operations</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(95,770</td> <td>)</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(561,915</td> <td>)</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(9,975</td> <td>)</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(667,660</td> <td>)</td></tr> </table>    <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="14" style="text-align: center">For the Six Months Ended</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center">March 31, 2020</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Stealthco</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center">WCUI</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center">PSI</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Authentication</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Corporate</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Medical Devices</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">and Encryption</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 42%">Trade Sales</td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">5,000</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">5,000</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Cost of goods sold</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Gross profit</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">5,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">5,000</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Operating expenses</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">240,962</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">382,110</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">137,331</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">760,403</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Loss from operations</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(240,962</td> <td>)</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(382,110</td> <td>)</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(132,331</td> <td>)</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(755,403</td> <td>)</td></tr> </table>

NOTE 7 – LEGAL MATTERS   The Company is periodically engaged in legal proceedings arising from and relating to its business operations. Except as otherwise described herein and in Note 4, we currently are not involved in any other litigation that we believe could have a material adverse effect on our financial condition or results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our Company or any of our subsidiaries, threatened against or affecting our Company, our common stock, any of our subsidiaries or of our Company’s or our subsidiaries’ officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect on our financial condition or results of operations.   We continue efforts to preserve revenue and reduce operating expenses through actions including, but not limited to, facilities consolidation and staff reductions, which we hope to implement through negotiated transactions with lessors, employees and other third parties. Such actions may result in disputes with and claims by such parties which, if not resolved through negotiations, may impact negatively the Company’s ability to continue as a going concern. To date, the Company has negotiated settlement of all ex-employee wage and benefits claims except for two. The first regards unpaid wages claimed due together with interest at the rate of 4% per annum on such amount as the Company originally agreed upon in settlement negotiations. The ex-employee claims additional amounts due for certain statutory damages under the Illinois Wage Payment and Collection which currently could exceed $21,600.00 and would increase at the rate of 2% of the wages due per month plus attorneys’ fees if the employee elects to file suit for a violation of the Act and is successful in obtaining a judgment on his claim.   The second claim was filed with the Illinois Department of Labor asserting a violation of the Illinois Wage Payment and Collection Act by the Company’s former CEO. That claim alleges unpaid wages in the amount of $158,714.60 and unpaid vacation pay in the amount of $20,833.33 for a total amount of $179,547.90, as well as certain statutory damages including, but not limited to, 2% of the wages due per month plus attorneys’ fees if the ex-CEO elects to file suit for a violation of the Act and is successful in obtaining a judgment on his claim. The Company has filed its response to such claim with the Department denying the substantive allegations therein and asserting certain factual and legal defenses, including breach of fiduciary duty, as a bar to all claimed compensation. The claim remains pending, but as the date hereof, no suit has been filed against the Company asserting a violation of the Act based on said claim.

Basis of Consolidation   The consolidated financial statements include the Company’s subsidiaries and the accounts of its subsidiaries for which it was determined that Company has operational and management control. The Company’s consolidated subsidiaries and/or controlled entities are as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center">Name of consolidated subsidiary or entity</td> <td> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">State or other jurisdiction of incorporation or organization</td> <td> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">Date of incorporation or formation (date of acquisition/disposition, if applicable)</td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Attributable interest at September 30, 2020</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Attributable interest at March 31, 2021</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Psoria-Shield Inc. (“PSI”)</td> <td> </td> <td style="text-align: center">The State of Florida</td> <td> </td> <td style="text-align: center">June 2009 (August 2012)</td> <td> </td> <td> </td> <td style="text-align: right">51%</td> <td>(1)</td> <td> </td> <td> </td> <td style="text-align: right">51%</td> <td>(1)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 43%">StealthCo, Inc. (“StealthCo”)</td> <td style="width: 1%"> </td> <td style="width: 12%; text-align: center">The State of Illinois</td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: center">March 2014</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 12%; text-align: right">100</td> <td style="width: 1%">%</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 12%; text-align: right">100</td> <td style="width: 1%">%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Psoria Development Company LLC. (“PDC”)</td> <td> </td> <td style="text-align: center">The State of Illinois</td> <td> </td> <td style="text-align: center">January 2015/November 2018</td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>NEO Phototherapy LLC (“NEO”)</td> <td> </td> <td style="text-align: center">The State of Illinois</td> <td> </td> <td style="text-align: center">December 2018</td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Protec Scientific, Inc (“Protec”)</td> <td> </td> <td style="text-align: center">The State of New York</td> <td> </td> <td style="text-align: center">April 2020</td> <td> </td> <td> </td> <td style="text-align: right">32</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">32</td> <td>%</td></tr> </table>   (1) - Effective April 30, 2020, the Company’s 51% interest in NEO was converted into a 51% interest in PSI.

Revenue Recognition   The company records revenue under the guidance of Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers (Topic 606) which requires a company to recognize revenue to depict the transfer of goods or services to a customer at an amount that reflects the consideration it expects to receive in exchange for those goods or services.   For trade sales, the Company generates its revenue from sales contracts with customers with revenues being generated upon the shipment of merchandise, or for consulting services, revenue is recognized in the period services are rendered and earned under service arrangements with clients.   We sell our products through two main sales channels: 1) directly to customers who use our products (the “Direct Channel”) and 2) to distribution partners who resell our products (the “Indirect Channel”).   Under the Direct Channel, we sell our products to and we receive payment directly from customers who purchase our products. Under our Indirect Channel, we have entered into distribution agreements that allow the distributors to sell our products and fulfill performance obligations under the agreements.   We determine revenue recognition through the following steps:   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 48px; text-align: justify"> </td> <td style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 48px; text-align: justify">●</td> <td style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: justify">Identification of the contract, or contracts, with a customer</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px; text-align: justify"> </td> <td style="width: 48px; text-align: justify">●</td> <td style="text-align: justify">Identification of the performance obligations in the contract</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px; text-align: justify"> </td> <td style="width: 48px; text-align: justify">●</td> <td style="text-align: justify">Determination of the transaction price</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px; text-align: justify"> </td> <td style="width: 48px; text-align: justify">●</td> <td style="text-align: justify">Allocation of the transaction price to the performance obligations in the contract</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px; text-align: justify"> </td> <td style="width: 48px; text-align: justify">●</td> <td style="text-align: justify">Recognition of revenue when, or as, we satisfy a performance obligation.</td></tr> </table>   Revenue is generally recognized upon shipment or when a service has been completed, unless we have significant performance obligations for services still to be completed. We recognize revenue when a material reversal is no longer probable. Payments received before the relevant criteria for revenue recognition are satisfied are recorded as deferred revenue. There was no deferred revenue at March 31, 2021 and September 30, 2020.

Non-controlling Interests   PSI   In December 2018, PSI entered into a Joint Venture Agreement with GEN2 for further development, marketing, licensing and/or sale of PSI technology and products to be conducted through NEO Phototherapy, Inc. (“NEO”). PSI and GEN2 were the members of NEO, owning 50.5% and 36.0%, respectively, of NEO. As of April 30, 2020, the Company controlled 51% of the joint venture, GEN2 controlled 39% and another individual controlled the remaining 10%.   Effective April 30, 2020, the GEN2 shareholders exchanged their common shares in GEN2, and the individual exchanged his membership interests in NEO, for common shares representing 49% ownership in PSI. The Company retained its common shares in PSI, which provides the Company a 51% economic interest in the PSI technology and products developed by the joint venture. During three and six months ended March 31, 2021, PSI recorded a loss of $187,077 and $338,510, respectively, relating to its operations, of which $91,668 and $165,870, respectively, was allocated to the non-controlling interest.   As of September 30, 2019, GEN2 had received $975,000 of investments to contribute to NEO. Repayment of the $975,000 investment will begin through and upon the date which PSI has realized and retained cumulative net income/distributable cash in the amount of $300,000. As of March 31, 2021, PSI had not recorded any cumulative net income/distributable cash. The minority interest of PSI ownership consists of accredited investors, and investment participation of $750,000 from several WCUI officers and directors, including Calvin R. O’Harrow and Roy M. Harsch.   Protec   In May 2020, the Company’s subsidiary, PSI, agreed to become a majority shareholder in Protec Scientific, Inc. (“Protec”), a company formed in April 2020. As of September 30, 2020, PSI had contributed $191,000 to Protec with the Company’s share being approximately 32%, based on its PSI ownership. The remaining share is attributed to PSI’s minority shareholders. During the year ended September 30, 2020, Protec received an additional $120,000 from non-affiliated investors. The additional investments gave the non-controlling interests a 68% ownership interest in Protec. During the three and six months ended March 31, 2021, Protec recorded a loss of $141,365 and $242,857, respectively, of which $96,665 and $166,065 was allocated to the non-controlling interests. The Company’s consolidated subsidiaries and/or controlled entities are as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center">Name of consolidated subsidiary or entity</td> <td> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">State or other jurisdiction of incorporation or organization</td> <td> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">Date of incorporation or formation (date of acquisition/disposition, if applicable)</td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Attributable interest at September 30, 2020</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Attributable interest at March 31, 2021</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Psoria-Shield Inc. (“PSI”)</td> <td> </td> <td style="text-align: center">The State of Florida</td> <td> </td> <td style="text-align: center">June 2009 (August 2012)</td> <td> </td> <td> </td> <td style="text-align: right">51%</td> <td>(1)</td> <td> </td> <td> </td> <td style="text-align: right">51%</td> <td>(1)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 43%">StealthCo, Inc. (“StealthCo”)</td> <td style="width: 1%"> </td> <td style="width: 12%; text-align: center">The State of Illinois</td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: center">March 2014</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 12%; text-align: right">100</td> <td style="width: 1%">%</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 12%; text-align: right">100</td> <td style="width: 1%">%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Psoria Development Company LLC. (“PDC”)</td> <td> </td> <td style="text-align: center">The State of Illinois</td> <td> </td> <td style="text-align: center">January 2015/November 2018</td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>NEO Phototherapy LLC (“NEO”)</td> <td> </td> <td style="text-align: center">The State of Illinois</td> <td> </td> <td style="text-align: center">December 2018</td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Protec Scientific, Inc (“Protec”)</td> <td> </td> <td style="text-align: center">The State of New York</td> <td> </td> <td style="text-align: center">April 2020</td> <td> </td> <td> </td> <td style="text-align: right">32</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">32</td> <td>%</td></tr> </table>   (1) - Effective April 30, 2020, the Company’s 51% interest in NEO was converted into a 51% interest in PSI.

The table below summarizes the Company’s stock option activities for the six months ended March 31, 2021:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Number of Option Shares</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Exercise Price Range Per Share</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 46%">Balance, September 30, 2020</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right">14,127,738</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">0.03 - 2.00</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">0.29</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Granted</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Cancelled</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Exercised</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Expired</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(1,525,000</td> <td>)</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.14 - 2.00</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1.36</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Balance, March 31, 2021</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double; text-align: right">12,602,738</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.03 - 0.40</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.10</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Vested and exercisable, March 31, 2021</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double; text-align: right">10,102,738</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.03 - 0.40</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.11</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Unvested, March 31, 2021</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double; text-align: right">2,500,000</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.04</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.04</td> <td> </td></tr> </table>

The table below summarizes the Company’s warrants activities for the six months ended March 31, 2021:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Number of Warrant Shares</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Exercise Price Range Per Share</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 46%">Balance, September 30, 2020</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right">67,634,049</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right">$ 0.07 - 0.40</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">0.16</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Granted</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Cancelled</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Exercised</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Expired</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(13,254,291</td> <td>)</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.15</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.15</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Balance, March 31, 2021</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">54,379,758</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.07 - 0.40</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.17</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Vested and exercisable, March 31, 2021</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">54,379,758</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.07 - 0.40</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.17</td> <td> </td></tr> </table>

The detailed segment information of the Company is as follows:   Assets By Segment   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center">March 31, 2021</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Corporate</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Medical Devices</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Authentication and Encryption</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>ASSETS</td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Current Assets</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 42%">Cash</td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">523</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">141,994</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">3,622</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">146,139</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Accounts receivable</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">9,018</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">9,018</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Inventories</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">132,493</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">132,493</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Prepaid expenses and other current assets</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Total current assets</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">523</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">283,505</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">3,622</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">287,650</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>TOTAL ASSETS</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">523</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">283,505</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">3,622</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">287,650</td> <td> </td></tr> </table>

Operations by Segment for the Three Months Ended March 31, 2021 and 2020   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="14" style="text-align: center">For the Three Months Ended</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center">March 31, 2021</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Corporate</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Medical Devices</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Authentication and Encryption</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 42%">Trade Sales</td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">51,650</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">51,650</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Cost of goods sold</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">58,950</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">58,950</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Gross profit</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(7,300</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(7,300</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Operating expenses</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">46,661</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">308,543</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">7,014</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">362,218</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Loss from operations</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(46,661</td> <td>)</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(315,843</td> <td>)</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(7,014</td> <td>)</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(369,518</td> <td>)</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="14" style="text-align: center">For the Three Months Ended</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center">March 31, 2020</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Stealthco</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center">WCUI</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center">PSI</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Authentication and</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Corporate</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Medical Devices</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Encryption</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 42%">Trade Sales</td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">5,000</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">5,000</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Cost of goods sold</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Gross profit</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">5,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">5,000</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Operating expenses</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">142,500</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">206,824</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">73,806</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">423,130</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Loss from operations</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(142,500</td> <td>)</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(206,824</td> <td>)</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(68,806</td> <td>)</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(418,130</td> <td>)</td></tr> </table>   Operations by Segment for the Six Months Ended March 31, 2021 and 2020   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="14" style="text-align: center">For the Six Months Ended</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center">March 31, 2021</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Corporate</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Medical Devices</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Authentication and Encryption</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 42%">Trade Sales</td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">142,149</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">142,149</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Cost of goods sold</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">139,050</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">139,050</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Gross profit</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3,099</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3,099</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Operating expenses</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">95,770</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">565,014</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">9,975</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">670,759</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Loss from operations</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(95,770</td> <td>)</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(561,915</td> <td>)</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(9,975</td> <td>)</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(667,660</td> <td>)</td></tr> </table>    <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="14" style="text-align: center">For the Six Months Ended</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center">March 31, 2020</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Stealthco</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center">WCUI</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center">PSI</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Authentication</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Corporate</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Medical Devices</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">and Encryption</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 42%">Trade Sales</td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">5,000</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">5,000</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Cost of goods sold</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Gross profit</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">5,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">5,000</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Operating expenses</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">240,962</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">382,110</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">137,331</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">760,403</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Loss from operations</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(240,962</td> <td>)</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(382,110</td> <td>)</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(132,331</td> <td>)</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(755,403</td> <td>)</td></tr> </table>

The following table summarizes restricted common stock activity:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Number of Restricted Shares</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Fair Value</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Weighted Average Grant Date Fair Value</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 49%">Non-vested, September 30, 2020</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right">10,275,000</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">308,250</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">0.03</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Granted</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Vested</td> <td> </td> <td> </td> <td style="text-align: right">(2,775,000</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">(83,250</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">0.03</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Forfeited</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Non-vested, March 31, 2021</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">7,500,000</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">225,00</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.03</td> <td> </td></tr> </table>

Effective April 30, 2020, the Company's 51% interest in NEO was converted into a 51% interest in PSI.

EX-101.SCH 7 wcui-20210331.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Shareholders' Deficit (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Loans Payable from Officers and Shareholders link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Lease Liabilities link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Segment Reporting link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Legal Matters link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Shareholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Segment Reporting (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Basis of Presentation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Summary of Significant Accounting Policies - Schedule of Company's Consolidated Subsidiaries (Details) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Summary of Significant Accounting Policies - Schedule of Company's Consolidated Subsidiaries (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Loans Payable from Officers and Shareholders (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Lease Liabilities (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Shareholders' Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Shareholders' Equity - Summary of Restricted Common Stock (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Shareholders' Equity - Schedule of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Shareholders' Equity - Schedule of Outstanding and Exercisable Options by Exercise Price Range (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Shareholders' Equity - Schedule of Warrant Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Shareholders' Equity - Schedule of Outstanding and Exercisable Warrants by Exercise Price Range (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Segment Reporting - Schedule of Assets of Reportable Segments (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Segment Reporting - Schedule of Operations of Reportable Segments (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Legal Matters (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 wcui-20210331_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 wcui-20210331_def.xml XBRL DEFINITION FILE EX-101.LAB 10 wcui-20210331_lab.xml XBRL LABEL FILE Plan Name [Axis] 2010 Non-Qualified Stock Option Plan [Member] Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Accumulated Deficit [Member] Total WCUI Deficit [Member] Non-controlling Interest [Member] Segments [Axis] Corporate [Member] Medical Devices [Member] Authentication and Encryption [Member] Legal Entity [Axis] GEN2 [Member] Title of Individual [Axis] Individual [Member] Board of Directors [Member] Vesting [Axis] Vest Monthly from April 2020 Through March 2021 [Member] Vest Monthly from April 2020 Through March 2023 [Member] Vest Over Time [Member] Protec Scientific, Inc [Member] Hanover Hoffman Estates LLC [Member] Range [Axis] Minimum [Member] Maximum [Member] Exercise Price Range [Axis] Exercise Price Range One [Member] Exercise Price Range Two [Member] Warrant [Member] Antidilutive Securities [Axis] Stock Option [Member] Warrants [Member] Ownership [Axis] Psoria-Shield, Inc [Member] StealthCo, Inc. [Member] Psoria Development Company LLC. [Member] NEO Phototherapy, LLC, [Member] Award Date [Axis] April 30, 2020 [Member] Award Type [Axis] Restricted Stock [Member] Stock Option [Member] 2010 Non-Qualified Stock Option Plan [Member] Subsequent Event Type [Axis] Subsequent Event [Member] April 2023 Through March 2024 [Member] Officers and Directors [Member] April 2025 [Member] CEO [Member] September 2021 through December 2021 [Member] Gen 2 Funding, Inc [Member] Ex- Employee [Member] Former CEO [Member] Officers and Shareholders [Member] Related Party [Axis] Joint Venture [Member] Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Flag Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS Current Assets Cash Accounts receivable Inventories, net Prepaid expenses and other current assets Total Current Assets Right of use asset Total Other Assets TOTAL ASSETS LIABILITIES AND SHAREHOLDERS' DEFICIT Current Liabilities Accounts payable and accrued expenses Payroll taxes payable, past due Lease liability Lease abandonment liability Loans payable from officers and shareholders, including $830,250 past due at March 31, 2021 Total Current Liabilities Long-term Liabilities U.S. Small Business Administration PPP loan payable Total Liabilities Shareholders' Deficit Common stock, par value $0.001, 200,000,000 shares authorized; 121,027,077 and 118,252,077 shares issued and outstanding, respectively Additional paid-in capital Accumulated deficit Total Wellness Center USA shareholders' deficit Non-controlling interest Total Shareholder's deficit TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT Loans payable from officers and shareholders, past due amount Common stock, par value Common stock, shares authorized Common stock, shares, issued Common stock, shares, outstanding Income Statement [Abstract] Trade sales Cost of goods sold Gross profit (loss) Operating expenses Loss from operations Other expenses Cost of warrant modification Interest expense Total other expenses NET LOSS Net loss attributable to non-controlling interest NET LOSS ATTRIBUTABLE TO WELLNESS CENTER USA, INC. BASIC AND DILUTED LOSS PER SHARE WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING BASIC AND DILUTED Statement [Table] Statement [Line Items] Balance Balance, shares Fair value of vested stock options Cost of warrant modification Contribution of capital by joint venture partners Fair value of common stock issued for services Fair value of common stock issued for services, shares Net loss Balance Balance, shares Statement of Cash Flows [Abstract] Cash Flows from Operating Activities Adjustments to reconcile net loss to net cash used in operating activities: Depreciation expense Amortization of right-of-use asset Provision for excess and slow moving inventories Fair value of common shares issued for services Fair value of stock options issued for services Cost of warrant modification Changes in Assets and Liabilities (Increase) Decrease in: Accounts receivable Inventories Prepaid expenses and other assets (Decrease) Increase in: Accounts payable and accrued expenses Payroll taxes payable Lease liability Net cash used in operating activities Cash Flows from Financing Activities Proceeds from loans payable from officers and shareholders Contribution of capital by joint venture partner Net cash provided by financing activities Net increase (decrease) in cash Cash beginning of period Cash end of period Supplemental cash flows disclosures: Interest paid Taxes paid Supplemental non-cash disclosures: Initial recognition of right-of-use assets and operating lease liabilities upon adoption of ASC Topic 842 Reclassification of prepaid expenses to inventories Accounting Policies [Abstract] Basis of Presentation Summary of Significant Accounting Policies Debt Disclosure [Abstract] Loans Payable from Officers and Shareholders Leases [Abstract] Lease Liabilities Equity [Abstract] Shareholders' Equity Segment Reporting [Abstract] Segment Reporting Commitments and Contingencies Disclosure [Abstract] Legal Matters Subsequent Events [Abstract] Subsequent Events Basis of Consolidation Use of Estimates Income (Loss) Per Share Revenue Recognition Non-controlling Interests Inventories Stock-based Compensation Recently Issued Accounting Pronouncements Schedule of Company's Consolidated Subsidiaries Summary of Restricted Common Stock Schedule of Stock Option Activity Schedule of Outstanding and Exercisable Options by Exercise Price Range EX-101.PRE 11 wcui-20210331_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	6 Months Ended
Document and Entity Information	Mar. 31, 2021 shares
Cover [Abstract]
Entity Registrant Name	Wellness Center USA, Inc.
Entity Central Index Key	0001516887
Document Type	10-Q
Document Period End Date	Mar. 31, 2021
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding	121,027,077
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2021

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2021	Sep. 30, 2020
Current Assets
Cash	$ 146,139	$ 51,320
Accounts receivable	9,018
Inventories, net	132,493	94,560
Prepaid expenses and other current assets		500
Total Current Assets	287,650	146,380
Right of use asset		6,961
Total Other Assets		6,961
TOTAL ASSETS	287,650	153,341
Current Liabilities
Accounts payable and accrued expenses	517,864	408,297
Payroll taxes payable, past due	84,834	92,334
Lease liability		6,961
Lease abandonment liability	672,878	672,878
Loans payable from officers and shareholders, including $830,250 past due at March 31, 2021	1,825,250	1,165,250
Total Current Liabilities	3,100,826	2,345,720
Long-term Liabilities
U.S. Small Business Administration PPP loan payable	37,166	37,166
Total Liabilities	3,137,992	2,382,886
Shareholders' Deficit
Common stock, par value $0.001, 200,000,000 shares authorized; 121,027,077 and 118,252,077 shares issued and outstanding, respectively	121,027	118,252
Additional paid-in capital	25,155,855	25,053,616
Accumulated deficit	(27,977,238)	(27,583,363)
Total Wellness Center USA shareholders' deficit	(2,700,356)	(2,411,495)
Non-controlling interest	(149,986)	181,950
Total Shareholder's deficit	(2,850,342)	(2,229,545)
TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT	$ 287,650	$ 153,341

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Mar. 31, 2021	Sep. 30, 2020
Statement of Financial Position [Abstract]
Loans payable from officers and shareholders, past due amount	$ 830,250
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares, issued	121,027,077	118,252,077
Common stock, shares, outstanding	121,027,077	118,252,077

- Definition

Portion of the carrying amount as of the balance sheet date of obligations due all related parties that is payable after one year or beyond the normal operating cycle if longer.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.23)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(C))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

+ Details

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020
Income Statement [Abstract]
Trade sales	$ 51,650	$ 5,000	$ 142,149	$ 5,000
Cost of goods sold	58,950		139,050
Gross profit (loss)	(7,300)	5,000	3,099	5,000
Operating expenses	362,218	423,130	670,759	760,403
Loss from operations	(369,518)	(418,130)	(667,660)	(755,403)
Other expenses
Cost of warrant modification		(507,265)		(507,265)
Interest expense	(31,993)	(16,211)	(58,151)	(25,534)
Total other expenses	(31,993)	(523,476)	(58,151)	(532,799)
NET LOSS	(401,511)	(941,606)	(725,811)	(1,288,202)
Net loss attributable to non-controlling interest	188,334	22,050	331,936	44,179
NET LOSS ATTRIBUTABLE TO WELLNESS CENTER USA, INC.	$ (213,177)	$ (919,556)	$ (393,875)	$ (1,244,023)
BASIC AND DILUTED LOSS PER SHARE	$ (0.00)	$ (0.01)	$ (0.01)	$ (0.01)
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING BASIC AND DILUTED	120,333,327	107,497,077	119,639,577	107,497,077

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Shareholders' Deficit (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total WCUI Deficit [Member]	Non-controlling Interest [Member]	Total
Balance at Sep. 30, 2019	$ 107,497	$ 23,777,647	$ (25,362,287)	$ (1,477,143)	$ 393,149	$ (1,083,994)
Balance, shares at Sep. 30, 2019	107,497,077
Fair value of vested stock options		131,538		131,538		131,538
Cost of warrant modification		507,265		507,265		507,265
Contribution of capital by joint venture partners		25,500		25,500	24,500	50,000
Net loss			(1,244,023)	(1,244,023)	(44,179)	(1,288,202)
Balance at Mar. 31, 2020	$ 107,497	24,441,950	(26,606,310)	(2,056,863)	373,470	(1,683,393)
Balance, shares at Mar. 31, 2020	107,497,077
Balance at Dec. 31, 2019	$ 107,497	23,868,885	(25,686,754)	(1,710,372)	395,520	(1,314,852)
Balance, shares at Dec. 31, 2019	107,497,077
Fair value of vested stock options		65,800		65,800		65,800
Fair value of common stock issued for services		507,265		507,265		507,265
Fair value of common stock issued for services, shares
Net loss			(919,556)	(919,556)	(22,050)	(941,606)
Balance at Mar. 31, 2020	$ 107,497	24,441,950	(26,606,310)	(2,056,863)	373,470	(1,683,393)
Balance, shares at Mar. 31, 2020	107,497,077
Balance at Sep. 30, 2020	$ 118,252	25,053,616	(27,583,363)	(2,411,495)	181,950	(2,229,545)
Balance, shares at Sep. 30, 2020	118,252,077
Fair value of vested stock options		21,764		21,764		21,764
Fair value of common stock issued for services	$ 2,775	80,475		83,250		83,250
Fair value of common stock issued for services, shares	2,775,000
Net loss			(393,875)	(393,875)	(331,936)	(725,811)
Balance at Mar. 31, 2021	$ 121,027	25,155,855	(27,977,238)	(2,700,356)	(149,986)	(2,850,342)
Balance, shares at Mar. 31, 2021	121,027,077
Balance at Dec. 31, 2020	$ 119,639	25,104,736	(27,764,061)	(2,539,686)	38,348	(2,501,338)
Balance, shares at Dec. 31, 2020	119,639,577
Fair value of vested stock options		10,882		10,882		10,882
Fair value of common stock issued for services	$ 1,388	40,237		41,625		41,625
Fair value of common stock issued for services, shares	1,387,500
Net loss			(213,177)	(213,177)	(188,334)	(401,511)
Balance at Mar. 31, 2021	$ 121,027	$ 25,155,855	$ (27,977,238)	$ (2,700,356)	$ (149,986)	$ (2,850,342)
Balance, shares at Mar. 31, 2021	121,027,077

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 23: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 31: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

+ Details

- Definition

Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 23
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(3)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 5
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793

Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (d)(2)
-URI http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (d)(3)
-URI http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4I
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900

Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (f)(1)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(3)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Publisher FASB
-Subparagraph (a)(3)(iii)(03)

+ Details

XML 17 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash Flows from Operating Activities
Net loss	$ (725,811)	$ (1,288,202)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense		1,562
Amortization of right-of-use asset	6,961	10,483
Provision for excess and slow moving inventories	100,000
Fair value of common shares issued for services	83,250
Fair value of stock options issued for services	21,764	131,538
Cost of warrant modification		507,265
(Increase) Decrease in:
Accounts receivable	(9,018)	(5,000)
Inventories	(137,933)	(10,660)
Prepaid expenses and other assets	500	(500)
(Decrease) Increase in:
Accounts payable and accrued expenses	109,567	132,496
Payroll taxes payable	(7,500)	(1,500)
Lease liability	(6,961)	(10,483)
Net cash used in operating activities	(565,181)	(533,001)
Cash Flows from Financing Activities
Proceeds from loans payable from officers and shareholders	660,000	470,000
Contribution of capital by joint venture partner		50,000
Net cash provided by financing activities	660,000	520,000
Net increase (decrease) in cash	94,819	(13,001)
Cash beginning of period	51,320	53,147
Cash end of period	146,139	40,146
Supplemental cash flows disclosures:
Interest paid
Taxes paid
Supplemental non-cash disclosures:
Initial recognition of right-of-use assets and operating lease liabilities upon adoption of ASC Topic 842		27,841
Reclassification of prepaid expenses to inventories		$ 55,000

XML 18 R7.htm IDEA: XBRL DOCUMENT

Basis of Presentation

6 Months Ended

Mar. 31, 2021

Accounting Policies [Abstract]

Basis of Presentation

NOTE 1 – BASIS OF PRESENTATION

Organization and Operations

Basis of Presentation of Unaudited Financial Information

COVID-19 Considerations

Going Concern

XML 19 R8.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

6 Months Ended

Mar. 31, 2021

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Consolidation

Name of consolidated subsidiary or entity	State or other jurisdiction of incorporation or organization	Date of incorporation or formation (date of acquisition/disposition, if applicable)	Attributable interest at September 30, 2020			Attributable interest at March 31, 2021
Psoria-Shield Inc. (“PSI”)	The State of Florida	June 2009 (August 2012)		51%	(1)		51%	(1)
StealthCo, Inc. (“StealthCo”)	The State of Illinois	March 2014		100	%		100	%
Psoria Development Company LLC. (“PDC”)	The State of Illinois	January 2015/November 2018		0	%		0	%
NEO Phototherapy LLC (“NEO”)	The State of Illinois	December 2018		0	%		0	%
Protec Scientific, Inc (“Protec”)	The State of New York	April 2020		32	%		32	%

(1) - Effective April 30, 2020, the Company’s 51% interest in NEO was converted into a 51% interest in PSI.

Use of Estimates

Income (Loss) Per Share

Revenue Recognition

We determine revenue recognition through the following steps:

●

Identification of the contract, or contracts, with a customer

●

Identification of the performance obligations in the contract

●

Determination of the transaction price

●

Allocation of the transaction price to the performance obligations in the contract

●

Recognition of revenue when, or as, we satisfy a performance obligation.

Non-controlling Interests

PSI

Protec

Inventories

Stock-Based Compensation

Recently Issued Accounting Pronouncements

XML 20 R9.htm IDEA: XBRL DOCUMENT

Loans Payable from Officers and Shareholders

6 Months Ended

Mar. 31, 2021

Debt Disclosure [Abstract]

Loans Payable from Officers and Shareholders

NOTE 3 – LOANS PAYABLE FROM OFFICERS AND SHAREHOLDERS

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI http://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

+ Details

XML 21 R10.htm IDEA: XBRL DOCUMENT

Lease Liabilities

6 Months Ended

Mar. 31, 2021

Leases [Abstract]

Lease Liabilities

NOTE 4 – LEASE LIABILITIES

Operating Lease

Other Leases

XML 22 R11.htm IDEA: XBRL DOCUMENT

Shareholders' Equity

6 Months Ended

Mar. 31, 2021

Equity [Abstract]

Shareholders' Equity

NOTE 5 – SHAREHOLDERS’ EQUITY

Restricted Stock Grants

The following table summarizes restricted common stock activity:

	Number of Restricted Shares			Fair Value			Weighted Average Grant Date Fair Value

Non-vested, September 30, 2020		10,275,000		$	308,250		$	0.03
Granted		-			-			-
Vested		(2,775,000	)		(83,250	)		0.03
Forfeited		-			-			-
Non-vested, March 31, 2021		7,500,000		$	225,00		$	0.03

Stock Options

The table below summarizes the Company’s stock option activities for the six months ended March 31, 2021:

	Number of Option Shares			Exercise Price Range Per Share		Weighted Average Exercise Price

Balance, September 30, 2020		14,127,738		$	0.03 - 2.00	$	0.29
Granted		-			-		-
Cancelled		-			-		-
Exercised		-			-		-
Expired		(1,525,000	)		0.14 - 2.00		1.36
Balance, March 31, 2021		12,602,738		$	0.03 - 0.40	$	0.10
Vested and exercisable, March 31, 2021		10,102,738		$	0.03 - 0.40	$	0.11

Unvested, March 31, 2021		2,500,000		$	0.04	$	0.04

The following table summarizes information concerning outstanding and exercisable options as of March 31, 2021:

		Options Outstanding						Options Exercisable
Range of Exercise Prices		Number Outstanding		Average Remaining Contractual Life (in years)		Weighted Average Exercise Price		Number Exercisable		Average Remaining Contractual Life (in years)		Weighted Average Exercise Price

$	0.03 - 0.39		12,540,238		5.09	$	0.09		10,040,238		4.12	$	0.11
	0.40		62,500		1.00		0.40		62,500		1.00		0.40
$	0.03 - 0.40		12,602,738		5.07	$	0.10		10,102,738		4.10	$	0.11

Stock Warrants

The table below summarizes the Company’s warrants activities for the six months ended March 31, 2021:

	Number of Warrant Shares			Exercise Price Range Per Share		Weighted Average Exercise Price

Balance, September 30, 2020		67,634,049			$ 0.07 - 0.40	$	0.16
Granted		-			-		-
Cancelled		-			-		-
Exercised		-			-		-
Expired		(13,254,291	)		0.15		0.15
Balance, March 31, 2021		54,379,758		$	0.07 - 0.40	$	0.17
Vested and exercisable, March 31, 2021		54,379,758		$	0.07 - 0.40	$	0.17

The following table summarizes information concerning outstanding and exercisable warrants as of March 31, 2021:

		Warrants Outstanding						Warrants Exercisable
Range of Exercise Prices		Number Outstanding		Average Remaining Contractual Life (in years)		Weighted Average Exercise Price		Number Exercisable		Average Remaining Contractual Life (in years)		Weighted Average Exercise Price

$	0.12 – 0.20		47,175,093		1.97	$	0.15		47,175,093		1.97	$	0.15
	0.21 – 0.40		7,204,665		0.40		0.26		7,204,665		0.40		0.26

$	0.12 – 0.67		54,379,758		1.76	$	0.17		54,379,758		1.76	$	0.17

There was no aggregate intrinsic value for warrant shares outstanding at March 31, 2021.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

XML 23 R12.htm IDEA: XBRL DOCUMENT

Segment Reporting

6 Months Ended

Mar. 31, 2021

Segment Reporting [Abstract]

Segment Reporting

NOTE 6 – SEGMENT REPORTING

The Company operates in the following business segments:

The detailed segment information of the Company is as follows:

Assets By Segment

	March 31, 2021
	Corporate		Medical Devices		Authentication and Encryption		Total
ASSETS
Current Assets
Cash	$	523	$	141,994	$	3,622	$	146,139
Accounts receivable		-		9,018		-		9,018
Inventories		-		132,493		-		132,493
Prepaid expenses and other current assets		-		-		-		-
Total current assets		523		283,505		3,622		287,650

TOTAL ASSETS	$	523	$	283,505	$	3,622	$	287,650

Operations by Segment for the Three Months Ended March 31, 2021 and 2020

	For the Three Months Ended
	March 31, 2021
	Corporate			Medical Devices			Authentication and Encryption			Total

Trade Sales	$	-		$	51,650		$	-		$	51,650

Cost of goods sold		-			58,950			-			58,950

Gross profit		-			(7,300	)		-			(7,300	)

Operating expenses		46,661			308,543			7,014			362,218

Loss from operations	$	(46,661	)	$	(315,843	)	$	(7,014	)	$	(369,518	)

	For the Three Months Ended
	March 31, 2020
							Stealthco
	WCUI			PSI			Authentication and
	Corporate			Medical Devices			Encryption			Total

Trade Sales	$	-		$	-		$	5,000		$	5,000

Cost of goods sold		-			-			-			-

Gross profit		-			-			5,000			5,000

Operating expenses		142,500			206,824			73,806			423,130

Loss from operations	$	(142,500	)	$	(206,824	)	$	(68,806	)	$	(418,130	)

Operations by Segment for the Six Months Ended March 31, 2021 and 2020

	For the Six Months Ended
	March 31, 2021
	Corporate			Medical Devices			Authentication and Encryption			Total

Trade Sales	$	-		$	142,149		$	-		$	142,149

Cost of goods sold		-			139,050			-			139,050

Gross profit		-			3,099			-			3,099

Operating expenses		95,770			565,014			9,975			670,759

Loss from operations	$	(95,770	)	$	(561,915	)	$	(9,975	)	$	(667,660	)

	For the Six Months Ended
	March 31, 2020
							Stealthco
	WCUI			PSI			Authentication
	Corporate			Medical Devices			and Encryption			Total

Trade Sales	$	-		$	-		$	5,000		$	5,000

Cost of goods sold		-			-			-			-

Gross profit		-			-			5,000			5,000

Operating expenses		240,962			382,110			137,331			760,403

Loss from operations	$	(240,962	)	$	(382,110	)	$	(132,331	)	$	(755,403	)

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI http://asc.fasb.org/topic&trid=2134510

+ Details

XML 24 R13.htm IDEA: XBRL DOCUMENT

Legal Matters

6 Months Ended

Mar. 31, 2021

Commitments and Contingencies Disclosure [Abstract]

Legal Matters

NOTE 7 – LEGAL MATTERS

XML 25 R14.htm IDEA: XBRL DOCUMENT

Subsequent Events

6 Months Ended

Mar. 31, 2021

Subsequent Events [Abstract]

Subsequent Events

NOTE 8 – SUBSEQUENT EVENTS

XML 26 R15.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)

6 Months Ended

Mar. 31, 2021

Accounting Policies [Abstract]

Basis of Consolidation

Basis of Consolidation

Name of consolidated subsidiary or entity	State or other jurisdiction of incorporation or organization	Date of incorporation or formation (date of acquisition/disposition, if applicable)	Attributable interest at September 30, 2020			Attributable interest at March 31, 2021
Psoria-Shield Inc. (“PSI”)	The State of Florida	June 2009 (August 2012)		51%	(1)		51%	(1)
StealthCo, Inc. (“StealthCo”)	The State of Illinois	March 2014		100	%		100	%
Psoria Development Company LLC. (“PDC”)	The State of Illinois	January 2015/November 2018		0	%		0	%
NEO Phototherapy LLC (“NEO”)	The State of Illinois	December 2018		0	%		0	%
Protec Scientific, Inc (“Protec”)	The State of New York	April 2020		32	%		32	%

(1) - Effective April 30, 2020, the Company’s 51% interest in NEO was converted into a 51% interest in PSI.

Use of Estimates

Use of Estimates

Income (Loss) Per Share

Income (Loss) Per Share

Revenue Recognition

Revenue Recognition

We determine revenue recognition through the following steps:

●

Identification of the contract, or contracts, with a customer

●

Identification of the performance obligations in the contract

●

Determination of the transaction price

●

Allocation of the transaction price to the performance obligations in the contract

●

Recognition of revenue when, or as, we satisfy a performance obligation.

Non-controlling Interests

Non-controlling Interests

PSI

Protec

Inventories

Inventories

Stock-based Compensation

Stock-Based Compensation

Recently Issued Accounting Pronouncements

Recently Issued Accounting Pronouncements

- Definition

Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.

+ References + Details

- Definition

Disclosure of accounting policy for revenue from contract with customer.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 20
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 20
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 20
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 20
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045

+ Details

XML 27 R16.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

6 Months Ended

Mar. 31, 2021

Accounting Policies [Abstract]

Schedule of Company's Consolidated Subsidiaries

The Company’s consolidated subsidiaries and/or controlled entities are as follows:

Name of consolidated subsidiary or entity	State or other jurisdiction of incorporation or organization	Date of incorporation or formation (date of acquisition/disposition, if applicable)	Attributable interest at September 30, 2020			Attributable interest at March 31, 2021
Psoria-Shield Inc. (“PSI”)	The State of Florida	June 2009 (August 2012)		51%	(1)		51%	(1)
StealthCo, Inc. (“StealthCo”)	The State of Illinois	March 2014		100	%		100	%
Psoria Development Company LLC. (“PDC”)	The State of Illinois	January 2015/November 2018		0	%		0	%
NEO Phototherapy LLC (“NEO”)	The State of Illinois	December 2018		0	%		0	%
Protec Scientific, Inc (“Protec”)	The State of New York	April 2020		32	%		32	%

(1) - Effective April 30, 2020, the Company’s 51% interest in NEO was converted into a 51% interest in PSI.

XML 28 R17.htm IDEA: XBRL DOCUMENT

Shareholders' Equity (Tables)

6 Months Ended

Mar. 31, 2021

Equity [Abstract]

Summary of Restricted Common Stock

The following table summarizes restricted common stock activity:

	Number of Restricted Shares			Fair Value			Weighted Average Grant Date Fair Value

Non-vested, September 30, 2020		10,275,000		$	308,250		$	0.03
Granted		-			-			-
Vested		(2,775,000	)		(83,250	)		0.03
Forfeited		-			-			-
Non-vested, March 31, 2021		7,500,000		$	225,00		$	0.03

Schedule of Stock Option Activity

The table below summarizes the Company’s stock option activities for the six months ended March 31, 2021:

	Number of Option Shares			Exercise Price Range Per Share		Weighted Average Exercise Price

Balance, September 30, 2020		14,127,738		$	0.03 - 2.00	$	0.29
Granted		-			-		-
Cancelled		-			-		-
Exercised		-			-		-
Expired		(1,525,000	)		0.14 - 2.00		1.36
Balance, March 31, 2021		12,602,738		$	0.03 - 0.40	$	0.10
Vested and exercisable, March 31, 2021		10,102,738		$	0.03 - 0.40	$	0.11

Unvested, March 31, 2021		2,500,000		$	0.04	$	0.04

Schedule of Outstanding and Exercisable Options by Exercise Price Range

The following table summarizes information concerning outstanding and exercisable options as of March 31, 2021:

		Options Outstanding						Options Exercisable
Range of Exercise Prices		Number Outstanding		Average Remaining Contractual Life (in years)		Weighted Average Exercise Price		Number Exercisable		Average Remaining Contractual Life (in years)		Weighted Average Exercise Price

$	0.03 - 0.39		12,540,238		5.09	$	0.09		10,040,238		4.12	$	0.11
	0.40		62,500		1.00		0.40		62,500		1.00		0.40
$	0.03 - 0.40		12,602,738		5.07	$	0.10		10,102,738		4.10	$	0.11

Schedule of Warrant Activity

The table below summarizes the Company’s warrants activities for the six months ended March 31, 2021:

	Number of Warrant Shares			Exercise Price Range Per Share		Weighted Average Exercise Price

Balance, September 30, 2020		67,634,049			$ 0.07 - 0.40	$	0.16
Granted		-			-		-
Cancelled		-			-		-
Exercised		-			-		-
Expired		(13,254,291	)		0.15		0.15
Balance, March 31, 2021		54,379,758		$	0.07 - 0.40	$	0.17
Vested and exercisable, March 31, 2021		54,379,758		$	0.07 - 0.40	$	0.17

Schedule of Outstanding and Exercisable Warrants by Exercise Price Range

The following table summarizes information concerning outstanding and exercisable warrants as of March 31, 2021:

		Warrants Outstanding						Warrants Exercisable
Range of Exercise Prices		Number Outstanding		Average Remaining Contractual Life (in years)		Weighted Average Exercise Price		Number Exercisable		Average Remaining Contractual Life (in years)		Weighted Average Exercise Price

$	0.12 – 0.20		47,175,093		1.97	$	0.15		47,175,093		1.97	$	0.15
	0.21 – 0.40		7,204,665		0.40		0.26		7,204,665		0.40		0.26

$	0.12 – 0.67		54,379,758		1.76	$	0.17		54,379,758		1.76	$	0.17

XML 29 R18.htm IDEA: XBRL DOCUMENT

Segment Reporting (Tables)

6 Months Ended

Mar. 31, 2021

Segment Reporting [Abstract]

Schedule of Assets of Reportable Segments

The detailed segment information of the Company is as follows:

Assets By Segment

	March 31, 2021
	Corporate		Medical Devices		Authentication and Encryption		Total
ASSETS
Current Assets
Cash	$	523	$	141,994	$	3,622	$	146,139
Accounts receivable		-		9,018		-		9,018
Inventories		-		132,493		-		132,493
Prepaid expenses and other current assets		-		-		-		-
Total current assets		523		283,505		3,622		287,650

TOTAL ASSETS	$	523	$	283,505	$	3,622	$	287,650

Schedule of Operations of Reportable Segments

Operations by Segment for the Three Months Ended March 31, 2021 and 2020

	For the Three Months Ended
	March 31, 2021
	Corporate			Medical Devices			Authentication and Encryption			Total

Trade Sales	$	-		$	51,650		$	-		$	51,650

Cost of goods sold		-			58,950			-			58,950

Gross profit		-			(7,300	)		-			(7,300	)

Operating expenses		46,661			308,543			7,014			362,218

Loss from operations	$	(46,661	)	$	(315,843	)	$	(7,014	)	$	(369,518	)

	For the Three Months Ended
	March 31, 2020
							Stealthco
	WCUI			PSI			Authentication and
	Corporate			Medical Devices			Encryption			Total

Trade Sales	$	-		$	-		$	5,000		$	5,000

Cost of goods sold		-			-			-			-

Gross profit		-			-			5,000			5,000

Operating expenses		142,500			206,824			73,806			423,130

Loss from operations	$	(142,500	)	$	(206,824	)	$	(68,806	)	$	(418,130	)

Operations by Segment for the Six Months Ended March 31, 2021 and 2020

	For the Six Months Ended
	March 31, 2021
	Corporate			Medical Devices			Authentication and Encryption			Total

Trade Sales	$	-		$	142,149		$	-		$	142,149

Cost of goods sold		-			139,050			-			139,050

Gross profit		-			3,099			-			3,099

Operating expenses		95,770			565,014			9,975			670,759

Loss from operations	$	(95,770	)	$	(561,915	)	$	(9,975	)	$	(667,660	)

	For the Six Months Ended
	March 31, 2020
							Stealthco
	WCUI			PSI			Authentication
	Corporate			Medical Devices			and Encryption			Total

Trade Sales	$	-		$	-		$	5,000		$	5,000

Cost of goods sold		-			-			-			-

Gross profit		-			-			5,000			5,000

Operating expenses		240,962			382,110			137,331			760,403

Loss from operations	$	(240,962	)	$	(382,110	)	$	(132,331	)	$	(755,403	)

XML 30 R19.htm IDEA: XBRL DOCUMENT

Basis of Presentation (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
Basis of Presentation (Details Narrative) - USD ($)	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020	Sep. 30, 2020	Dec. 31, 2019	Sep. 30, 2019
Accounting Policies [Abstract]
Net loss	$ (401,511)	$ (941,606)	$ (725,811)	$ (1,288,202)
Cash used in operations			(565,181)	(533,001)
Shareholders' deficit	(2,850,342)	$ (1,683,393)	(2,850,342)	(1,683,393)	$ (2,501,338)	$ (2,229,545)	$ (1,314,852)	$ (1,083,994)
Loans payable	830,250		830,250
Payroll taxes due	84,834		84,834			92,334
Cash on hand	$ 146,139		146,139			$ 51,320
Short-term lonas from officers			$ 660,000	$ 470,000

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

XML 31 R20.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended
	May 30, 2020	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020	Sep. 30, 2020	Apr. 30, 2020	Sep. 30, 2019	Apr. 30, 2019	Dec. 31, 2018
Deferred revenue
Operating loss		(369,518)	$ (418,130)	(667,660)	$ (755,403)
Non-controlling interest		(188,334)	$ (22,050)	(331,936)	$ (44,179)
Additional paid-in capital		25,155,855		25,155,855		25,053,616
Inventory reserves		100,000		$ 100,000		100,000
April 30, 2020 [Member]
Non-controlling interest, description				GEN2 shareholders exchanged their common shares in GEN2, and the individual exchanged his membership interests in NEO, for common shares representing 49% ownership in PSI. The Company retained its common shares in PSI, which provides the Company a 51% economic interest in the PSI technology and products developed by the joint venture. During three and six months ended March 31, 2021, PSI recorded a loss of $187,077 and $338,510, respectively, relating to its operations, of which $91,668 and $165,870, respectively, was allocated to the non-controlling interest.
Operating loss		187,077		$ 338,510
Non-controlling interest		91,668		165,870
Repayment from investment				975,000
Distributable cash		300,000		300,000
Joint Venture [Member]
Ownership percentage							51.00%
GEN2 [Member]
Ownership percentage									39.00%
Investments to others								$ 975,000
Individual [Member]
Ownership percentage							10.00%
Protec Scientific, Inc [Member]
Operating loss		141,365		242,857
Acquisition description	In May 2020, the Company's subsidiary, PSI, agreed to become a majority shareholder in Protec Scientific, Inc. ("Protec"), a company formed in April 2020. As of September 30, 2020, PSI had contributed $191,000 to Protec with the Company's share being approximately 32%, based on its PSI ownership. The remaining share is attributed to PSI's minority shareholders. During the year ended September 30, 2020, Protec received an additional $120,000 from non-affiliated investors. The additional investments gave the non-controlling interests a 68% ownership interest in Protec. During the three and six months ended March 31, 2021, Protec recorded a loss of $141,365 and $242,857, respectively, of which $96,665 and $166,065 was allocated to the non-controlling interests.
Additional paid-in capital						$ 120,000
Loss allocated to the non-controlling interests		$ 96,665		166,065
Psoria-Shield, Inc [Member]
Ownership percentage										50.50%
Proceeds from investment				$ 750,000
Gen 2 Funding, Inc [Member]
Ownership percentage										36.00%
Stock Option [Member]
Antidilutive securities excluded from computation of earnings per share				12,602,738	14,837,738
Warrants [Member]
Antidilutive securities excluded from computation of earnings per share				54,379,758	66,484,049

XML 32 R21.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Schedule of Company's Consolidated Subsidiaries (Details)

6 Months Ended

Mar. 31, 2021

Sep. 30, 2020

Psoria-Shield, Inc [Member]

Name of consolidated subsidiary or entity

Psoria-Shield Inc. ("PSI")

State or other jurisdiction of incorporation or organization

The State of Florida

Month and Year of incorporation or formation

2009-06

Month and Year of acquisition/disposition

2012-08

Attributable interest

^[1]

51.00%

StealthCo, Inc. [Member]

Name of consolidated subsidiary or entity

StealthCo, Inc. ("StealthCo")

State or other jurisdiction of incorporation or organization

The State of Illinois

Month and Year of incorporation or formation

2014-03

Attributable interest

100.00%

Psoria Development Company LLC. [Member]

Name of consolidated subsidiary or entity

Psoria Development Company LLC. ("PDC")

State or other jurisdiction of incorporation or organization

The State of Illinois

Month and Year of incorporation or formation

2015-01

Month and Year of acquisition/disposition

2018-11

Attributable interest

0.00%

NEO Phototherapy, LLC, [Member]

Name of consolidated subsidiary or entity

NEO Phototherapy LLC ("NEO")

State or other jurisdiction of incorporation or organization

The State of Illinois

Month and Year of incorporation or formation

2018-12

Attributable interest

0.00%

Protec Scientific, Inc [Member]

Name of consolidated subsidiary or entity

Protec Scientific, Inc ("Protec")

State or other jurisdiction of incorporation or organization

The State of New York

Month and Year of incorporation or formation

2020-04

Attributable interest

32.00%

[1]	Effective April 30, 2020, the Company's 51% interest in NEO was converted into a 51% interest in PSI.

XML 33 R22.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Schedule of Company's Consolidated Subsidiaries (Details) (Parenthetical)

Mar. 31, 2021

Sep. 30, 2020

NEO Phototherapy, LLC, [Member]

Attributable interest

0.00%

Psoria-Shield, Inc [Member]

Attributable interest

^[1]

51.00%

April 30, 2020 [Member] | NEO Phototherapy, LLC, [Member]

Attributable interest

51.00%

April 30, 2020 [Member] | Psoria-Shield, Inc [Member]

Attributable interest

51.00%

[1]	Effective April 30, 2020, the Company's 51% interest in NEO was converted into a 51% interest in PSI.

XML 34 R23.htm IDEA: XBRL DOCUMENT

Loans Payable from Officers and Shareholders (Details Narrative) - USD ($)	6 Months Ended
	Mar. 31, 2021	Sep. 30, 2020
Debt Disclosure [Abstract]
Loans payable to officers and shareholders	$ 1,825,250	$ 1,165,250
Proceeds from officers and shareholders	660,000
Loans payable from officers and shareholders, past due amount	$ 830,250

- Definition

Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(C))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

+ Details

- Definition

Portion of the carrying amount as of the balance sheet date of obligations due all related parties that is payable after one year or beyond the normal operating cycle if longer.

+ References

+ Details

XML 35 R24.htm IDEA: XBRL DOCUMENT

Lease Liabilities (Details Narrative) - USD ($)		1 Months Ended	3 Months Ended	6 Months Ended
Lease Liabilities (Details Narrative) - USD ($)	Jun. 29, 2020	Feb. 28, 2019	Mar. 31, 2021	Mar. 31, 2021	Mar. 31, 2020	Sep. 30, 2020
Lease term		24 months
Payment for lease liability		$ 1,850	$ 1,613	$ 6,961
Lease expiration date		Jan. 31, 2021
Right of use assets		$ 27,841				$ 6,961
Lease, discount rate		4.00%
Lease liability						$ 6,961
Lease rent expense			1,794	7,142
Amortization of right of use asset			1,613	6,961	$ 10,483
Monthly lease payment				11,000
Lease obligation remaining			$ 631,587	$ 631,587
Hanover Hoffman Estates LLC [Member]
Lease rent expense	$ 672,878

XML 36 R25.htm IDEA: XBRL DOCUMENT

Shareholders' Equity (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended	6 Months Ended
Shareholders' Equity (Details Narrative) - USD ($)	Apr. 30, 2020	Mar. 31, 2021	Mar. 31, 2021	Sep. 30, 2020	Jan. 02, 2018	Dec. 29, 2017
Common stock, shares authorized		200,000,000	200,000,000	200,000,000
Stock options remaining available shares		12,602,738	12,602,738	14,127,738
Aggregate intrinsic value for warrant		$ 22,500	$ 22,500	$ 308,250
Restricted Stock [Member]
Number of vested shares		1,387,500	2,775,000
Stock based compensation		$ 41,625	$ 83,250
Unvested compensation		$ 225,000	$ 225,000
Stock Option [Member]
Number of vested shares		10,882	21,764
Unvested compensation		$ 75,000	$ 75,000
Aggregate intrinsic value		$ 625	$ 625
2010 Non-Qualified Stock Option Plan [Member]
Common stock, shares authorized					30,000,000	7,500,000
2010 Non-Qualified Stock Option Plan [Member] \| Stock Option [Member]
Stock options remaining available shares		17,397,262	17,397,262
Vest Monthly from April 2020 Through March 2021 [Member]
Number of vested shares	1,800,000
Vest Monthly from April 2020 Through March 2023 [Member]
Number of vested shares	11,250,000
Vest Over Time [Member]
Number of vested shares	13,050,000
Board of Directors [Member]
Number of restricted shares issued during period, shares	20,170,000
Number of vested shares	7,120,000
Warrant [Member]
Aggregate intrinsic value for warrant

XML 37 R26.htm IDEA: XBRL DOCUMENT

Shareholders' Equity - Summary of Restricted Common Stock (Details)	6 Months Ended
	Mar. 31, 2021 USD ($) $ / shares shares
Equity [Abstract]
Number of Restricted Shares Non-vested, Beginning balance \| shares	10,275,000
Number of Restricted Shares Non-vested, Granted \| shares
Number of Restricted Shares Non-vested, Vested \| shares	(2,775,000)
Number of Restricted Shares Non-vested, Forfeited \| shares
Number of Restricted Shares Non-vested, Ending balance \| shares	7,500,000
Fair Value Non-vested, Beginning balance \| $	$ 308,250
Fair Value Non-vested, Granted \| $
Fair Value Non-vested, Vested \| $	(83,250)
Fair Value Non-vested, Forfeited \| $
Fair Value Non-vested, Ending balance \| $	$ 22,500
Weighted Average Grant Date Fair Value Non-vested, Beginning balance \| $ / shares	$ 0.03
Weighted Average Grant Date Fair Value Non-vested, Granted \| $ / shares
Weighted Average Grant Date Fair Value Non-vested, Vested \| $ / shares	0.03
Weighted Average Grant Date Fair Value Non-vested, Forfeited \| $ / shares
Weighted Average Grant Date Fair Value Non-vested, Ending balance \| $ / shares	$ 0.03

XML 38 R27.htm IDEA: XBRL DOCUMENT

Shareholders' Equity - Schedule of Stock Option Activity (Details)	6 Months Ended
	Mar. 31, 2021 $ / shares shares
Number of Option Shares Outstanding, Number, Beginning balance \| shares	14,127,738
Number of Option Shares Outstanding, Granted \| shares
Number of Option Shares Outstanding, Cancelled \| shares
Number of Option Shares Outstanding, Exercised \| shares
Number of Option Shares Outstanding, Expired \| shares	(1,525,000)
Number of Option Shares Outstanding, Number, Ending balance \| shares	12,602,738
Number of Option Shares Outstanding, Vested and exercisable, Ending balance \| shares	10,102,738
Number of Option Shares Outstanding, Unvested, Ending balance \| shares	2,500,000
Exercise Price Range Per Share, Granted
Exercise Price Range Per Share, Cancelled
Exercise Price Range Per Share, Exercised
Exercise Price Range Per Share, Unvested, Ending balance	0.04
Weighted Average Exercise Price, Number, Beginning balance	0.29
Weighted Average Exercise Price, Granted
Weighted Average Exercise Price, Cancelled
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Expired	1.36
Weighted Average Exercise Price, Number, Ending balance	0.10
Weighted Average Exercise Price, Vested and exercisable, Ending balance	0.11
Weighted Average Exercise Price, Unvested, Ending balance	0.04
Minimum [Member]
Exercise Price Range Per Share, Number, Beginning balance	0.03
Exercise Price Range Per Share, Expired	0.14
Exercise Price Range Per Share, Number, Ending balance	0.03
Exercise Price Range Per Share, Vested and exercisable, Ending balance	0.03
Maximum [Member]
Exercise Price Range Per Share, Number, Beginning balance	2.00
Exercise Price Range Per Share, Expired	2.00
Exercise Price Range Per Share, Number, Ending balance	0.40
Exercise Price Range Per Share, Vested and exercisable, Ending balance	$ 0.40

XML 39 R28.htm IDEA: XBRL DOCUMENT

Shareholders' Equity - Schedule of Outstanding and Exercisable Options by Exercise Price Range (Details) - $ / shares	6 Months Ended
	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020
Range of Exercise Prices, Lower Limit	$ 0.03
Range of Exercise Prices, Upper Limit	$ 0.40
Number of Options, Outstanding, Number	12,602,738		14,127,738
Number of Options, Outstanding, Weighted Average Remaining Contractual Term	5 years 26 days
Number of Options, Outstanding, Weighted Average Exercise Price	$ 0.10		$ 0.29
Number of Options, Exercisable, Number	10,102,738
Number of Options, Exercisable, Weighted Average Remaining Contractual Term	4 years 1 month 6 days
Number of Options, Exercisable, Weighted Average Exercise Price	$ 0.11
Exercise Price Range One [Member]
Range of Exercise Prices, Lower Limit	0.03
Range of Exercise Prices, Upper Limit	$ 0.39
Number of Options, Outstanding, Number	12,540,238
Number of Options, Outstanding, Weighted Average Remaining Contractual Term	5 years 1 month 2 days
Number of Options, Outstanding, Weighted Average Exercise Price	$ 0.09
Number of Options, Exercisable, Number	10,040,238
Number of Options, Exercisable, Weighted Average Remaining Contractual Term	4 years 1 month 13 days
Number of Options, Exercisable, Weighted Average Exercise Price	$ 0.11
Exercise Price Range Two [Member]
Range of Exercise Prices, Upper Limit	$ 0.40
Number of Options, Outstanding, Number		62,500
Number of Options, Outstanding, Weighted Average Remaining Contractual Term	1 year
Number of Options, Outstanding, Weighted Average Exercise Price		$ 0.40
Number of Options, Exercisable, Number		62,500
Number of Options, Exercisable, Weighted Average Remaining Contractual Term	1 year
Number of Options, Exercisable, Weighted Average Exercise Price		$ 0.40

XML 40 R29.htm IDEA: XBRL DOCUMENT

Shareholders' Equity - Schedule of Warrant Activity (Details) - Warrant [Member]	6 Months Ended
	Mar. 31, 2021 $ / shares shares
Number of Warrant Shares Outstanding, Number, Beginning Balance \| shares	67,634,049
Number of Warrant Shares Outstanding, Granted \| shares
Number of Warrant Shares Outstanding, Cancelled \| shares
Number of Warrant Shares Outstanding, Exercised \| shares
Number of Warrant Shares Outstanding, Expired \| shares	(13,254,291)
Number of Warrant Shares Outstanding, Number, Ending Balance \| shares	54,379,758
Number of Warrant Shares Outstanding, Vested and exercisable, Ending Balance \| shares	54,379,758
Weighted Average Exercise Price, Number, Beginning Balance	$ 0.16
Weighted Average Exercise Price, Granted
Weighted Average Exercise Price, Cancelled
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Expired	0.15
Weighted Average Exercise Price, Number, Ending Balance	0.17
Weighted Average Exercise Price, Vested and exercisable, Ending Balance	0.17
Minimum [Member]
Weighted Average Exercise Price, Number, Beginning Balance	0.07
Weighted Average Exercise Price, Granted
Weighted Average Exercise Price, Cancelled
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Expired
Weighted Average Exercise Price, Number, Ending Balance	0.07
Weighted Average Exercise Price, Vested and exercisable, Ending Balance	0.07
Maximum [Member]
Weighted Average Exercise Price, Number, Beginning Balance	0.40
Weighted Average Exercise Price, Granted
Weighted Average Exercise Price, Cancelled
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Expired
Weighted Average Exercise Price, Number, Ending Balance	0.40
Weighted Average Exercise Price, Vested and exercisable, Ending Balance	$ 0.40

XML 41 R30.htm IDEA: XBRL DOCUMENT

Shareholders' Equity - Schedule of Outstanding and Exercisable Warrants by Exercise Price Range (Details) - Warrant [Member] - $ / shares	6 Months Ended
	Mar. 31, 2021	Sep. 30, 2020
Range of Exercise Prices, Lower Limit	$ 0.12
Range of Exercise Prices, Upper Limit	$ 0.67
Number of Warrants, Outstanding, Number	54,379,758	67,634,049
Number of Warrants, Outstanding, Weighted Average Remaining Contractual Term	1 year 9 months 3 days
Number of Warrants, Outstanding, Weighted Average Exercise Price	$ 0.17
Number of Warrants, Exercisable, Number	54,379,758
Number of Warrants, Exercisable, Weighted Average Remaining Contractual Term	1 year 9 months 3 days
Number of Warrants, Exercisable, Weighted Average Exercise Price	$ .17
Exercise Price Range One [Member]
Range of Exercise Prices, Lower Limit	0.12
Range of Exercise Prices, Upper Limit	$ 0.20
Number of Warrants, Outstanding, Number	47,175,093
Number of Warrants, Outstanding, Weighted Average Remaining Contractual Term	1 year 11 months 19 days
Number of Warrants, Outstanding, Weighted Average Exercise Price	$ 0.15
Number of Warrants, Exercisable, Number	47,175,093
Number of Warrants, Exercisable, Weighted Average Remaining Contractual Term	1 year 11 months 19 days
Number of Warrants, Exercisable, Weighted Average Exercise Price	$ 0.15
Exercise Price Range Two [Member]
Range of Exercise Prices, Lower Limit	0.21
Range of Exercise Prices, Upper Limit	$ 0.40
Number of Warrants, Outstanding, Number	7,204,665
Number of Warrants, Outstanding, Weighted Average Remaining Contractual Term	4 months 24 days
Number of Warrants, Outstanding, Weighted Average Exercise Price	$ 0.26
Number of Warrants, Exercisable, Number	7,204,665
Number of Warrants, Exercisable, Weighted Average Remaining Contractual Term	4 months 24 days
Number of Warrants, Exercisable, Weighted Average Exercise Price	$ 0.26

XML 42 R31.htm IDEA: XBRL DOCUMENT

Segment Reporting - Schedule of Assets of Reportable Segments (Details) - USD ($)	Mar. 31, 2021	Sep. 30, 2020
Cash	$ 146,139	$ 51,320
Accounts receivable	9,018
Inventories	132,493	94,560
Prepaid expenses and other current assets		500
Total current assets	287,650	146,380
TOTAL ASSETS	287,650	$ 153,341
Corporate [Member]
Cash	523
Accounts receivable
Inventories
Prepaid expenses and other current assets
Total current assets	523
TOTAL ASSETS	523
Medical Devices [Member]
Cash	141,994
Accounts receivable	9,018
Inventories	132,493
Prepaid expenses and other current assets
Total current assets	283,505
TOTAL ASSETS	283,505
Authentication and Encryption [Member]
Cash	3,622
Accounts receivable
Inventories
Prepaid expenses and other current assets
Total current assets	3,622
TOTAL ASSETS	$ 3,622

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

+ Details

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

+ Details

XML 43 R32.htm IDEA: XBRL DOCUMENT

Segment Reporting - Schedule of Operations of Reportable Segments (Details) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020
Total Sales	$ 51,650	$ 5,000	$ 142,149	$ 5,000
Cost of goods sold	58,950		139,050
Gross profit	(7,300)	5,000	3,099	5,000
Operating expenses	362,218	423,130	670,759	760,403
Loss from operations	(369,518)	(418,130)	(667,660)	(755,403)
Corporate [Member]
Total Sales
Cost of goods sold
Gross profit
Operating expenses	46,661	142,500	95,770	240,962
Loss from operations	(46,661)	(142,500)	(95,770)	(240,962)
Medical Devices [Member]
Total Sales	51,650		142,149
Cost of goods sold	58,950		139,050
Gross profit	(7,300)		3,099
Operating expenses	308,543	206,824	565,014	382,110
Loss from operations	(315,843)	(206,824)	(561,915)	(382,110)
Authentication and Encryption [Member]
Total Sales		5,000		5,000
Cost of goods sold
Gross profit		5,000		5,000
Operating expenses	7,014	73,806	9,975	137,331
Loss from operations	$ (7,014)	$ (68,806)	$ (9,975)	$ (132,331)

- Definition

Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1,2)
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

+ Details

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

XML 44 R33.htm IDEA: XBRL DOCUMENT

Legal Matters (Details Narrative)	6 Months Ended
Legal Matters (Details Narrative)	Mar. 31, 2021 USD ($)
Interest rate of negotiated settlement	4.00%
Ex- Employee [Member]
Claims amount	$ 21,600
Wages increase rate	2.00%
Former CEO [Member]
Claims amount	$ 179,548
Wages increase rate	2.00%
Claim alleges unpaid wages	$ 158,715
Unpaid vacation amount	$ 20,833

XML 45 R34.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details Narrative) - USD ($)		1 Months Ended	6 Months Ended
Subsequent Events (Details Narrative) - USD ($)	Apr. 01, 2021	Apr. 30, 2020	Mar. 31, 2021	Jun. 30, 2021
Number of stock options granted to purchase
Number of stock options cancelled
Board of Directors [Member]
Number of restricted shares issued during period, shares		20,170,000
Number of vested shares		7,120,000
Subsequent Event [Member] \| Officers and Shareholders [Member]
Loans payable to related parties				$ 66,000
Subsequent Event [Member] \| Board of Directors [Member] \| April 2023 Through March 2024 [Member]
Number of restricted shares issued during period, shares	3,750,000
Fair value of options granted	$ 187,500
Subsequent Event [Member] \| Officers and Directors [Member]
Number of restricted shares issued during period, shares	10,085,714
Fair value of options granted	$ 504,286
Number of vested shares	7,060,000
Subsequent Event [Member] \| Officers and Directors [Member] \| April 2025 [Member]
Number of vested shares	3,025,714
Subsequent Event [Member] \| CEO [Member]
Fair value of options granted	$ 670,000
Number of vested shares	9,052,500
Number of stock options granted to purchase	13,449,429
Share exercise price	$ 0.05
Subsequent Event [Member] \| CEO [Member] \| April 2023 Through March 2024 [Member]
Fair value of options granted	$ 65,000
Number of stock options granted to purchase	1,300,000
Share exercise price	$ 0.05
Subsequent Event [Member] \| CEO [Member] \| April 2025 [Member]
Number of vested shares	4,396,929
Subsequent Event [Member] \| CEO [Member] \| September 2021 through December 2021 [Member]
Number of stock options cancelled	5,277,778

EXCEL 46 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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
-/Q^GT6QK@<'Q@_V2]:R]; M(G')V4^:J6+FW#B084X:IN[Y_C-V?B+#EW(F[3_LV]@/D0-I(Q4O.[!64-*J M?9+G+@\#@'\.$'2 X'_ Y P@[ "A-=HJL[961)%D*O@>A(G6;&9@##LLE!V4X5IN6.+;>YZ$^) M?Q-$0:1M/PT3=B+.CX_BCL1'O?AH5/Q:\!0QD^V!>Y/REC@:*(IC3_]."XI[ M0?$;LCFNZDK'2059@T!*WE3JE,SX5>)N0N]UWMS!S2U1[&Q#DY :VO82]ZM] MSYS;5N'^"V\;KC[\.ZI-,,PUU+LV+4JT3:R=*%[;/K#E2G<5.RQTWT=A O3[ MG'-UF)@-^B])\A=02P,$% @ ]C'A4DQF?6&D P 70T !D !X;"]W M;W)K&ULK5?;;MLX$'UNOX(0ND +="U1=P>V@2;. M98MD$33H]J'H VV/;:*2J"5I.]FO7U)2%-NB617MBZW+G.&9.9SA:+1C_+M8 M TCTF&>%&#MK*1$#%@)A7JS9#PG4MWRE2M*#F11@?+,]3TO=G-" M"VZ[NW-;+@N90",H*Q&$Y=C[@LVL<:$!E\0^%G=B[1CJ4&6/?]$"LDQ[4CS^;9PZ[9H:N'_][/VJ"EX%,R,"+ECVA2[D>NRD#EK MDFPR^8GM;J )*-+^YBP3U2_:U;:A,IYOA&1Y U8, ( N"\@:0!))5:=W4J:*9%D,N)LA[BV M5M[T1:5OA5:*T$)OQ0?)U5NJ<')R"TI'=$O)C&944A#H[10DH9E ?Q/.B=XH M[]"?Z//#%+U]\V[D2K6HAKKS9H'S>@'_Q (?-\4 ^K8P/\\M?@5_WAIMBO[? '*!7<,\%=)7.KM=]J[5?^ M0JO6$GANTL&.]4.4LT*NA85'T/((K+[NR9-J9A*I1HJRBE/6[+\G$[':65PY MTYUU.\%II/*QW=\&!J,8!X=&EUVC>!CCUN@@F+ -)NR15'@LJ2X6U5P71((I M#+N;CZ2HMLKK5Z^Z>^V 6-02BZP>JU,%L27:*'Y$")#"1"OJY,1/TA ?I=>Z ME#XNST1)YC!VU'DH@&_!F2!3N?TF/]==UJ>5C-N$Q3]6\CU:4#%G&[4]^0DA M[5["@>?]89$O:=DD/?:5K3"F5@<_(%O9>AP+.&=:=;??;4=.>R[M?&X]/KAH(]SSM!8&\J MP3UD9[.,KNK<@*,T.4KIC^T.Z;X:EY9T4(HV9<*Z T2I2NO9_GZ1K*R&B5G3*K!M+I&ULK5A1;Z,X$/XK%CKI=J7=@DT"M$HB-4W:NY/: M[37;W8?3/;C@!*N L[9)MJ?[\6<#A:00EUS;AP;(?./Y9H9O'(^VC#^*F! ) M?J9))L96+.7ZS+9%&),4BQ.V)IGZ9LEXBJ6ZY2M;K#G!40%*$QLYCF>GF&;6 M9%0\N^63$OYP1U=Q5(_L">C-5Z1!9'WZUNN M[NS:2T13D@G*,L#)=,717T+M*H(S70K+B17WU*%DY-%C#F)61(1+GX%\Q\YE4_@PXQ(3!,!;C#G M6/?*1_ 9W"]FX,,O'T>V5.MJM!U6:TS+-="!-2"X9IF,!9AG$8DZ\!=FO/L: M?F;&>P:\K?)5)PT])VV*C [/U_P$N,XG@!SD=/$QPZ^QAL,"#KOHO T^-\,7 M9&T,_M(,_P-G)\!!&@Z##OB5&3XCX0E IP7<-Y3"K?O7+?P-#OB[8&FJ%$V] M)^'C)R!T-PN :K0#>J!<4/R2DXMQ%=- *"B+/0;X;O.#9UW#>83B MR-\UW&,YK%D.C2S/5RM.5E@20#/)J1IT(=C@)"= #5NPU2J4R2Z*I5MO-^]H MV*IC+ZMYV\IU F773(0,A2M9$26+=T M5ZA!JPX#Z*'ABT#;5H%[L%BG=9BGQC#OLRJ1K\5XVMU1+[/YJME>E-!IAK;3 M(YU?"E7HTU!P9SL WZNE*D][/>4$ 7J1@PXS!'UO<" 'J(D4O4^M*C^[5? [ M:O6JV7Z"[IS[R6B]P#\M] LU4@.:Q\$V]P>7F/'D"2\Y2H+;6 M-"FVIN!KS%F^BH':[X9QL=GME;U&ZZ%9[/M+W;3RM)>"P-!,J%%R9%;RXS+@ M]LD :L0>O9?83U&'V,-BEAU*02/DR"SD10J^;%0@7VE*>C%LQ!>9Q?<8ANT] M/'0=$\-&6I%96J<,\T@',:.&419],:6CKIOZI9DA#(YS(+)S'%,-KJS=$AB :S41FS?Q>_ICH58!&QY!9 MQ_[W[Q>S7WT.>2;6."1C:ZTR1?B&6!/0>63P=D@, &@. M 9 >&PO=V]R:W-H965T<< MN%P8;KAXE!F 0D]%SN3(RY1:GON^3#(HB#SA2V#ZSYR+@BC=% M?+@60U!H5 MN1\&0=\O"&7>>&C[[L1XR%0(YWXP\[+UTW--%IDR'/QXN MR0*FH+XM[X1N^967E!; ).4,"9B/O M\/L&Q,; C'BAL9.,;&2HSSA]-XTLZ M\@*#"')(E'%!]&L-EY#GQI/&\6OKU*MB&L/F]XOW&TM>DYD1"9<\_TY3E8V\ MV$,IS,DJ5_=\\QFVA'K&7\)S:9]HLQT;>"A92<6+K;%&4%!6OLG35HB&031H M,0BW!J'%70:R**^((N.AX!LDS&CMS7Q8JM9:@Z/,S,I4"?V7:CLUGF9$0,;S M%(1\AZY_K:AZ1L=H6DX2XG-T#U()FBA(T24O"JWD5/'D$;V_ D5H+C\,?:6! M&'=^L@TZ*8.&+4'[Z)8SE4ETS5)(_[;W-8&*1?C"8A(Z'=X2<8(B_!&%08B_ M3:_0^Z,/1\A'TK"3Y=,1)JK$BFR8J"7,5IX?%S,MB5Y//QT^3RN?I];G:8O/ MKZMB!N(?H>VL2/25L^.U[H7T(YK @C)&V4(OPIRP!-!OM(]8*5<9LV=CFL1< MCW$0#GI!$ S]]1ZTO0IM[R!H/PG"S"\71F5!!'!P$HMZ7YD#_A](9Z^TZQQ6)^" D]![P MVE4=[^AMQ6Z3^ZQ">N9$>D.H0 \D7\%_,^YH'ZS2>[\!*PKBL->""@?UUAQT MP57GUEXT;J=OGV_<*"6X"]XJD?;#Q;M)%$?MZH4UFK +FF;.[ ?D=-M!O[JZ MX*@+XIT$V0\[VEF%H5:Q3<:Z/&%W??INSS5:KHLU"'U.*Y ZK>ZAIU45X>ZN'E'4P?HW7F2I3#7)L&)P.]R$5YK2D;BB_M56+&E;Z8 MV,],7P5!F 'Z_YQS]=(P :K+Y?@/4$L#!!0 ( /8QX5)_!]+Y800 "47 M 9 >&PO=V]R:W-H965T7)@DJ("SMI-TI?OCSS8$IPJ8I/0EP8!G M/F-FY@N>[!A_%BL B5ZR-!=3;R7E^LKW1;2"C(H>6T.NKBP8SZA40[[TQ9H# MC07]?W7(W\RDJ<9)"+A.6(PV+J7>.KFY#H">:.;PGLQ,$QTJ$\ M,?:L!W_'4R_01)!")+4)JOZV< MIJBTICI^E4:_RJ2<>'N^M_VF"5\$\40&W M+/V>Q'(U]48>BF%!-ZE\8+O/4 ;4U_8BE@KSBW;EO8&'HHV0+"LG*X(LR8M_ M^E(NQ,&$L&D"*2>8A? +1X;R$Y5T-N%LA[B^6UG3!R94,UO!);E^*H^2JZN) MFB=GCRO*8<72&+CX@.Y^;A+Y"WU$C^KIQYL4$%N@1\FB9_1E;5;Q6J^BON?W M3R!IDHH_)KY4'-J:'Y4^;PJ?I,'G ,U9+E<"W>4QQ*_G^XJ_"H+L@[@A3H-S MRGLHQ!>(! 3_AGPD=%2B^'78#ZM%"HW]RP;[_VRR)^!Z+-%)+F M<9(O+U!QTP6Z@662Y^J4RI:4YA&@_U =21%8X;AO'.L*VL[P)2;#83B:^-L: MY,L*^;([\E^X95V)-(YAZJBD(X%OP9LBQY/V*O]^=_U8O;YJV M1.!T='X$@RJ"0?<([EZ 1XEHB<#IZ/P(AE4$P_>(8)WP%O[A49)_Q'W2#X*@ M/LE'%>#H_>KRSHQ/*LK1<5&204 :BW)<\8Z[\WX#H6M2#1$4V4&?4CB+?WS, M'V '/PZL6@3=(_B:;TT,9S&7C@^A388TY0@^4#CL9-[7&+KGB8)XH/E2':LH M#'O5!6NAG);/KSQ,+#3I!%VUOEILI^TW8%NAQ&ZE;,.N^ETMMM/V&["M6&*W M6K9A-V5T;12%J_%!(@>]X+(ABZT>8K<@?C?OEZHQ7&^!J_=E])K9\?Y1"]FO M@23C!D@K>=BM>:V0KEI[9Y7#5N:P6^=:J=W%YC3^!FZK?M@M?ZW<[FIS&G\# MMU5![);!$[C-.T4M]?@H<7$O'-0G+K&Z1MRZ=G)UM==_Z>EU:>$&0"MBQ"UB MK8"GO3;4 N,ZX"9BJV#$K6"MQ.O?[!SF0%? MFOU9@2*VR66QB5F=K?: KXN=3WM[L8$\IUREG$ I+-34H#=4SY$7>[+%0+*U MV0=]8E*RS!RN@,; ]0WJ^H(QN1]H!]7.^.Q_4$L#!!0 ( /8QX5*]?"6. M-P0 -,4 9 >&PO=V]R:W-H965TTD)($UYKE? M( _?>\^UC\\!#U:,?Q-+ (G>XR@10VK.K;($80R)"%F".,R'SAW^\$"Z.B ?\4\(*]&X M1KJ5*6/?],W'8.AX&A%$,),Z!55?;S"&*-*9%([O95*GJJD#F]>;['_FS:MF MIE3 F$5?PT NAT[/00',:1;)5[;Z"\J&VCK?C$4B_T2K %(&D)T O"^@50:TC@WPRP _GYFBE7P>'JBDHP%G*\3U M:)5-7^23F4>K]L-$K_M$Q;*-?H#312_@BP" MQ.;H.9-"TB0(DP527^CQ'?@L%'2J7C^G>O4$FJXWCP&]\' &Z)4F"T"_/8"D M821^5SE_02X2NIP8N%)!UP#<60GSOH!)]L#LH">6R*5 CTD P7:\JUJN^B:; MON^)->$3Y;>HA6\0\0@VX!G;PQ]@5H5[AO '>_@$4A7NF<*WNFE5J]C*\_E[ M\A63K=9J>Q'$#?K$5L#1IS .I6G6B[2]/*V6B+>1=^NU!NZ; 8Q?@?'/!/,E M36U@? ,8WXRE76%I6['\G<5355*SN&#J39/.-ZAX;P)3Y&TWP\4BWU:L0 M%2MM&.ACTFT.W(+>J:!W+H+^-9@5M,[K73I6>X4K1\LSJF,:1O7IE>U4KO MU%8:FF@C5>]'KGAXFU1;B/H5HOY%B"[DBKVX7W(%HUAK-#I(&>S5YN1=MZ_# MI"DK[K &F^\Y ?3O$^@>_K/-!ZFKD)^C\V7>_E%"CVO;P>?Z MS@&IQR;C:>W9E[AV'FRWGO/EODR\K?=MWR/[MB:N+0A?YD$7;LX#U=L[NY,< MW)VU0>$K.]01N[-C^D&RCQ>U]^"3S>=(Q2X3;TNV9^-%[2+X,ANYE!?VZKNJ MC5L'B5&[$;ZR'1U!C/X)LDUJ@R%V@S'*]N<5.T:V26T.Q&X.9\MDF?>HG\2D M=A%B=Y&S57)<)F[NA@YI>]X>1+6/$+N/_&2)/% =YUO!MM*U 9'+#.ATYH_) M"7^+2&U*Y&13.DX1Q^3'/SPV#M1N0DYVDVO*X8'JASE0FPVYS&S.X8#I;\PN M!]S&*5 ,?)&?I@DT8UDBBP.AZFEU8G>7GU.Y]?#BN.^)\D68"!3!7(5ZMUVU MVKPX02MN)$OS,Z4IDY+%^>42: !<#U#OYXS)S8TN4)UCCOX'4$L#!!0 ( M /8QX5)40Z&PO=V]R:W-H965TJCZ8Y +6)C%K.S K M])BSQNX*:&9,QT7]U[X=,QRF= ,7C@2>9H2 M_GT&"=M-'-_9W_A,5VNI;[C3\8:LX!7DWYL7KEIN726F*62"L@QQ6$Z<1_]A M%F ]H.CQA<).'%PC;67!V%?=^".>.)Y6! E$4I<@ZFL+3Y DNI+2\:TJZM1S MZH&'U_OJOQ7FE9D%$?#$DC<:R_7$&3HHAB7)$_F9[3Y!9:BOZT4L$<4GVE5] M/0=%N9 LK08K!2G-RF_R7BW$P8#@U !<#2@6PBTG*E1^))),QYSM$->]535] M45@M1BMQ--._RJODZBE5X^3T=4TXK%D2 Q<_H^=O.97?T0?TJG[].$\ L25Z M(YR33*)'O8#Z\2\?01*:B%]5Q_W#?^:0+H#_.W:E4J5KNU&E8%8JP"<4#-"< M97(MT',60WP\WE5N:DMX;VF&K07GA-^CP+]#V,/^3\A%0GL4Y:>E?E O65#4 M[YVH_V>NG1ZN3+&( OV52R%)%M-L=8?*7G=H!BN:9>H6FI&$9!&@_U"3E-)9 M.7._F%EOJ.UT$ Z"GM<;C=UM@^9>K;EW \V_ZR<06Q5:Y]$9\B V)(*)HT)" M -^",T661>_7!OHW,/"D%SA)SEBPSG2]A4%M87 #"\_OP",JSEBPSG2]A;"V M$-[$PH;R,P;"'U[T#WZ ^ST\\IO?]&$M<7C#W?EW?^+%->3S[>B[ M>'<=9T&CPGZ3PO"$0@,VWTZVLPHO2Z]&Q8-K%!N.^7:0S6E&TSP]\6_K<5%# M'M^.GAO'X+#!N1=Z1W\G8.D;^/AV^G1*16OIZWO(5N0R'G4/C:KF8=6P>[!\6L*?%4<,@L4L3R3Y4EL?;<^R'XLCV]-]_(4?$ZXRC"! M$EBJH=Y]J/*6EP?+94.R37&8NV!2LK2X7 .)@>L.ZOF2,;EOZ GJX_WI_U!+ M P04 " #V,>%2:DHL#C,$ K%0 &0 'AL+W=O(Y6&^DGC"GXRU=PQSDU^T35R.S\.('$<0B8#'B ML)H8=_C#C RU0;KB[P!VHO*.="H+QK[IP9_^Q+ T(@AA*;4+JAZO,(,PU)X4 MCN^Y4Z.(J0VK[P?OOZ?)JV065,",A2^!+S<38V@@'U8T">4SV_T!>4*.]K=D MH4A_T2Y?:QEHF0C)HMQ8(8B".'O2MWPC*@;$:3 @N0'YP0#;#0:#W&"0)IHA M2]/Z2"6=CCG;(:Y7*V_Z)=V;U%IE$\3Z&.>2JZ^!LI/3^89RV+#0!R[>HX?O M22#WZ#>P M5>96:FZUP!D41S-(_=D-_K(-5 =PO+'B!GUB.^#H4Q %LF[;,K?#U*TNX]>I M=8O)V'RM 6,78.P+P7S=;MO V#5@7*\>C%. <5K!_)5H_F@T!_[=5%EZ@[(% M=7 RQTX%CF,/O)'G# M(V5G_O-#UW(%MV:-Z[&Z!W>V'_27M/."CNU?@JI.B M9]#M6%??3/&=J\:7T!!] 1[5)=@>':,]4(Y&*,I*9X!\NA-U!G6. 5PG.DUP2M'![:K3H]'GGJOE:GO8F$FG7K&KG3< REXN#S)>?$5IY[/H,0@Y3:0]J%H+9]?]FQ4]HW*46"M(O$Q>T[]WOHNS#SD#XKN-FQ_*3#D?($YL6OGGD_G1"DEI*>4].5$>_AS M.%$*$;FV$)W B>$IG# KUU$1\'5Z2R?0DB6QS&ZFBMGB)O NO?\RR^79->(C MY>L@%BB$E3*U;CUU^#R[FL&J ]<+U#?5XS)PT '*.Y' MI_\!4$L#!!0 ( /8QX5(.Y;0& 00 &82 9 >&PO=V]R:W-H965T M^QR#9T?&?X@=@$3/:9*)N;63 M,K^U;1'N(*7BAN60J2<;QE,J59-O;9%SH%$!2A.;.,[(3FF<68M9<>^!+V9L M+Y,X@P>.Q#Y-*?_Y 1)VG%O8>KGQ&&]W4M^P%[.<;B$ ^25_X*IEUU&B.(5, MQ"Q#'#9S:XEO5V2B 46/KS$5H1I! *'4(JOX.L((D MT9$4CW^KH%8]I@:>7K]$_[-(7B6SI@)6+/D61W(WMR86BF!#]XE\9,>_H$K( MU_%"EHCB%QVKOHZ%PKV0+*W BD$:9^4_?:X*<0+ 7@^ 5 R%.!6 +=(M&16 MI'5')5W,.#LBKGNK:/JBJ$V!5MG$F9[&0'+U-%8XN0A@JR9%HD?(&9=QMD5_ MH$"ME6B? &(;M!0"I-!790^Z5OI+<(?>_?9^9DM%2P>W MPXK"AY("Z:%P3_D-N*M MJ-AU)5&B1@5*B^.PP-X(N].9?3@EV^[F8U<3.W1P<0PCQ M04]"%\4RB'\R]M3!DU<$C2-IU[@5.0UA;BE;$, /8"V0H:Q>G8)G3.%3=E!+ MAO$81!=UKT5=5(V->3TS29$ *H];09#(>^[*0&XDQZ2XYKDV$SR\]/R;[0,@H]/01>Y\3!RX[8Z?=?U<#>Y24UN8O8" MQI7I40GH^SVD:^#_&)0PK8-.KS*8:7L%$+>;/W8:>W?^#^*H:*'K-AL>9?T.+FT49^/VY@B-KOBV^1FC/WK^3VFINMC%O*?>=$< M($'2>!HQ>UKO*WG;P]P1(3V9-29&S"8V4(#F*%08>*N&VYAO766"XQ6^Y%"4]:+[<=P]HGAP#Z!$9] M5F_C3* $-@KFW(P5;5X>:I0-R?+B7&#-I&1I<;D#&@'7'=3S#6/RI:&/&NJC MI<5_4$L#!!0 ( /8QX5(.EFZ<,@4 /P< 9 >&PO=V]R:W-H965T MYV/!;+++/A![$R6]42'EA[%MQ\.OJ;F05(Z(I7_W]E_*L4K,2^QH#.6_I6LY/9N%(S0BJ[C M?2J?V>$76@DJ![ADJ2C_HD.%M49HN1>2956P&D&6Y,?_\5M5B), Q0,'D"J M= .<,P%V%6#WS>!4 4[?#&X54$H?'[67A9O',IY..#L@7J 56_&CK'X9K>J5 MY,5$64BNKB8J3DX7=*-NNT3/=,>X3/(-^H(6:C:N]BE%;(U^WU$>%[=4%$=' M5/RBKE6! GV:4QDGJ?BL(K\NYNC3#Y\G8ZF&5B08+ZMA/!R'0UT>B)'P,>8WR,8_(F(1#(QGUC_<@N1\+'OT MO[.WBF'7D\0N^9PS?'\P&:=H$:=40+?V&.R5P45C>IVZV'-5XM?3@@$HR^J MYCH(.P0[81L67>!JB71JD8Y1Y(P)680&]M=L3K,\RW?[UYWK@,XWW7/R@YJV<&%IY^KI2V6%/W]2+,7 MRO\Q/"!A31I^I&\:@_MWB=E //.!>**/\[2JC:W&RU@#M' SR15U'XIH/A11 M- !1N_0G-A)_:"TPAU]3](&(YD,110,0M8M.FJ*3 1:GBJ2U['B>ASN-&H I M[^5J2S& "UW?[_9I $8<*_0(W*=QXT6QV8SV7: JFO;* ^D&<+!P @J!W!& MZ8U#Q6:+^DA7R5*M*'/ZFBRIZ+-4X<;,8;.;N[!88RYVN@V#7IC,.>ZIFYZ/O"=88"$[;HU!A.;'>;%I0*R>/I[ M@SG+-173\P$O%P.D:]>K<:;8;$U[=OD 4!&XCMTMFXXCEA<0I]OM=)RK'G?L M=.L"Y T(QF?>NW#CG;'9//?N\R'P)H+=0%<. &'I -#U<(C=KG8HM4$\:9PL M,3O9^[W=BC[Y/&N1&S<[O0]\W15QBWBNC"B_Y0 MZ:)+Z=K5:BP7,5NN?DW?3')-T08BF@]%% U U"Y]8_R(V?A=6C?,X=<473=P MT$P=*%UT*5V[7(U9)&:SV&_9(/HG1E]K\C,(90>6URV)#@M#O]LU 12V?=O& M9Q0W#I:8'6S?%:.B.?U\_ 42#<"\ % -X"#9 S;1-<]/MG-R2C?E-MH BW9 M/I?';_;UV7JK[K[&ULK579;MLP$/R5A= ""=!:A^] %A [+AJ@;H,$:1Z*/M#2VB9"D2I)'_G[ MDI2L.(VM%&A?)%XS.SL2=^.MD(]JA:AAES.N1MY*Z^+"]U6ZPIRHEBB0FYV% MD#G19BJ7OBHDDLR!2%#K/"?R:8Q,;$=> MZ.T7;NERI>V"G\0%6>(=ZOOB1IJ97[-D-$>NJ. @<3'R+L.+<>@ [L1WBEMU M, :;RER(1SNYSD9>8!4APU1;"F)>&YP@8Y;)Z/A5D7IU3 L\'._9/[GD33)S MHG BV /-]&KD#3S(<$'63-^*[6>L$NI:OE0PY9ZP+<^VAQZD:Z5%7H&-@ISR M\DUVE1$'@"@\ 8@J0.1TEX&QA/ZTHQR5E=(*R!S/!]4K! ME&>8O<3[1EZM,=IK'$>-A#,B6] ./T 41.']W16<$[34W M.:/28#)%$ O@N!2:FDD&"K5F:/X^?2S_9MY.*PC>-^CKU/HZC3S3W4>8Y@43 M3XCP8X;Y'.7/!MYNS=MMY)TP0G,%)!?KX^F5\)Z#VUN]2:*P%P2QOSD2M5=' M[35&?3!W7 'EJ:D="IWGQV(WDT1O6-NOQ?0;>>R%1@F3Z;>_,790LP[^S=C! M*V/#_K#;&1QW=EB''?X/9YM)WG(V#)X+2O"V"T 80RMKS0M",]A:C4=+2?#: MD^Z@'W:/>Q(>U+6P4<9]&7A#4E*6_Y-?I2)Z\;\'@W;[#P7^09$U/\_2M1(% MJ:4MZVV]6K>KR[)(/Q\O>YTI:$O*%3!<&&C0ZIL;)\OV44ZT*%S)G@MM&H ; MKDS+16D/F/V%$'H_L0'J)I[\!E!+ P04 " #V,>%2O:!<2'($ !1% M&0 'AL+W=OD3-5G?OR%U@,*3+R(I[+Z!L?Z7NB J)2*9[58.\A8?OHE M]W4B.@+D#PAP+Y6X-5%D.1?\"(2Y6T9UJGEIMQ*^JVDN0*W!_TMP:LU582E$GPD0A SC:_! MS^#+9@U>_?1Z[BK=J9&Z4=W!ZM0!'NC@;2&N $1O (88G9'?C)![L)+#,_*U M7?Z!&/EP[[=V^?LR;WI_)'=UHIMLXR;;N(KG#\3[6&9;*@#? 3VQT5? "[-: M)-@+DBL: \5!48HHT95_;JS6X 8IU[(@$5TXFAF2B@-UEL#BVFM<>\]R'9$\ MTBN\6D->[M5OO/I6KRM.1&RLKIG0+.)"@K\^4./_;TOTH(D>C,R$-JT$ MB\RDR83H%F!2EKH5EX+E>U!0P7C\IKYXKNY//0553P;GAR6&: +U9^X>SG@, M&X_A2(\'[;'Q=\Y"V+,P07C8P:1Q,+$Z>,R49@; /^#3;L%Y#'8&&<) M3V,Z;IJFC8&IU+E/@&99E)A3_IA<(=@^ >#_5=2KNJMN27F3 M8+BD4.O.%()P&$^0/I*D%,;*3^/()\WL3%D ?3\,!)RVTT5AJ/T7$%>I3 M>0)#2_VV5$9V+/] U71Q$(RJI9;4R([J2U(SZ2]M[6>X4EI:(SNN;:FYN?TT M:L0MD9$=R9>7Y:S_9+ \IG'+73R6NT_F'O>Q.H,!'H09;K&*[5C]L3?251W] M/_SP?'_FX]F L\ZK\A.8-=D ])Z*B$D*] *(SELXA9EV+, K& QTWU(6VRD[ MMBA?XEF-6ZCB%X8J[D,U#(:+MV4J'LO4Y]5-G[/(@Y95U7(6/\'9L6437E(V M+5#Q\]]]A\IF%--QBU-LQ^DE7)GVIL'W9N%LN-)>_X/[0KK\_@ $_T9_HH5VYG-\9LMFD6[)F.GM*= M5L*KB0XA3OM7IX;B1;5!L^5*\:PZ3"C1?XK,#?KZCG/UT#![/LTNXO)?4$L# M!!0 ( /8QX5+[B)C8$ , # 1 - >&PO5;H*%;(6>A$EO"MSM2SX)X_1] M&#BZF#N)^].3@9W9Y>']E,+G(61E_3B&:3G@P%.#"!& MGCZ/_"EN2QUU"9J."RGV\P0&$YM4-+@G?!+."&=SQ<"K(!7C:V<>@F$AN52! M-@4R8F*P- \.CMT,:M?Q5$Q(96.[".[OO%M^ &QF()!QW@LVZ-@I+1=;Q\"+<.MB;"3*7*J>J#Q.'&]-TS&D!_2#E[$&]3L7NK/K=F.L'-H%GJM:,%6=KXJ>@$8>XRSD[KFZT^TZ?UCSO*+%2&L +Q"3\#B\K?!LTF+>,:R:ZV9+E.16/SC=#K\G1%1JC/"/5Q M7CYD9C]8'+]/9B[_3K,L2=(4R^ALYE4PP_*6IO#ULV':P .+ Y'^+-=XM?$. M>;H/L)H^U2'83O%.Q':*YQH0?][ (\O\U<;B@ =6!:QW(+X_#O24WR=)H*J8 M-NP)QI$LPQ#H17^/IBF2G10^_OI@3TF29)D? *NQS $P( L !? M3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2 M?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'%2L?+%"3T# !; M%P #P 'AL+W=OE%3:;UL MJ]2U45/U=7+@D%@U=FJ;]/+K=R#*8MKL:"]N7D)LC/DXX//9/G[2YF&J]0-[ MKJ2RHVCNW.(HCFT^AXK;KWH!"L^4VE3<8=',8KLPP L[!W"5C-->;QA77*CH MY'C=U]C$?D$[R)W0"BN;BGL!3W9SOBFRI;!B*J1P+Z.H_2\A8I50HA*O4(RB M7L3L7#_]U$:\:N6XG.1&2SF*DM6)>S!.Y.^J)PWD'9_:ML;QZ2U'D%$T[&&' MI3#6M2W:_CDR+@$;KTJUT]^%=&#.N8,?1M<+H69--_@4L?<8;1S6QU40C\S_ MA%&7I9$9#93B G#0Y>ZD'V"Y)" '(:%/.566*9+ M-C9@L>G;,;U/H.V'19O45<7-2P,W$3,E\#*.:>A;GNL:TY '>4! 'H2%O-)< M63;F+QQORTJC*W;37FMLDS ]R$,"\C P)' +[$KPUG$"K)^T>U36[@5^Q7-N M8*YE@>'ZQ"X>:Y2+ST8:);!2)C!KM7<+"XUV5S,?C+)($E@C5S#CDOWB#F<' MG3=)62,)K(U)/;7P6#,,D426!5D%NFH(J%#MRMQ)2TD@"6V.K==G>.3@NI/6GJPFEC22P M-^B/LN_/JBF+I*$M0F(.?$Q**&EHH9"80Q^37*2$U@LUH^DDS)023AI8.._F M-)OA<\V-\3$I_:2A];,U8?XE]3$I_:2A];,-\PM;?[(^)J6?=!?Z04SLNJ@; MD@TF): TM( HS.X0HBR4!K80C>G/.5+*0FEH"Y&8OH4RRD)9: N]FW5L/DS, M^3XF9:'LHY49UMTH5':QWAM>[VN?_ %02P,$ M% @ ]C'A4HS?7ZUN 0 W10 !H !X;"]?'+UIF_=JVKKKV+[DW=NE15WO'B=&9T?O?W/Q*XHKKG][/+OQK;^C\'Z MIQMNKK+6J^B<#:7UJ=+W>K[M]'2AU3A91:=+JH;3A90.'<00Q.&## 29\$%K M"%J'#]I T"9\4 )!2?B@+01MPP?M(&@7/F@/0?OP012CC+& I 76 K0FY)H$ M>$T(-@D0FY!L$F V(=HD0&U"MDF VX1PDP"Y">DF 783XDT"]&;4FP7HS:@W M"]";%S_; O1FU)L%Z,VH-PO0FU%O%J WH]XL0&]&O5F WHQZLP"]&?5F 7H; MU-L(T-N@WD: W@;U-@+T-HO#$@%Z&]3;O%-OYQ^U=7//%2!E="=X\! !P%0 $P %M# M;VYT96YT7U1Y<&5S72YX;6S-F,UNPC 0A%\ERA418Z>E/P(N;:\MA[Z FVR( M11);MJ'P]G7"C]2*1B J=2ZQ$N_.C+W2=\CD?6O(19NZ:MPT+KTWCXRYK*1: MND0;:L).H6TM?7BU"V9DMI0+8F(T&K-,-YX:/_2M1CR;/%,A5Y6/7C;ALU.Z MF<:6*A='3[O"UFL:2V,JE4D?]MFZR7^X#/<.2>CL:ERIC!N$@IB==&AW?C?8 M][VMR5J54S27UK_*.E2Q3<6%2!T%-8H$ "Q $ M @ $ 9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0 ( /8QX5*L MP /$[0 "L" 1 " :\ !D;V-0&UL4$L! A0#% @ ]C'A4L1>%2UQM[ M1+8" !'!P & @('B$0 >&PO=V]R:W-H965T&UL4$L! A0#% @ ]C'A4B:E?R,K!0 :1, !@ M ("!SA0 'AL+W=O%2/ P.3%H& !>&0 & M @('B(0 >&PO=V]R:W-H965T&UL4$L! A0#% M @ ]C'A4F,3?06J"@ 4AH !@ ("!%2P#=Z&84( F&0 &0 @(&0 M3P >&PO=V]R:W-H965T&UL4$L! A0#% @ ]C'A4FL(@]'I!@ ]0\ !D M ("!\UT 'AL+W=O%2@G8B;)L$ "3# &0 @($390 >&PO=V]R:W-H M965T5I !X;"]W;W)K&UL4$L! M A0#% @ ]C'A4K V,=*G P , @ !D ("!('P 'AL M+W=O%2KB4,N/D$ M "T$ &0 @('^?P >&PO=V]R:W-H965T&UL4$L! A0#% @ ]C'A M4A<1B@?' P ;@T !D ("![(D 'AL+W=O%2-\L^0$0( "(( &0 M @('JC0 >&PO=V]R:W-H965T&UL4$L! A0#% @ ]C'A4E/%,[,! P /0H M !D ("!?)L 'AL+W=O%2M[P037X" !5!@ &0 @(&TG@ M>&PO=V]R:W-H965T&UL4$L! A0#% @ ]C'A4J/F*P#O! K!4 !D M ("!1*4 'AL+W=O%24DD RGH# !H#@ &0 @(%JJ@ >&PO=V]R:W-H965T M&UL4$L! A0# M% @ ]C'A4KU\)8XW! TQ0 !D ("!L[( 'AL+W=O M%25$.G'S4$ #J M%P &0 @($AMP >&PO=V]R:W-H965T&UL4$L! A0#% @ ]C'A4@[E MM 8!! 9A( !D ("!][\ 'AL+W=O%2#I9NG#(% #\' &0 M @($OQ >&PO=V]R:W-H965T\TY?LP( - ' 9 " @9C) !X;"]W;W)K&UL4$L! A0#% @ ]C'A4KV@7$AR! 410 !D M ("!@LP 'AL+W=O%2^XB8V! # P$0 #0 @ $KT0 >&PO M%2C-]?K6X! #=% &@ @ &YV >&PO7W)E M;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " #V,>%2!E="=X\! !P M%0 $P @ %?V@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 1 *@ J %T+ ?W ! end XML 47 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 48 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 49 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 162 285 1 true 44 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://wellnesscenterusa.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://wellnesscenterusa.com/role/BalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://wellnesscenterusa.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://wellnesscenterusa.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Shareholders' Deficit (Unaudited) Sheet http://wellnesscenterusa.com/role/StatementsOfShareholdersDeficit Condensed Consolidated Statements of Shareholders' Deficit (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://wellnesscenterusa.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Basis of Presentation Sheet http://wellnesscenterusa.com/role/BasisOfPresentation Basis of Presentation Notes 7 false false R8.htm 00000008 - Disclosure - Summary of Significant Accounting Policies Sheet http://wellnesscenterusa.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 00000009 - Disclosure - Loans Payable from Officers and Shareholders Sheet http://wellnesscenterusa.com/role/LoansPayableFromOfficersAndShareholders Loans Payable from Officers and Shareholders Notes 9 false false R10.htm 00000010 - Disclosure - Lease Liabilities Sheet http://wellnesscenterusa.com/role/LeaseLiabilities Lease Liabilities Notes 10 false false R11.htm 00000011 - Disclosure - Shareholders' Equity Sheet http://wellnesscenterusa.com/role/ShareholdersEquity Shareholders' Equity Notes 11 false false R12.htm 00000012 - Disclosure - Segment Reporting Sheet http://wellnesscenterusa.com/role/SegmentReporting Segment Reporting Notes 12 false false R13.htm 00000013 - Disclosure - Legal Matters Sheet http://wellnesscenterusa.com/role/LegalMatters Legal Matters Notes 13 false false R14.htm 00000014 - Disclosure - Subsequent Events Sheet http://wellnesscenterusa.com/role/SubsequentEvents Subsequent Events Notes 14 false false R15.htm 00000015 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://wellnesscenterusa.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://wellnesscenterusa.com/role/SummaryOfSignificantAccountingPolicies 15 false false R16.htm 00000016 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://wellnesscenterusa.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://wellnesscenterusa.com/role/SummaryOfSignificantAccountingPolicies 16 false false R17.htm 00000017 - Disclosure - Shareholders' Equity (Tables) Sheet http://wellnesscenterusa.com/role/ShareholdersEquityTables Shareholders' Equity (Tables) Tables http://wellnesscenterusa.com/role/ShareholdersEquity 17 false false R18.htm 00000018 - Disclosure - Segment Reporting (Tables) Sheet http://wellnesscenterusa.com/role/SegmentReportingTables Segment Reporting (Tables) Tables http://wellnesscenterusa.com/role/SegmentReporting 18 false false R19.htm 00000019 - Disclosure - Basis of Presentation (Details Narrative) Sheet http://wellnesscenterusa.com/role/BasisOfPresentationDetailsNarrative Basis of Presentation (Details Narrative) Details http://wellnesscenterusa.com/role/BasisOfPresentation 19 false false R20.htm 00000020 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://wellnesscenterusa.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://wellnesscenterusa.com/role/SummaryOfSignificantAccountingPoliciesTables 20 false false R21.htm 00000021 - Disclosure - Summary of Significant Accounting Policies - Schedule of Company's Consolidated Subsidiaries (Details) Sheet http://wellnesscenterusa.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfCompanysConsolidatedSubsidiariesDetails Summary of Significant Accounting Policies - Schedule of Company's Consolidated Subsidiaries (Details) Details 21 false false R22.htm 00000022 - Disclosure - Summary of Significant Accounting Policies - Schedule of Company's Consolidated Subsidiaries (Details) (Parenthetical) Sheet http://wellnesscenterusa.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfCompanysConsolidatedSubsidiariesDetailsParenthetical Summary of Significant Accounting Policies - Schedule of Company's Consolidated Subsidiaries (Details) (Parenthetical) Details 22 false false R23.htm 00000023 - Disclosure - Loans Payable from Officers and Shareholders (Details Narrative) Sheet http://wellnesscenterusa.com/role/LoansPayableFromOfficersAndShareholdersDetailsNarrative Loans Payable from Officers and Shareholders (Details Narrative) Details http://wellnesscenterusa.com/role/LoansPayableFromOfficersAndShareholders 23 false false R24.htm 00000024 - Disclosure - Lease Liabilities (Details Narrative) Sheet http://wellnesscenterusa.com/role/LeaseLiabilitiesDetailsNarrative Lease Liabilities (Details Narrative) Details http://wellnesscenterusa.com/role/LeaseLiabilities 24 false false R25.htm 00000025 - Disclosure - Shareholders' Equity (Details Narrative) Sheet http://wellnesscenterusa.com/role/ShareholdersEquityDetailsNarrative Shareholders' Equity (Details Narrative) Details http://wellnesscenterusa.com/role/ShareholdersEquityTables 25 false false R26.htm 00000026 - Disclosure - Shareholders' Equity - Summary of Restricted Common Stock (Details) Sheet http://wellnesscenterusa.com/role/ShareholdersEquity-SummaryOfRestrictedCommonStockDetails Shareholders' Equity - Summary of Restricted Common Stock (Details) Details 26 false false R27.htm 00000027 - Disclosure - Shareholders' Equity - Schedule of Stock Option Activity (Details) Sheet http://wellnesscenterusa.com/role/ShareholdersEquity-ScheduleOfStockOptionActivityDetails Shareholders' Equity - Schedule of Stock Option Activity (Details) Details 27 false false R28.htm 00000028 - Disclosure - Shareholders' Equity - Schedule of Outstanding and Exercisable Options by Exercise Price Range (Details) Sheet http://wellnesscenterusa.com/role/ShareholdersEquity-ScheduleOfOutstandingAndExercisableOptionsByExercisePriceRangeDetails Shareholders' Equity - Schedule of Outstanding and Exercisable Options by Exercise Price Range (Details) Details 28 false false R29.htm 00000029 - Disclosure - Shareholders' Equity - Schedule of Warrant Activity (Details) Sheet http://wellnesscenterusa.com/role/ShareholdersEquity-ScheduleOfWarrantActivityDetails Shareholders' Equity - Schedule of Warrant Activity (Details) Details 29 false false R30.htm 00000030 - Disclosure - Shareholders' Equity - Schedule of Outstanding and Exercisable Warrants by Exercise Price Range (Details) Sheet http://wellnesscenterusa.com/role/ShareholdersEquity-ScheduleOfOutstandingAndExercisableWarrantsByExercisePriceRangeDetails Shareholders' Equity - Schedule of Outstanding and Exercisable Warrants by Exercise Price Range (Details) Details 30 false false R31.htm 00000031 - Disclosure - Segment Reporting - Schedule of Assets of Reportable Segments (Details) Sheet http://wellnesscenterusa.com/role/SegmentReporting-ScheduleOfAssetsOfReportableSegmentsDetails Segment Reporting - Schedule of Assets of Reportable Segments (Details) Details 31 false false R32.htm 00000032 - Disclosure - Segment Reporting - Schedule of Operations of Reportable Segments (Details) Sheet http://wellnesscenterusa.com/role/SegmentReporting-ScheduleOfOperationsOfReportableSegmentsDetails Segment Reporting - Schedule of Operations of Reportable Segments (Details) Details 32 false false R33.htm 00000033 - Disclosure - Legal Matters (Details Narrative) Sheet http://wellnesscenterusa.com/role/LegalMattersDetailsNarrative Legal Matters (Details Narrative) Details http://wellnesscenterusa.com/role/LegalMatters 33 false false R34.htm 00000034 - Disclosure - Subsequent Events (Details Narrative) Sheet http://wellnesscenterusa.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://wellnesscenterusa.com/role/SubsequentEvents 34 false false All Reports Book All Reports wcui-20210331.xml wcui-20210331.xsd wcui-20210331_cal.xml wcui-20210331_def.xml wcui-20210331_lab.xml wcui-20210331_pre.xml http://xbrl.sec.gov/dei/2021 http://fasb.org/us-gaap/2021-01-31 http://fasb.org/srt/2021-01-31 true true ZIP 51 0001493152-21-015795-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-21-015795-xbrl.zip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end

Shareholders' Equity - Summary of Restricted Common Stock (Details)	6 Months Ended
	Mar. 31, 2021 USD ($) $ / shares shares
Equity [Abstract]
Number of Restricted Shares Non-vested, Beginning balance \| shares	10,275,000
Number of Restricted Shares Non-vested, Granted \| shares
Number of Restricted Shares Non-vested, Vested \| shares	(2,775,000)
Number of Restricted Shares Non-vested, Forfeited \| shares
Number of Restricted Shares Non-vested, Ending balance \| shares	7,500,000
Fair Value Non-vested, Beginning balance \| $	$ 308,250
Fair Value Non-vested, Granted \| $
Fair Value Non-vested, Vested \| $	(83,250)
Fair Value Non-vested, Forfeited \| $
Fair Value Non-vested, Ending balance \| $	$ 22,500
Weighted Average Grant Date Fair Value Non-vested, Beginning balance \| $ / shares	$ 0.03
Weighted Average Grant Date Fair Value Non-vested, Granted \| $ / shares
Weighted Average Grant Date Fair Value Non-vested, Vested \| $ / shares	0.03
Weighted Average Grant Date Fair Value Non-vested, Forfeited \| $ / shares
Weighted Average Grant Date Fair Value Non-vested, Ending balance \| $ / shares	$ 0.03